Processing 00000000.tx.1: Rescue of a human mRNA splicing defect by the plant cytokinin kinetin Susan A. 

Phrase: "Rescue of a human mRNA splicing defect"

Phrase: "by the plant cytokinin kinetin Susan A."
Processing 00000000.tx.2: Slaugenhaupt1,2,*, James Mull1,2, Maire Leyne1,2, Math P. 

Phrase: "Slaugenhaupt1,"

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "*,"

Phrase: "James Mull1,"

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "Maire Leyne1,"

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "Math P."
Processing 00000000.tx.3: Cuajungco1,2, Sandra P. 

Phrase: "Cuajungco1,"

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "Sandra P."
Processing 00000000.tx.4: Gill1,2, Matthew M. 

Phrase: "Gill1,"

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "Matthew M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.5: Hims1,2, Fabiola Quintero1,2, Felicia B. 

Phrase: "Hims1,"

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "Fabiola Quintero1,"

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "Felicia B."
Processing 00000000.tx.6: Axelrod3 and James F. 

Phrase: "Axelrod3"

Phrase: "and"

Phrase: "James F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.7: Gusella1,2 1Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Charlestown, MA 02129, USA, 2Harvard Institute of Human Genetics, Harvard Medical School, Boston, MA 02115, USA and 3Department of Pediatrics, New York University Medical School, New York, NY 10021, USA Received October 16, 2003; 

Phrase: "Gusella1,"

Phrase: "2 1Molecular Neurogenetics Unit,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0439148:Unit [Quantitative Concept]
   812   C1519795:Unit [Quantitative Concept]
   812   C1704753:Unit [Manufactured Object]
   812   C1880519:Unit [Quantitative Concept]

Phrase: "Center for Human Genetic Research,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C0683939:center research [Manufactured Object,Organization]
   770   C0085142:Center, Birth [Health Care Related Organization,Manufactured Object]
   760   C0205099:Center [Spatial Concept]

Phrase: "Massachusetts General Hospital,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   901   C0020008:general hospital [Health Care Related Organization,Manufactured Object]
   827   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   827   C0205246:General [Spatial Concept]
   827   C1510665:Hospital [Qualitative Concept]
   827   C1553889:General [Idea or Concept]
   743 E C1609061:Hospitals [Intellectual Product]

Phrase: "Charlestown,"

Phrase: "MA 02129,"

Phrase: "USA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: "2Harvard Institute of Human Genetics,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0021622:institute [Organization]
   760   C1272753:Institute [Idea or Concept]

Phrase: "Harvard Medical School,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0036378:School, Medical [Health Care Related Organization,Manufactured Object]
   827   C0036375:School [Manufactured Object,Organization]

Phrase: "Boston,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006037:Boston [Geographic Area]

Phrase: "MA 02115,"

Phrase: "USA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: "and"

Phrase: "3Department of Pediatrics,"

Phrase: "New York University Medical School,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   840   C0036378:School, Medical [Health Care Related Organization,Manufactured Object]
   804   C0036375:School [Manufactured Object,Organization]

Phrase: "New York,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027976:New York [Geographic Area]
   861   C0205314:New [Temporal Concept]

Phrase: "NY 10021,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0027976:NY [Geographic Area]
   861   C1879958:NY [Intellectual Product]

Phrase: "USA Received October 16,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0041703:USA [Geographic Area]
   812   C1514756:Received [Qualitative Concept]

Phrase: "2003"

Phrase: ";"
Processing 00000000.tx.8: Accepted December 17, 2003  ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  The defective splicing of pre-mRNA is a major cause of human disease. 

Phrase: "Accepted December 17,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1272684:Accepted [Qualitative Concept]
   827   C1548435:Accepted [Idea or Concept]

Phrase: "2003  ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The defective splicing of pre-mRNA"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   820   C1622990:pre-mRNA splicing [Genetic Function]
   783   C0086934:mRNA splicing [Genetic Function]
   753   C0035687:Splicing [Genetic Function]
   753   C2610186:splicing [Genetic Function]

Phrase: "is"

Phrase: "a major cause of human disease."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C1314792:disease cause [Functional Concept]
   753   C0015127:cause [Functional Concept]
   753   C0205164:Major [Qualitative Concept]
   753   C1524003:Cause [Conceptual Entity]
Processing 00000000.tx.9: Exon skipping is a common result of splice mutations and has been reported in a wide variety of genetic disorders, yet the underlying mechanism is poorly understood. 

Phrase: "Exon skipping"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0560435:skipping [Finding]

Phrase: "is"

Phrase: "a common result of splice mutations"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1274040:Result [Functional Concept]
   753   C1546471:Result [Idea or Concept]
   753   C2825142:Result [Finding]

Phrase: "and"

Phrase: "has"

Phrase: "been"

Phrase: "reported in a wide variety of genetic disorders,"
Meta Candidates (Total=15; Excluded=3; Pruned=0; Remaining=12)
   770   C0019247:Genetic Disorders [Disease or Syndrome]
   770   C2924406:Genetic disorders [Laboratory Procedure]
   744   C0012634:Disorders [Disease or Syndrome]
   744   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   744   C0314603:Genetic [Functional Concept]
   744   C0332464:Wide [Spatial Concept]
   744   C0684224:Reported [Intellectual Product]
   744   C0700287:Reported [Health Care Activity]
   744   C1883525:Variety [Conceptual Entity]
   744   C2346866:Variety [Conceptual Entity]
   744   C3496591:Reported [Clinical Attribute]
   743 E C0242354:birth disorders [Congenital Abnormality,Disease or Syndrome]
   729 E C0178829:Genital Disorders [Disease or Syndrome]
   711 E C3273238:Report [Intellectual Product]
   704   C2919603:Original report [Intellectual Product]

Phrase: "yet"

Phrase: "the underlying mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]

Phrase: "is"

Phrase: "poorly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205169:Poorly [Qualitative Concept]

Phrase: "understood."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0162340:Understand [Mental Process]
Processing 00000000.tx.10: Often, such mutations are incompletely penetrant, and low levels of normal transcript and protein are maintained. 

Phrase: "Often,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332183:Often [Temporal Concept]

Phrase: "such mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "incompletely penetrant,"

Phrase: "and"

Phrase: "low levels of normal transcript"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   760   C0441889:Levels [Qualitative Concept]
   726 E C0456079:Level [Classification]
   726 E C1547707:Level [Geographic Area]
   726 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "are"

Phrase: "maintained."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1314677:Maintained [Functional Concept]
   966 E C0024501:Maintain [Activity]
Processing 00000000.tx.11: Familial dysautonomia (FD) is caused by mutations in IKBKAP, and all cases described to date involve an intron 20 mutation that results in a unique pattern of tissue-specific exon skipping. 

Phrase: "Familial dysautonomia (FD)"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]

Phrase: "is"

Phrase: "caused by mutations"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0026882:Mutations [Genetic Function]
   756   C0015127:cause [Functional Concept]
   756   C1524003:Cause [Conceptual Entity]
   756 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "in IKBKAP,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416379:IKBKAP [Gene or Genome]

Phrase: "and"

Phrase: "all cases"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]

Phrase: "described to date"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0011008:Date [Temporal Concept]
   790   C1552738:described [Idea or Concept]
   790   C2348077:Date [Food]

Phrase: "involve"

Phrase: "an intron 20 mutation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C1881250:Intron Mutation [Genetic Function]
   827   C0026882:Mutation [Genetic Function]
   827   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that results in a unique pattern of tissue-specific exon skipping."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   704   C1274040:Result [Functional Concept]
   704   C1546471:Result [Idea or Concept]
   704   C2825142:Result [Finding]
Processing 00000000.tx.12: Accurate splicing of the mutant IKBKAP allele is particularly inefficient in the nervous system. 

Phrase: "Accurate splicing of the mutant IKBKAP allele"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035687:Splicing [Genetic Function]
   748   C2610186:splicing [Genetic Function]

Phrase: "is"

Phrase: "particularly inefficient in the nervous system."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0231185:Inefficient [Functional Concept]
Processing 00000000.tx.13: Here we show that treatment with the plant cytokinin kinetin alters splicing of IKBKAP. 

Phrase: "Here"

Phrase: "we"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "that treatment with the plant cytokinin kinetin"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   748   C0039798:treatment [Functional Concept]
   748   C0087111:Treatment [Therapeutic or Preventive Procedure]
   748   C1522326:Treatment [Functional Concept]
   748   C1533734:Treatment [Therapeutic or Preventive Procedure]
   748   C1705169:Treatment [Conceptual Entity]
   748   C3538994:TREATMENT [Research Activity]

Phrase: "alters"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "splicing of IKBKAP."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0035687:Splicing [Genetic Function]
   790   C2610186:splicing [Genetic Function]
Processing 00000000.tx.14: Kinetin significantly increases inclusion of exon 20 from the endogenous gene, as well as from an IKBKAP minigene. 

Phrase: "Kinetin significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "inclusion of exon 20"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1512693:Inclusion [Qualitative Concept]

Phrase: "from the endogenous gene,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017337:Gene [Gene or Genome]

Phrase: "as well as from an IKBKAP minigene."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0205170:Well [Qualitative Concept]
   748   C1416379:IKBKAP [Gene or Genome]
   748   C3146287:Well [Manufactured Object]
Processing 00000000.tx.15: By contrast the drug does not enhance inclusion of alternatively spliced exon 31 in MYO5A. 

Phrase: "By"

Phrase: "contrast"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "the drug"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0013227:Drug [Pharmacologic Substance]
  1000   C1254351:Drug [Pharmacologic Substance]
   944 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   944 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   907 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "enhance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhance [Activity]

Phrase: "inclusion of alternatively spliced exon 31"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1512693:Inclusion [Qualitative Concept]

Phrase: "in MYO5A."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1417565:MYO5A [Gene or Genome]
Processing 00000000.tx.16: Benzyladenine, the most closely related cytokinin, showed a similar but less dramatic effect. 

Phrase: "Benzyladenine,"

Phrase: "the most closely related cytokinin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0010815:cytokinin [Biologically Active Substance]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "a similar"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2348205:Similar [Qualitative Concept]

Phrase: "but"

Phrase: "less dramatic effect."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1280500:Effect [Qualitative Concept]
   827   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.17: Our findings reveal a remarkable impact on splicing fidelity by these small molecules, which therefore provide new tools for the dissection of mechanisms controlling tissue-specific pre-mRNA splicing. 

Phrase: "Our findings"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C2607943:findings [Functional Concept]
  1000   C2926606:Findings [Clinical Attribute]
  1000   C3539655:Findings [Intellectual Product]
   966 E C0037088:Finding [Sign or Symptom]
   966 E C0243095:Finding [Finding]
   966 E C2825141:Finding [Finding]

Phrase: "reveal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:reveal [Qualitative Concept]

Phrase: "a remarkable impact on splicing fidelity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1825598:IMPACT [Gene or Genome]

Phrase: "by these small molecules,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1328819:Small molecules [Organic Chemical]
   861   C0567416:molecules [Substance]
   777 E C1521991:Molecular [Qualitative Concept]

Phrase: "which therefore"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "new tools for the dissection of mechanisms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   714   C0336791:Tool [Manufactured Object]
   714   C2827396:Tool [Manufactured Object]

Phrase: "controlling"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0332298:controlling [Functional Concept]
  1000   C2587213:Controlling [Functional Concept]
   966 E C0243148:control [Qualitative Concept]
   966 E C1550141:Control [Substance]
   966 E C1882979:Control [Conceptual Entity]
   966 E C3274648:Control [Qualitative Concept]

Phrase: "tissue-specific pre-mRNA splicing."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   911   C1519517:Tissue-Specific Splicing [Genetic Function]
   884   C1622990:pre-mRNA splicing [Genetic Function]
   840   C0086934:mRNA splicing [Genetic Function]
   804   C0035687:Splicing [Genetic Function]
   804   C2610186:splicing [Genetic Function]
Processing 00000000.tx.18: Further, kinetin should be explored as a treatment for increasing the level of normal IKAP in FD, and for other splicing disorders that may share a similar mechanism.  

Phrase: "Further,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "should"

Phrase: "be"

Phrase: "explored as a treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "for increasing"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442808:Increasing [Functional Concept]
   966 E C0442805:Increase [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "the level of normal IKAP"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1547707:Level [Geographic Area]
   760   C2946261:Level [Pharmacologic Substance]

Phrase: "in FD,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]

Phrase: "and for other splicing disorders"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0012634:Disorders [Disease or Syndrome]
   760   C0035687:Splicing [Genetic Function]
   760   C1515981:And [Idea or Concept]
   760   C2610186:splicing [Genetic Function]

Phrase: "that"

Phrase: "may"

Phrase: "share"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0237876:Share [Social Behavior]

Phrase: "a similar mechanism."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.19: INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  The recent sequencing of the human genome has led to surprisingly low estimates of the number of human genes, in contrast to the significantly higher estimates that were previously based on expressed sequence tags in the public databases (1,2). 

Phrase: "INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The recent sequencing of the human genome"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C1328887:genome sequencing [Molecular Biology Research Technique]
   748   C1553778:Sequencing [Intellectual Product]
   748   C1561491:Sequencing [Functional Concept]

Phrase: "has"

Phrase: "led"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C1708698:LED [Manufactured Object]
   966 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   966 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   966 E C1522538:Lead [Functional Concept]
   966 E C2348269:Lead [Element, Ion, or Isotope]
   966 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "to surprisingly low estimates of the number of human genes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0750572:estimates [Quantitative Concept]

Phrase: "in contrast to the significantly higher"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C0205250:High [Qualitative Concept]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]
   777 E C0489786:Height [Organism Attribute]

Phrase: "estimates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750572:Estimate [Quantitative Concept]

Phrase: "that"

Phrase: "were"

Phrase: "previously"

Phrase: "based on expressed sequence tags"
Meta Candidates (Total=15; Excluded=6; Pruned=0; Remaining=9)
   862   C0600510:Expressed Sequence Tags [Indicator, Reagent, or Diagnostic Aid,Nucleic Acid, Nucleoside, or Nucleotide]
   781   C0004793:Base Sequence [Nucleotide Sequence]
           Sequence
   760   C0162326:Sequence [Nucleotide Sequence]
   760   C0162327:Sequence [Nucleotide Sequence]
   760   C1139855:tags [Medical Device]
   760   C1519249:Sequence [Functional Concept]
   760   C1527178:Based [Functional Concept]
   760   C1705938:Based [Idea or Concept]
   726 E C0002055:base [Inorganic Chemical]
   726 E C0037293:Tag [Neoplastic Process]
   726 E C0178499:Base [Chemical Viewed Functionally]
   726 E C0181496:Tag [Manufactured Object]
   726 E C1710492:TAG [Gene or Genome]
   726 E C1880279:Base [Biomedical or Dental Material]

Phrase: "in the public databases"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0242356:Databases [Intellectual Product]
   827 E C0993637:Database [Intellectual Product]

Phrase: "(1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")."
Processing 00000000.tx.20: This apparent disparity suggests a major role for alternative splicing in creating genetic complexity, and has brought the study of splicing regulation to the forefront of molecular genetics. 

Phrase: "This apparent disparity"

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "a major role for alternative splicing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "in creating genetic complexity,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   755   C0439855:Complex [Qualitative Concept]
   755   C1704241:Complex [Chemical Viewed Structurally]

Phrase: "and"

Phrase: "has"

Phrase: "brought"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332302:brought [Functional Concept]

Phrase: "the study of splicing regulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0557651:Study [Manufactured Object]
   760   C2603343:Study [Research Activity]

Phrase: "to the forefront"

Phrase: "of molecular genetics."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0086345:Genetics, Molecular [Biomedical Occupation or Discipline]
   861   C0017398:Genetics [Biomedical Occupation or Discipline]
   861   C0017399:genetics [Biologic Function]
   861   C1521991:Molecular [Qualitative Concept]
   789 E C0567416:Molecule [Substance]
Processing 00000000.tx.21: Indeed, the misregulation of this process is a common cause of genetic disease as 15% of all known human mutations result in defective pre-mRNA splicing (3). 

Phrase: "Indeed,"

Phrase: "the misregulation of this process"

Phrase: "is"

Phrase: "a common cause of genetic disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C1314792:disease cause [Functional Concept]
   753   C0015127:cause [Functional Concept]
   753   C1524003:Cause [Conceptual Entity]

Phrase: "as 15%"

Phrase: "of all known human mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "result in defective pre-mRNA splicing"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   833   C1622990:pre-mRNA splicing [Genetic Function]
   790   C0026661:Pre-mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   790   C0035695:Pre-mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   790   C0086934:mRNA splicing [Genetic Function]
   753   C0035687:Splicing [Genetic Function]
   753   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0332152:Pre [Temporal Concept]
   753   C0332452:Defective [Functional Concept]
   753   C0740175:Pre [Qualitative Concept]
   753   C1274040:Result [Functional Concept]
   753   C1546471:Result [Idea or Concept]
   753   C2257086:PRE [Genetic Function]
   753   C2610186:splicing [Genetic Function]
   753   C2825142:Result [Finding]

Phrase: "(3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")."
Processing 00000000.tx.22: The splicing reaction is carried out by the spliceosome, which consists of five small nuclear ribonucleoprotein complexes, or snRNPs, and as many as 50100 non-snRNP proteins (4,5). 

Phrase: "The splicing reaction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0443286:Reaction [Functional Concept]
   861   C1114821:Reaction [Clinical Attribute]

Phrase: "is"

Phrase: "carried"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:carried [Activity]
  1000   C0699809:carried [Finding]

Phrase: "out by the spliceosome,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0162771:spliceosome [Cell Component]
   770   C0439787:Out [Spatial Concept]
   770   C0849355:Out [Qualitative Concept]
   770   C2984264:Spliceosome [Functional Concept]

Phrase: "which"

Phrase: "consists of five small nuclear ribonucleoprotein complexes,"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   814   C0142661:Small Nuclear Ribonucleoprotein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   814   C1167162:small nuclear ribonucleoprotein [Cell Component]
   748   C0035544:Ribonucleoprotein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0205451:Five [Quantitative Concept]
   748   C0332529:CONSIST [Qualitative Concept]
   748   C0521447:Nuclear [Spatial Concept]
   748   C0700321:Small [Quantitative Concept]
   748   C1167298:ribonucleoprotein [Cell Component]
           Ribonucleoprotein complex
   748   C1704241:Complexes [Chemical Viewed Structurally]
   714 E C0439855:Complex [Qualitative Concept]

Phrase: "or"

Phrase: "snRNPs,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0142661:snrnps [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C0443929:snrnps [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "and as many as 50100 non-snRNP proteins"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C1515981:And [Idea or Concept]
   744   C1518422:Non [Functional Concept]

Phrase: "(4,"

Phrase: "5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.23: Spliceosome assembly also requires SR proteins, a family of sequence specific splicing factors that have one or two RNA-recognition motifs followed by an arginine/serine rich domain. 

Phrase: "Spliceosome assembly also"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1158740:Spliceosome Assembly [Cell Function]
   827   C1706853:Assembly [Activity]
   827   C1879748:Assembly [Manufactured Object]

Phrase: "requires"

Phrase: "SR proteins,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "a family of sequence specific splicing factors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0015576:Family [Family Group]
   748   C1704727:Family [Conceptual Entity]

Phrase: "that"

Phrase: "have"

Phrase: "one"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205447:One [Quantitative Concept]

Phrase: "or"

Phrase: "two RNA-recognition motifs"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   890   C1522002:RNA Recognition Motif [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   875   C3178797:RNA Motifs [Nucleotide Sequence]
   812   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0524637:Recognition [Mental Process]
   779   C1514562:Motif [Amino Acid Sequence]

Phrase: "followed by an arginine/serine rich domain."
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   778   C0332283:Followed by [Temporal Concept]
           followed
   748   C0003765:Arginine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   748   C0036720:Serine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   748   C0699759:Rich [Qualitative Concept]
   748   C1880389:Domain [Functional Concept]
   748   C1883221:Domain [Conceptual Entity]
   748   C3541951:Domain [Intellectual Product]
   714 E C1719822:Follow [Intellectual Product]
Processing 00000000.tx.24: Numerous SR proteins have been identified to date, and they have diverse roles in constitutive and alternative splicing (6). 

Phrase: "Numerous SR proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "have"

Phrase: "been"

Phrase: "identified to date,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0011008:Date [Temporal Concept]
   790   C0205396:Identified [Qualitative Concept]
   790   C1550043:Identified [Finding]
   790   C1551388:Identified [Functional Concept]
   790   C2348077:Date [Food]

Phrase: "and"

Phrase: "they"

Phrase: "have"

Phrase: "diverse roles in constitutive"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0035820:Roles [Social Behavior]
   737 E C1705810:Role [Conceptual Entity]

Phrase: "and"

Phrase: "alternative splicing"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0002345:Alternative Splicing [Genetic Function]
   861   C0035687:Splicing [Genetic Function]
   861   C2610186:splicing [Genetic Function]

Phrase: "(6"

Phrase: ")."
Processing 00000000.tx.25: Members of the heterogeneous nuclear ribonucleoprotein (hnRNP) factor family also play a role in splicing by promoting the use of distal 5' splice sites, which can affect both exon skipping as well as exon inclusion (7,8). 

Phrase: "Members of the heterogeneous nuclear ribonucleoprotein (hnRNP) factor family also"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   762   C0086282:Family Members [Family Group]
   745 E C1611821:Family Member [Intellectual Product]
   742   C0680022:members [Population Group]
   708 E C2698041:Member [Professional or Occupational Group]

Phrase: "play"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:play [Finding]

Phrase: "a role in splicing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]

Phrase: "by promoting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promoting [Activity]

Phrase: "the use of distal 5' splice sites,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   778   C1524063:Use of [Functional Concept]
   748   C0042153:use [Functional Concept]
   748   C0457083:Use [Functional Concept]
   748   C1947944:Use [Intellectual Product]

Phrase: "which"

Phrase: "can"

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "both exon skipping"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0560435:skipping [Finding]

Phrase: "as well as"

Phrase: "exon inclusion"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1512693:Inclusion [Qualitative Concept]

Phrase: "(7,"

Phrase: "8"

Phrase: ")."
Processing 00000000.tx.26: Several SRs and hnRNPs have been shown to modify the splicing pattern of human transcripts carrying splice mutations. 

Phrase: "Several SRs"

Phrase: "and"

Phrase: "hnRNPs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0123538:hnRNP [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "have"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "modify"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392747:MODIFY [Functional Concept]

Phrase: "the splicing pattern of human transcripts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0449774:Pattern [Spatial Concept]

Phrase: "carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206243:Carrying [Activity]
   966 E C0699809:carry [Finding]

Phrase: "splice mutations."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0026882:Mutations [Genetic Function]
   827 E C1705285:Mutation [Cell or Molecular Dysfunction]
Processing 00000000.tx.27: HnRNP A1 and ASF/SF2, and their adenoviral analogs E4-ORF6 and E4-ORF3, have been shown to modulate the splicing pattern of CFTR alleles that carry cystic fibrosis causing mutations (9). 

Phrase: "HnRNP A1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0950469:hnRNP A1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1415634:hnRNP-A1 [Gene or Genome]

Phrase: "and"

Phrase: "ASF/SF2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1419989:SF2 [Gene or Genome]

Phrase: "and"

Phrase: "their adenoviral analogs E4-ORF6"

Phrase: "and"

Phrase: "E4-ORF3,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1540210:Orf3 [Gene or Genome]

Phrase: "have"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "modulate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443264:modulate [Spatial Concept]

Phrase: "the splicing pattern of CFTR alleles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0449774:Pattern [Spatial Concept]

Phrase: "that"

Phrase: "carry"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:Carry [Activity]
  1000   C0699809:carry [Finding]

Phrase: "cystic fibrosis causing mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0026882:Mutations [Genetic Function]
   779 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(9"

Phrase: ")."
Processing 00000000.tx.28: Htra2-1, an SR-like splicing factor, dramatically enhanced the inclusion of exon 7 in SMN2 transcripts resulting in an increased amount of full-length protein (10). 

Phrase: "Htra2-1,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1825553:HTRA2 [Gene or Genome]

Phrase: "an SR-like splicing factor,"

Phrase: "dramatically"

Phrase: "enhanced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhanced [Activity]

Phrase: "the inclusion of exon 7"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1512693:Inclusion [Qualitative Concept]

Phrase: "in SMN2 transcripts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "resulting in an increased amount of full-length protein"
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   764   C0332294:Resulting in [Functional Concept]
   742   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   742   C0205217:Increased [Quantitative Concept]
   742   C0442805:Increased [Functional Concept]
   742   C0443225:Full [Qualitative Concept]
   742   C0678226:resulting [Functional Concept]
   742   C1265611:Amount [Quantitative Concept]
   742   C1444754:Length [Quantitative Concept]
   742   C1706316:LENGTH [Research Activity]
   708 E C1274040:Result [Functional Concept]
   708 E C1546471:Result [Idea or Concept]
   708 E C2825142:Result [Finding]

Phrase: "(10"

Phrase: ")."
Processing 00000000.tx.29: Further, it has been demonstrated that chemical compounds and drugs can also alter splicing. 

Phrase: "Further,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "it"

Phrase: "has"

Phrase: "been"

Phrase: "demonstrated"

Phrase: "that chemical compounds"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0220806:chemical compounds [Chemical]
   827   C0205198:Compound [Qualitative Concept]
   827   C1706082:Compound [Chemical]

Phrase: "and"

Phrase: "drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "can"

Phrase: "also"

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "splicing."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0035687:Splicing [Genetic Function]
  1000   C2610186:splicing [Genetic Function]
Processing 00000000.tx.30: Sodium butyrate, aclarubicin, sodium vanadate and valproic acid have all been shown to increase the amount of exon 7 containing SMN protein in spinal muscular atrophy (SMA) lymphoid cell lines, and treatment of SMA-like mice with sodium butyrate promoted increased expression of SMN protein in motor neurons and resulted in significant improvement of clinical symptoms (1115). 

Phrase: "Sodium butyrate,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0142812:Sodium Butyrate [Lipid,Pharmacologic Substance]
   861   C0006521:butyrate [Lipid]
   861   C0037473:Sodium [Biologically Active Substance,Element, Ion, or Isotope]
   861   C0220802:butyrate [Lipid]
   861   C0597484:Sodium+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "aclarubicin,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0001143:Aclarubicin [Antibiotic,Organic Chemical]
  1000   C0771002:Aclarubicin [Antibiotic,Organic Chemical]

Phrase: "sodium vanadate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0037568:Sodium Vanadate [Inorganic Chemical,Pharmacologic Substance]
   861   C0042305:Vanadate [Inorganic Chemical]

Phrase: "and"

Phrase: "valproic acid"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042291:Valproic Acid [Organic Chemical,Pharmacologic Substance]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "have"

Phrase: "all"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "the amount of exon 7 containing SMN protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1265611:Amount [Quantitative Concept]

Phrase: "in spinal muscular atrophy (SMA) lymphoid cell lines,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0007600:Cell lines [Cell]
   799   C0205132:lines [Spatial Concept]
   766 E C1550648:Line [Substance]
   766 E C1552960:Line [Quantitative Concept]

Phrase: "and"

Phrase: "treatment of SMA-"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "like mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]

Phrase: "with sodium butyrate"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0142812:Sodium Butyrate [Lipid,Pharmacologic Substance]
   861   C0006521:butyrate [Lipid]
   861   C0037473:Sodium [Biologically Active Substance,Element, Ion, or Isotope]
   861   C0220802:butyrate [Lipid]
   861   C0597484:Sodium+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "promoted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0033414:Promote [Activity]

Phrase: "increased expression of SMN protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   797   C1171362:expression protein [Genetic Function]
   760   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "in motor neurons"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0026609:Motor Neurons [Cell]
   861   C0027882:Neurons [Cell]
   861   C1513492:Motor [Functional Concept]
   861   C1705994:Motor [Manufactured Object]
   777 E C0521390:Neuronal [Immunologic Factor]

Phrase: "and"

Phrase: "resulted in significant improvement of clinical symptoms"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   748   C0205210:Clinical [Qualitative Concept]
   748   C0237881:significant [Quantitative Concept]
   748   C0683368:symptoms [Functional Concept]
   748   C0750502:Significant [Idea or Concept]
   748   C1457887:Symptoms [Sign or Symptom]
   748   C1546944:Significant [Qualitative Concept]
   748   C2986411:Improvement [Conceptual Entity]
   738   C2826293:Clinical Significance [Finding]
   714   C1274040:Result [Functional Concept]
   714   C1546471:Result [Idea or Concept]
   714   C2825142:Result [Finding]

Phrase: "(1115"

Phrase: ")."
Processing 00000000.tx.31: Familial dysautonomia (FD, RileyDay syndrome, hereditary sensory and autonomic neuropathy type III, MIM 223900) is a recessive disorder that has a remarkably high carrier frequency of 1 in 30 in the Ashkenazi Jewish population (16). 

Phrase: "Familial dysautonomia"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]

Phrase: "(FD,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]

Phrase: "RileyDay syndrome,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0039082:Syndrome [Disease or Syndrome]

Phrase: "hereditary sensory and autonomic neuropathy type III,"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
  1000   C0013364:Hereditary-Sensory and Autonomic Neuropathy Type III [Congenital Abnormality,Disease or Syndrome]
   913   C0027889:Hereditary sensory and autonomic neuropathy [Disease or Syndrome]
   868   C0699739:Sensory Neuropathy, Hereditary [Disease or Syndrome]
   861   C0598589:hereditary neuropathy [Disease or Syndrome]
   845   C0151313:Sensory neuropathy [Disease or Syndrome]
   818   C0259749:Autonomic neuropathy [Disease or Syndrome]
   818   C0441731:Type III [Classification]
   795   C0004388:Autonomic [Body System]
   795   C0332307:Type [Qualitative Concept]
   795   C0439070:III [Intellectual Product]
   795   C0439660:Hereditary [Functional Concept]
   795   C0442874:Neuropathy [Disease or Syndrome]
   795   C0445254:Sensory [Qualitative Concept]
   795   C1547052:*Type [Quantitative Concept]
   795   C1705160:III [Qualitative Concept]

Phrase: "MIM 223900"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1426941:MIM [Gene or Genome]

Phrase: ")"

Phrase: "is"

Phrase: "a recessive disorder"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012634:Disorder [Disease or Syndrome]

Phrase: "that"

Phrase: "has"

Phrase: "a remarkably high carrier frequency of 1"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C2986541:carrier frequency [Conceptual Entity]
   774   C0205212:High frequency [Temporal Concept]
   748   C0376249:frequency [Quantitative Concept]
   748   C0439603:Frequency [Temporal Concept]
   748   C0871396:Frequency [Quantitative Concept]
   748   C1561548:Frequency [Qualitative Concept]
   748   C1705502:Frequency [Quantitative Concept]

Phrase: "in 30"

Phrase: "in the Ashkenazi Jewish population"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0032659:Population [Quantitative Concept]
   827   C1257890:Population [Population Group]

Phrase: "(16"

Phrase: ")."
Processing 00000000.tx.32: The clinical spectrum of FD includes gastrointestinal dysfunction, abnormal respiratory responses to hypoxic and hypercarbic states, gastroesophageal reflux, vomiting crises, lack of overflow tears, profuse sweating and postural hypotension (17). 

Phrase: "The clinical spectrum of FD"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1883073:Spectrum [Quantitative Concept]
   753   C2827424:Spectrum [Conceptual Entity]

Phrase: "includes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:Includes [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "gastrointestinal dysfunction,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0679407:gastrointestinal dysfunction [Disease or Syndrome]
   861   C0031847:dysfunction [Functional Concept]
   861   C0277785:Dysfunction, NOS [Qualitative Concept]
   805 E C0231174:Malfunction [Functional Concept]
   805 E C1881681:MALFUNCTION [Phenomenon or Process]

Phrase: "abnormal respiratory responses to hypoxic"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   760   C0871261:responses [Organism Attribute]
   726 E C1704632:Response [Finding]
   726 E C1706817:Response [Intellectual Product]
   726 E C2911692:Response [Mental Process]

Phrase: "and"

Phrase: "hypercarbic states,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C1301808:states [Geographic Area]
   827 E C1442792:State [Functional Concept]
   827 E C3148680:State [Geographic Area]

Phrase: "gastroesophageal reflux,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0017168:Gastro-Esophageal Reflux [Disease or Syndrome]
           reflux
   861   C0232483:Reflux [Pathologic Function]
   861   C0744316:Gastroesophageal [Body Location or Region]
   861   C1882919:REFLUX [Phenomenon or Process]

Phrase: "vomiting"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0042963:Vomiting [Sign or Symptom]
  1000   C1963281:Vomiting [Finding]
   966 E C0042965:Vomit [Body Substance]

Phrase: "crises,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231224:crises [Finding]

Phrase: "lack of overflow tears,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0332268:lack [Qualitative Concept]

Phrase: "profuse sweating"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0700590:Profuse sweating [Sign or Symptom]
   861   C0038990:Sweating [Finding]
   827 E C0038984:Sweat [Body Substance]

Phrase: "and"

Phrase: "postural hypotension"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0020651:Hypotension, Postural [Finding]
   861   C0020649:Hypotension [Finding]
   861   C0205278:Postural [Functional Concept]
   861   C3163620:Hypotension [Pathologic Function]
   789 E C1262869:Posture [Organism Attribute]

Phrase: "(17"

Phrase: ")."
Processing 00000000.tx.33: Three FD mutations have been identified in the I--B kinase (IKK) complex-associated protein (IKBKAP), IVS20+6TC, which leads to variable, tissue-specific skipping of exon 20 (Fig.1A), R696P and P914L (1820). 

Phrase: "Three FD mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0026882:Mutations [Genetic Function]
   779 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "have"

Phrase: "been"

Phrase: "identified in the I--B kinase"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0021966:I- [Inorganic Chemical]
   753   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0205396:Identified [Qualitative Concept]
   753   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C1550043:Identified [Finding]
   753   C1551388:Identified [Functional Concept]

Phrase: "(IKK"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0663914:IKK [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1150571:IKK [Molecular Function]

Phrase: ")"

Phrase: "complex-associated protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   913   C1180347:complex protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(IKBKAP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416379:IKBKAP [Gene or Genome]

Phrase: ")"

Phrase: ","

Phrase: "IVS20+6TC,"

Phrase: "which"

Phrase: "leads to variable,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   790   C0181586:leads [Medical Device]
   790   C0439828:Variable [Qualitative Concept]
   790   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   790   C1522538:Lead [Functional Concept]
   790   C2348269:Lead [Element, Ion, or Isotope]
   790   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "tissue-specific skipping of exon 20"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0560435:skipping [Finding]

Phrase: "(Fig.1A"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450344:1A [Intellectual Product]
   861   C1553633:1a [Medical Device]

Phrase: ")"

Phrase: ","

Phrase: "R696P"

Phrase: "and"

Phrase: "P914L"

Phrase: "(1820"

Phrase: ")."
Processing 00000000.tx.34: All FD patients tested to date carry at least one IVS20+6TC mutation, with more than 99.5% being homozygous, and the remainder being heterozygous with either R696P or P914L on the alternate allele. 

Phrase: "All FD patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]

Phrase: "tested to date"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   841   C2826247:Test Date [Temporal Concept]
   790   C0011008:Date [Temporal Concept]
   790   C0392366:tested [Intellectual Product]
   790   C2348077:Date [Food]
   756 E C0022885:Test [Laboratory Procedure]
   756 E C0039593:Test [Functional Concept]

Phrase: "carry at least one IVS20+6TC mutation,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0026882:Mutation [Genetic Function]
   748   C0205447:One [Quantitative Concept]
   748   C0206243:Carry [Activity]
   748   C0699809:carry [Finding]
   748   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "with more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "than 99.5%"

Phrase: "being"

Phrase: "homozygous,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0019904:Homozygous [Organism Attribute]

Phrase: "and"

Phrase: "the remainder"

Phrase: "being"

Phrase: "heterozygous with either R696P"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0019425:Heterozygous [Organism Attribute]

Phrase: "or"

Phrase: "P914L on the alternate allele."
Processing 00000000.tx.35: This suggests that production of wild-type IKAP from the mutant allele is required for viability, and that the tissue-specific variability of IKAP results in the distinctive FD phenotype. 

Phrase: "This"

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that production of wild-type IKAP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0033268:production [Occupational Activity]

Phrase: "from the mutant allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0002085:Allele [Gene or Genome]

Phrase: "is"

Phrase: "required for viability,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0443348:viability [Qualitative Concept]
   790   C1514873:Required [Functional Concept]

Phrase: "and"

Phrase: "that"

Phrase: "the tissue-specific variability of IKAP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C2827666:Variability [Conceptual Entity]

Phrase: "results in the distinctive FD phenotype."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   778   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   748   C0013363:Dysautonomia [Disease or Syndrome]
   748   C0015576:familial [Family Group]
   748   C0031437:Phenotype [Organism Attribute]
   748   C0241888:Familial [Functional Concept]
   748   C1145628:dysautonomia [Disease or Syndrome]
   748   C1274040:Result [Functional Concept]
   748   C1285572:Phenotype [Laboratory Procedure]
   748   C1546471:Result [Idea or Concept]
   748   C2825142:Result [Finding]
Processing 00000000.tx.36: IKAP has been reported to be both a member of the Elongator complex (21), which plays a role in transcriptional elongation, and a c-Jun N-terminal kinase (JNK)-associated protein (22), which is involved in the mammalian stress response. 

Phrase: "IKAP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416379:IKAP [Gene or Genome]

Phrase: "has"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "both a member of the Elongator complex"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0680022:member [Population Group]
   748   C2698041:Member [Professional or Occupational Group]

Phrase: "(21"

Phrase: ")"

Phrase: ","

Phrase: "which"

Phrase: "plays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:Plays [Finding]

Phrase: "a role in transcriptional elongation,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0035820:Role [Social Behavior]
   760   C1705810:Role [Conceptual Entity]

Phrase: "and"

Phrase: "a c-Jun N-terminal kinase"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1367731:JUN N-terminal kinase [Gene or Genome]
   858   C0872053:JUN kinase [Amino Acid, Peptide, or Protein,Enzyme]
   858   C1334482:Jun kinase [Gene or Genome]
   858   C1367019:Jun Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(JNK)-associated protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(22"

Phrase: ")"

Phrase: ","

Phrase: "which"

Phrase: "is"

Phrase: "involved in the mammalian stress response."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0149784:stress response [Physiologic Function]
   753   C0024660:Mammalian [Mammal]
   753   C0038435:Stress [Finding]
   753   C0871261:Response [Organism Attribute]
   753   C1314939:Involved [Functional Concept]
   753   C1704632:Response [Finding]
   753   C1706817:Response [Intellectual Product]
   753   C2911692:Response [Mental Process]
Processing 00000000.tx.37: We have reported previously that all FD tissues tested express both wild-type (WT) and mutant (MU) IKBKAP mRNA (20,23). 

Phrase: "We"

Phrase: "have"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "previously"

Phrase: "that"

Phrase: "all FD tissues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0040300:Tissues [Tissue]
   793 E C1547928:Tissue [Intellectual Product]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]

Phrase: "tested"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]

Phrase: "express"

Phrase: "both wild-type (WT)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "mutant (MU) IKBKAP mRNA (20,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0596988:Mutant [Cell or Molecular Dysfunction]
   812   C1416379:IKBKAP [Gene or Genome]

Phrase: "23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.38: Accurate measurement of the ratio of the two mRNA species using both densitometry and real-time quantitative PCR has revealed that the levels of WT IKBKAP mRNA vary between tissues and are lowest in central and peripheral nervous systems (23). 

Phrase: "Accurate measurement of the ratio of the two mRNA species"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C1261161:Ratio measurement [Laboratory Procedure]
   739   C0242485:Measurement [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "both densitometry"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0011321:Densitometry [Laboratory Procedure]

Phrase: "and"

Phrase: "real-time quantitative PCR"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   923   C1709846:Real-Time PCR [Molecular Biology Research Technique]
   812   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   812   C0677874:pCR [Finding]

Phrase: "has"

Phrase: "revealed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:Revealed [Qualitative Concept]

Phrase: "that"

Phrase: "the levels of WT IKBKAP mRNA"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   748   C0441889:Levels [Qualitative Concept]
   714 E C0456079:Level [Classification]
   714 E C1547707:Level [Geographic Area]
   714 E C2946261:Level [Pharmacologic Substance]

Phrase: "vary between tissues"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0040300:Tissues [Tissue]
   756 E C1547928:Tissue [Intellectual Product]

Phrase: "and"

Phrase: "are"

Phrase: "lowest in central"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   790   C1708760:Lowest [Qualitative Concept]
   756 E C0205251:low [Qualitative Concept]
   756 E C1299352:Low [Qualitative Concept]
   756 E C1550472:low [Idea or Concept]

Phrase: "and"

Phrase: "peripheral nervous systems"
Meta Candidates (Total=19; Excluded=9; Pruned=0; Remaining=10)
  1000   C0206417:Systems, Peripheral Nervous [Body System]
   901   C0027763:Systems, Nervous [Body System]
   867 E C0422837:NERVOUS SYSTEM [Finding]
   867 E C1269560:Nervous system [Body System]
   843   C0031119:Peripheral Nerves [Body Part, Organ, or Organ Component]
   843   C1280200:Peripheral nerve [Body Part, Organ, or Organ Component]
   829 E C0205494:Neurologic [Qualitative Concept]
   827   C0027769:Nervous [Sign or Symptom]
   827   C0205100:Peripheral [Spatial Concept]
   827   C0599851:Nervous [Functional Concept]
   801 E C0027855:Neurology [Biomedical Occupation or Discipline]
   793   C0449913:System [Functional Concept]
   793   C1553451:System [Manufactured Object]
   793   C1704459:System [Medical Device]
   785 E C2707261:Neurological [Clinical Attribute]
   743 E C0205373:Systemic [Functional Concept]
   711 E C0027740:Nerve [Tissue]
   711 E C0027757:NERVE [Tissue]
   711 E C1280541:Nerve [Body Part, Organ, or Organ Component]

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.39: This leads to a drastic reduction in the amount of IKAP protein in these tissues. 

Phrase: "This"

Phrase: "leads to a drastic reduction"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0181586:leads [Medical Device]
   760   C0301630:Reduction [Natural Phenomenon or Process]
   760   C0392756:Reduction [Qualitative Concept]
   760   C0441610:Reduction [Therapeutic or Preventive Procedure]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "in the amount"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1265611:Amount [Quantitative Concept]

Phrase: "of IKAP protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "in these tissues."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040300:Tissues [Tissue]
   966 E C1547928:Tissue [Intellectual Product]
Processing 00000000.tx.40: Our observations suggest that the relative inefficiency of WT IKBKAP mRNA production from the mutant alleles in the nervous system underlies the selective degeneration of sensory and autonomic neurons in FD. 

Phrase: "Our observations"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0302523:observations [Research Activity]
  1000   C0700325:observations [Health Care Activity]
  1000   C3244290:observations [Functional Concept]
   966 E C1964257:Observation [Diagnostic Procedure]
   916 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the relative inefficiency of WT IKBKAP mRNA production"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0231184:Inefficiency [Finding]

Phrase: "from the mutant alleles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0002085:Alleles [Gene or Genome]

Phrase: "in the nervous system"
Meta Candidates (Total=15; Excluded=7; Pruned=0; Remaining=8)
  1000   C0027763:Nervous System [Body System]
  1000   C0422837:NERVOUS SYSTEM [Finding]
  1000   C1269560:Nervous system [Body System]
   944 E C0205494:Neurologic [Qualitative Concept]
   907 E C0027855:Neurology [Biomedical Occupation or Discipline]
   888 E C2707261:Neurological [Clinical Attribute]
   861   C0027769:Nervous [Sign or Symptom]
   861   C0449913:System [Functional Concept]
   861   C0599851:Nervous [Functional Concept]
   861   C1553451:System [Manufactured Object]
   861   C1704459:System [Medical Device]
   789 E C0205373:Systemic [Functional Concept]
   745 E C0027740:Nerve [Tissue]
   745 E C0027757:NERVE [Tissue]
   745 E C1280541:Nerve [Body Part, Organ, or Organ Component]

Phrase: "underlies"

Phrase: "the selective degeneration of sensory"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0011164:Degeneration [Pathologic Function]
   760   C1880269:Degeneration [Functional Concept]

Phrase: "and"

Phrase: "autonomic neurons in FD."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0206250:autonomic neuron [Body Part, Organ, or Organ Component]
   790   C0682693:Autonomic neuron [Cell]
   760   C0027882:Neurons [Cell]
Processing 00000000.tx.41: Given that neuronal degeneration continues throughout life in FD patients, a promising route toward effective therapies may come from enhancement of correct mRNA splicing in order to increase cellular levels of IKAP. 

Phrase: "Given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "that neuronal degeneration"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   964   C0027746:Neuron Degeneration [Cell or Molecular Dysfunction]
   861   C0011164:Degeneration [Pathologic Function]
   861   C1880269:Degeneration [Functional Concept]

Phrase: "continues throughout life"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0376558:Life [Idea or Concept]
   790   C0549178:Continue [Idea or Concept]
   706 E C0595998:lives [Finding]

Phrase: "in FD patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]

Phrase: "a promising route toward effective therapies"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0013153:ROUTE [Functional Concept]
   753   C0449444:Route [Spatial Concept]
   753   C1879941:ROUTE [Intellectual Product]

Phrase: "may"

Phrase: "come from enhancement of correct mRNA splicing"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0086934:mRNA splicing [Genetic Function]
   748   C0035687:Splicing [Genetic Function]
   748   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   748   C1627358:Enhancement [Therapeutic or Preventive Procedure]
   748   C2349182:Correct [Qualitative Concept]
   748   C2349975:Enhancement [Activity]
   748   C2610186:splicing [Genetic Function]

Phrase: "in order to"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C1705175:Order [Intellectual Product]
   861   C1705176:Order [Qualitative Concept]
   861   C1705177:Order [Classification]
   861   C1705178:Order [Activity]
   861   C1882348:Order [Qualitative Concept]

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "cellular levels of IKAP."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   770   C0441889:Levels [Qualitative Concept]
   737 E C0456079:Level [Classification]
   737 E C1547707:Level [Geographic Area]
   737 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.42: View larger version (34K): [in this window] [in a new window]  Figure 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(34K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 1."
Processing 00000000.tx.43: Kinetin significantly increases production of wild-type IKBKAP transcript in FD cells. 

Phrase: "Kinetin significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "production of wild-type IKBKAP transcript"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0033268:production [Occupational Activity]

Phrase: "in FD cells."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
Processing 00000000.tx.44: (A) Schematic diagram illustrating the location of the IVS20+6TC mutation in IKBKAP and the two IKBKAP isoforms produced from this allele in FD patients. 

Phrase: "(A) Schematic diagram"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0681494:Diagram [Intellectual Product]

Phrase: "illustrating"

Phrase: "the location of the IVS20+6TC mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0450429:Location [Spatial Concept]
   748   C1515974:Location [Body Location or Region]

Phrase: "in IKBKAP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416379:IKBKAP [Gene or Genome]

Phrase: "and"

Phrase: "the two IKBKAP isoforms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0597298:Isoforms [Amino Acid, Peptide, or Protein]

Phrase: "produced from this allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0002085:Allele [Gene or Genome]

Phrase: "in FD patients."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
Processing 00000000.tx.45: (B) Chemical structures of the cytokinins tested in this study: kinetin (6-furfurylaminopurine), benzyladenine (6-benzylaminopurine), 2iP (6-(,-dimethyallylamino)purine) and zeatin (6-(4-hydroxy-3-methylbut-2-enylamino)purine). 

Phrase: "(B) Chemical structures of the cytokinins"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   756   C0220807:Chemical Structure [Intellectual Product]
   753   C0220806:Chemical [Chemical]
   753   C0678594:structures [Spatial Concept]
   753   C3272558:Chemical [Intellectual Product]

Phrase: "tested in this study"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0392366:tested [Intellectual Product]
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]
   737 E C0022885:Test [Laboratory Procedure]
   737 E C0039593:Test [Functional Concept]

Phrase: ":"

Phrase: "kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "(6-furfurylaminopurine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:6-Furfurylaminopurine [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: ")"

Phrase: ","

Phrase: "benzyladenine"

Phrase: "(6-benzylaminopurine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0067833:6-benzylaminopurine [Nucleic Acid, Nucleoside, or Nucleotide]
   861   C1433730:benzylaminopurine [Organic Chemical]

Phrase: ")"

Phrase: ","

Phrase: "2iP"

Phrase: "(6-"

Phrase: "(,-"

Phrase: "dimethyallylamino"

Phrase: ")"

Phrase: "purine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034140:Purine [Organic Chemical]
  1000   C0220903:purine [Organic Chemical]

Phrase: ")"

Phrase: "and"

Phrase: "zeatin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043456:Zeatin [Biologically Active Substance,Organic Chemical]

Phrase: "(6-"

Phrase: "(4-hydroxy-3-methylbut-2-enylamino"

Phrase: ")"

Phrase: "purine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034140:Purine [Organic Chemical]
  1000   C0220903:purine [Organic Chemical]

Phrase: ")."
Processing 00000000.tx.46: (C) RTPCR analysis of two independent FD lymphoblast cell lines, tested in triplicate, following treatment with 10M kinetin in 0.1% DMSO or DMSO alone for 72h. 

Phrase: "(C) RTPCR analysis of two independent FD lymphoblast cell lines,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   738   C0002778:Analysis [Laboratory Procedure]
   738   C0599161:RT-PCR [Molecular Biology Research Technique]
   738   C0936012:Analysis [Research Activity]
   738   C1524024:analysis [Functional Concept]

Phrase: "tested in triplicate,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0205174:Triplicate [Quantitative Concept]
   790   C0392366:tested [Intellectual Product]
   756 E C0022885:Test [Laboratory Procedure]
   756 E C0039593:Test [Functional Concept]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "treatment with 10M kinetin"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "in 0.1% DMSO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]

Phrase: "or"

Phrase: "DMSO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]

Phrase: "alone for 72h."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0205171:Alone [Quantitative Concept]
   790   C0439044:alone [Finding]
   790   C0679994:alone [Group Attribute]
Processing 00000000.tx.47: Previous experiments demonstrated that DMSO has no effect on IKBKAP splicing. 

Phrase: "Previous experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "demonstrated"

Phrase: "that DMSO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]

Phrase: "has"

Phrase: "no effect on IKBKAP splicing."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C1301751:No effect [Qualitative Concept]
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.48: WT:MU ratios were determined using the integrated density value (IDV) obtained for each band and are shown beneath each lane. 

Phrase: "WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "MU ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0456603:Ratios [Quantitative Concept]
   861   C1610540:*Ratios [Quantitative Concept]
   827 E C1547037:Ratio [Intellectual Product]

Phrase: "were"

Phrase: "determined"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the integrated density value (IDV)"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   827   C0178587:density [Quantitative Concept]
   827   C1522609:Value [Quantitative Concept]
   755 E C0439794:Dense [Qualitative Concept]
   755   C1158478:Integration [Genetic Function]
   755   C1705422:Integration [Machine Activity]

Phrase: "obtained for each band"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0175723:Band [Medical Device]
   770   C0439645:Band [Spatial Concept]
   770   C1301820:Obtained [Functional Concept]
   770   C1521913:band [Cell Component]
   737 E C1706701:Obtain [Activity]

Phrase: "and"

Phrase: "are"

Phrase: "shown beneath each lane."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1708639:Lane [Spatial Concept]
   737   C1547282:Show [Intellectual Product]
Processing 00000000.tx.49: The sizes of the WT (including exon 20) and MU (excluding exon 20) PCR products are indicated on the right. 

Phrase: "The sizes of the WT"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0456389:SIZES [Spatial Concept]

Phrase: "("

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "exon 20"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ")"

Phrase: "and"

Phrase: "MU"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "(excluding exon 20"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   793   C0332196:Exclude [Functional Concept]
   793   C2828389:Exclude [Activity]

Phrase: ")"

Phrase: "PCR products"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1514468:Products [Entity]
   827 E C1704444:Product [Quantitative Concept]

Phrase: "are"

Phrase: "indicated on the right."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205090:Right [Spatial Concept]
   770   C1444656:Indicated [Finding]
Processing 00000000.tx.50: Primer sequences and PCR conditions have been previously described (23).  

Phrase: "Primer sequences"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   861   C0162326:Sequences [Nucleotide Sequence]
   827 E C0004793:Sequence [Nucleotide Sequence]
   827 E C0162327:Sequence [Nucleotide Sequence]
   827 E C1519249:Sequence [Functional Concept]
   777 E C1548958:Sequential [Idea or Concept]
   777 E C1705294:Sequential [Qualitative Concept]

Phrase: "and"

Phrase: "PCR conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]

Phrase: "have"

Phrase: "been"

Phrase: "previously"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.51: To this end, we devised an assay that provides stable and consistent measurement of the ratio of WT:MU FD IKBKAP mRNA splice products in lymphoblast cell-lines (23). 

Phrase: "To this end,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0444930:End [Spatial Concept]
  1000   C2746065:End [Temporal Concept]
   944 E C0205088:Terminal [Temporal Concept]
   944 E C1705314:Terminal [Manufactured Object]
   944 E C1705315:Terminal [Spatial Concept]

Phrase: "we"

Phrase: "devised"

Phrase: "an assay"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005507:Assay [Laboratory Procedure]
  1000   C0243073:assay [Qualitative Concept]
  1000   C1510438:Assay [Laboratory Procedure]

Phrase: "that"

Phrase: "provides"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0359589:provides [Food]
  1000   C1999230:Provide [Activity]

Phrase: "stable"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205360:Stable [Qualitative Concept]
  1000   C1547311:Stable [Intellectual Product]

Phrase: "and"

Phrase: "consistent measurement of the ratio of WT"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C1261161:Ratio measurement [Laboratory Procedure]
   766   C0237536:consistency of measurement [Qualitative Concept]
   744   C0242485:Measurement [Functional Concept]

Phrase: ":"

Phrase: "MU FD IKBKAP mRNA splice products in lymphoblast cell-lines"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   738   C1514468:Products [Entity]
   704 E C1704444:Product [Quantitative Concept]

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.52: This assay was employed as part of the Neurodegeneration Drug Screening Consortium (24) to identify compounds that increase the relative production of WT mRNA. 

Phrase: "This assay"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005507:Assay [Laboratory Procedure]
  1000   C0243073:assay [Qualitative Concept]
  1000   C1510438:Assay [Laboratory Procedure]

Phrase: "was"

Phrase: "employed as part of the Neurodegeneration Drug Screening Consortium"
Meta Candidates (Total=20; Excluded=4; Pruned=0; Remaining=16)
   764   C0013206:Drug Screening [Research Activity]
   764   C0373483:drug screening [Laboratory Procedure]
   764   C1292711:Part of [Spatial Concept]
   748 E C0038577:Drug Screen [Laboratory Procedure]
   742   C0013227:Drug [Pharmacologic Substance]
   742   C0027746:Neurodegeneration [Cell or Molecular Dysfunction]
   742   C0220908:Screening [Health Care Activity]
   742   C0220909:screening [Functional Concept]
   742   C0449719:Part [Spatial Concept]
   742   C0557351:Employed [Finding]
   742   C1254351:Drug [Pharmacologic Substance]
   742   C1513822:Consortium [Professional or Occupational Group]
   742   C1698960:screening [Intellectual Product]
   742   C1709471:Part [Quantitative Concept]
   742   C1710031:Screening [Diagnostic Procedure]
   742   C1710477:SCREENING [Research Activity]
   742   C1880171:Consortium [Professional or Occupational Group]
   708 E C0457083:Employ [Functional Concept]
   708 E C1305399:screen [Functional Concept]
   708 E C1705053:Screen [Medical Device]

Phrase: "(24"

Phrase: ")"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "identify"

Phrase: "compounds"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0205198:Compound [Qualitative Concept]
   966   C1706082:Compound [Chemical]

Phrase: "that"

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "the relative production of WT mRNA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0033268:production [Occupational Activity]
Processing 00000000.tx.53: Here we report that kinetin, a plant cytokinin, dramatically increases the amount of wild-type IKBKAP mRNA in FD cell lines. 

Phrase: "Here"

Phrase: "we"

Phrase: "report"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0684224:Report [Intellectual Product]
  1000   C0700287:Report [Health Care Activity]
  1000   C3273238:Report [Intellectual Product]

Phrase: "that kinetin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "a plant cytokinin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0010815:cytokinin [Biologically Active Substance]

Phrase: "dramatically"

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "the amount of wild-type IKBKAP mRNA"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   774   C1550420:Amount type [Classification]
   748   C1265611:Amount [Quantitative Concept]

Phrase: "in FD cell lines."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   861   C0007600:Cell lines [Cell]
   812   C0007634:Cell [Cell]
   812   C0205132:lines [Spatial Concept]
   812   C1269647:Cell [Cell]
   812   C1704653:Cell [Medical Device]
   812   C1948049:Cell [Spatial Concept]
   779 E C1550648:Line [Substance]
   779 E C1552960:Line [Quantitative Concept]
Processing 00000000.tx.54: Further, we show that this leads to a significant increase in the amount of IKAP protein and suggest that kinetin, an FDA approved drug, should be tested as a possible treatment for FD.  

Phrase: "Further,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "we"

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "that"

Phrase: "this"

Phrase: "leads to a significant increase"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0181586:leads [Medical Device]
   760   C0237881:significant [Quantitative Concept]
   760   C0442805:Increase [Functional Concept]
   760   C0750502:Significant [Idea or Concept]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C1546944:Significant [Qualitative Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "in the amount"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1265611:Amount [Quantitative Concept]

Phrase: "of IKAP protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that kinetin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "an FDA"
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
  1000   C0041714:Food and Drug Administration [Health Care Related Organization]
           food drug administration
   861   C0150270:Drug administration [Health Care Activity]
   861   C3469597:Drug administration [Health Care Activity]
   812   C0001554:Administration [Occupational Activity]
   812   C0013227:Drug [Pharmacologic Substance]
   812   C0016452:Food [Food]
   812   C1254351:Drug [Pharmacologic Substance]
   812   C1533734:Administration [Therapeutic or Preventive Procedure]
   756 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   756 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   719 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "approved"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205540:Approved [Qualitative Concept]

Phrase: "drug,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0013227:Drug [Pharmacologic Substance]
  1000   C1254351:Drug [Pharmacologic Substance]
   944 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   944 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   907 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "should"

Phrase: "be"

Phrase: "tested as a possible treatment"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0332149:Possible [Qualitative Concept]
   760   C0392366:tested [Intellectual Product]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C1705910:Possible [Qualitative Concept]
   760   C2362652:Possible [Qualitative Concept]
   760   C3538994:TREATMENT [Research Activity]
   726 E C0022885:Test [Laboratory Procedure]
   726 E C0039593:Test [Functional Concept]

Phrase: "for FD."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]
Processing 00000000.tx.55: RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  The initial screen was carried out using a single, standard FD lymphoblast cell line that was assayed after 72h in the presence of 10M test drug, using compounds dissolved in DMSO. 

Phrase: "RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The initial screen"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0220908:screen [Health Care Activity]
   861   C1305399:screen [Functional Concept]
   861   C1705053:Screen [Medical Device]

Phrase: "was"

Phrase: "carried"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:carried [Activity]
  1000   C0699809:carried [Finding]

Phrase: "out"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439787:Out [Spatial Concept]
  1000   C0849355:Out [Qualitative Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a single, standard FD lymphoblast cell line"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   818   C0007600:Cell Line [Cell]
   795   C0007634:Cell [Cell]
   795   C0205132:Line [Spatial Concept]
   795   C1269647:Cell [Cell]
   795   C1550648:Line [Substance]
   795   C1552960:Line [Quantitative Concept]
   795   C1704653:Cell [Medical Device]
   795   C1948049:Cell [Spatial Concept]

Phrase: "that"

Phrase: "was"

Phrase: "assayed after 72h"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C1292423:72H [Temporal Concept]
   756   C0005507:Assay [Laboratory Procedure]
   756   C0243073:assay [Qualitative Concept]
   756   C1510438:Assay [Laboratory Procedure]

Phrase: "in the presence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392148:Presence [Therapeutic or Preventive Procedure]
   928 E C0150312:Present [Quantitative Concept]
   928 E C0449450:Present [Idea or Concept]

Phrase: "of 10M test drug,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   901   C0038577:test drug [Laboratory Procedure]
   827   C0013227:Drug [Pharmacologic Substance]
   827   C1254351:Drug [Pharmacologic Substance]
   771 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   771 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   734 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "compounds"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0205198:Compound [Qualitative Concept]
   966   C1706082:Compound [Chemical]

Phrase: "dissolved in DMSO."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]
   756   C1549535:Dissolve [Functional Concept]
Processing 00000000.tx.56: The major FD splicing mutation results in production of a mutant IKBKAP mRNA that is missing exon 20 (Fig.1A). 

Phrase: "The major FD"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   901   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   827   C0013363:Dysautonomia [Disease or Syndrome]
   827   C0015576:familial [Family Group]
   827   C0241888:Familial [Functional Concept]
   827   C1145628:dysautonomia [Disease or Syndrome]
   755 E C1704727:Family [Conceptual Entity]

Phrase: "splicing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0035687:Splicing [Genetic Function]
  1000   C2610186:splicing [Genetic Function]

Phrase: "mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0026882:Mutation [Genetic Function]
  1000   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "results in production of a mutant IKBKAP mRNA"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   744   C0033268:production [Occupational Activity]
   744   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   744   C0596988:Mutant [Cell or Molecular Dysfunction]
   744   C1274040:Result [Functional Concept]
   744   C1416379:IKBKAP [Gene or Genome]
   744   C1546471:Result [Idea or Concept]
   744   C2825142:Result [Finding]

Phrase: "that"

Phrase: "is"

Phrase: "missing"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1551393:Missing [Idea or Concept]
  1000   C1705492:Missing [Qualitative Concept]
  1000   C3272743:MISSING [Qualitative Concept]
   966 E C2349206:Miss [Conceptual Entity]

Phrase: "exon 20"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(Fig.1A"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450344:1A [Intellectual Product]
   861   C1553633:1a [Medical Device]

Phrase: ")."
Processing 00000000.tx.57: We screened a panel of 1040 bioactive compounds (NINDS Custom Collection, MicroSource Discovery Systems), most of which have been approved for use by the Food and Drug Administration (FDA). 

Phrase: "We"

Phrase: "screened"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0220908:screen [Health Care Activity]
   966   C1305399:screen [Functional Concept]
   966   C1705053:Screen [Medical Device]

Phrase: "a panel of 1040 bioactive compounds"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0441833:Panel [Idea or Concept]
   753   C1999270:Panel [Intellectual Product]
   753   C3537156:Panel [Manufactured Object]

Phrase: "(NINDS Custom Collection,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C1516698:Collection [Functional Concept]
   827   C1704814:Collection [Idea or Concept]
   755 E C1516695:Collected [Idea or Concept]

Phrase: "MicroSource Discovery Systems"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   793   C0449913:System [Functional Concept]
   793   C1553451:System [Manufactured Object]
   793   C1704459:System [Medical Device]
   743 E C0205373:Systemic [Functional Concept]

Phrase: ")"

Phrase: ","

Phrase: "most of which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205393:Most [Quantitative Concept]

Phrase: "have"

Phrase: "been"

Phrase: "approved for use"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0042153:use [Functional Concept]
   790   C0205540:Approved [Qualitative Concept]
   790   C0457083:Use [Functional Concept]
   790   C1947944:Use [Intellectual Product]

Phrase: "by the Food and Drug Administration (FDA)."
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
  1000   C0041714:Food and Drug Administration [Health Care Related Organization]
           food drug administration
   861   C0150270:Drug administration [Health Care Activity]
   861   C3469597:Drug administration [Health Care Activity]
   812   C0001554:Administration [Occupational Activity]
   812   C0013227:Drug [Pharmacologic Substance]
   812   C0016452:Food [Food]
   812   C1254351:Drug [Pharmacologic Substance]
   812   C1533734:Administration [Therapeutic or Preventive Procedure]
   756 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   756 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   719 E C0456386:Medicament [Pharmacologic Substance]
Processing 00000000.tx.58: Prior to initiating the screen, we confirmed that DMSO had no effect on IKBKAP splicing and was not toxic to the cells at the test concentration of 0.1%. 

Phrase: "Prior to initiating"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1548602:Initiate [Idea or Concept]
   966   C1704686:Initiate [Functional Concept]

Phrase: "the screen,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0220908:screen [Health Care Activity]
  1000   C1305399:screen [Functional Concept]
  1000   C1705053:Screen [Medical Device]

Phrase: "we"

Phrase: "confirmed"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0521093:confirmed [Qualitative Concept]
  1000   C0750484:Confirmed [Idea or Concept]
   966 E C1456348:Confirm [Qualitative Concept]

Phrase: "that DMSO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]

Phrase: "had"

Phrase: "no effect on IKBKAP splicing"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C1301751:No effect [Qualitative Concept]
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "and"

Phrase: "was"

Phrase: "not toxic to the cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0600688:toxic [Injury or Poisoning]
   760   C1407029:Toxic [Qualitative Concept]

Phrase: "at the test concentration"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0086045:Concentration [Mental Process]
   861   C1446561:Concentration [Quantitative Concept]
   789 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "of 0.1%."
Processing 00000000.tx.59: One compound, kinetin (6-furfurylaminopurine) (Fig.1B), dramatically enhanced correct splicing in FD cells at the test concentration of 10M (Fig.1C). 

Phrase: "One compound,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205198:Compound [Qualitative Concept]
   861   C1706082:Compound [Chemical]

Phrase: "kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "(6-furfurylaminopurine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:6-Furfurylaminopurine [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: ")"

Phrase: "(Fig.1B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450345:1B [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "dramatically"

Phrase: "enhanced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhanced [Activity]

Phrase: "correct splicing in FD cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035687:Splicing [Genetic Function]
   753   C2610186:splicing [Genetic Function]

Phrase: "at the test concentration"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0086045:Concentration [Mental Process]
   861   C1446561:Concentration [Quantitative Concept]
   789 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "of 10M"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1442446:10M [Temporal Concept]

Phrase: "(Fig.1C"

Phrase: ")."
Processing 00000000.tx.60: We next tested concentrations of kinetin up to 100M and observed significant enhancement of WT IKBKAP production with increasing concentration in two independent FD lymphoblast lines (Fig.2A). 

Phrase: "We next tested concentrations of kinetin"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0086045:Concentrations [Mental Process]
   719 E C1446561:Concentration [Quantitative Concept]

Phrase: "up to 100M"

Phrase: "and"

Phrase: "observed significant enhancement of WT IKBKAP production"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1627358:Enhancement [Therapeutic or Preventive Procedure]
   744   C2349975:Enhancement [Activity]

Phrase: "with increasing concentration"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0086045:Concentration [Mental Process]
   861   C1446561:Concentration [Quantitative Concept]
   789 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "in two independent FD lymphoblast lines"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   799   C0205132:lines [Spatial Concept]
   766 E C1550648:Line [Substance]
   766 E C1552960:Line [Quantitative Concept]

Phrase: "(Fig.2A"

Phrase: ")."
Processing 00000000.tx.61: The increase in WT:MU mRNA was mirrored by a significant increase in production of IKAP protein (Fig.2B), confirming the improved production of functional WT mRNA. 

Phrase: "The increase in WT"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0442805:Increase [Functional Concept]

Phrase: ":"

Phrase: "MU mRNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "mirrored by a significant increase"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   760   C0181868:mirrored [Manufactured Object]
   760   C0237881:significant [Quantitative Concept]
   760   C0442805:Increase [Functional Concept]
   760   C0750502:Significant [Idea or Concept]
   760   C1546944:Significant [Qualitative Concept]
   726 E C1706183:Mirror [Manufactured Object]

Phrase: "in production"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033268:production [Occupational Activity]

Phrase: "of IKAP protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(Fig.2B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450354:2b [Intellectual Product]
   861   C1706096:2B [Research Activity]

Phrase: ")"

Phrase: ","

Phrase: "confirming"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0521093:confirming [Qualitative Concept]
  1000   C0750484:confirming [Idea or Concept]
   966 E C1456348:Confirm [Qualitative Concept]

Phrase: "the improved production of functional WT mRNA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0033268:production [Occupational Activity]
Processing 00000000.tx.62: Quantitative analysis of the western blot in Figure 2B shows a 200% increase in IKAP production with each 10-fold increase in kinetin concentration. 

Phrase: "Quantitative analysis of the western blot"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   820   C0949466:Western blot analysis [Laboratory Procedure]
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0392762:Quantitative [Quantitative Concept]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: "in Figure 2B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450354:2b [Intellectual Product]
   861   C1706096:2B [Research Activity]

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "a 200% increase in IKAP production"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0442805:Increase [Functional Concept]

Phrase: "with each 10-fold increase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0442805:Increase [Functional Concept]

Phrase: "in kinetin concentration."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0086045:Concentration [Mental Process]
   861   C1446561:Concentration [Quantitative Concept]
   789 E C1880165:Concentrated [Biomedical or Dental Material]
Processing 00000000.tx.63: To avoid DMSO toxicity at higher concentrations, we purchased kinetin from an independent source (Sigma) dissolved in water. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "avoid"

Phrase: "DMSO toxicity at higher concentrations,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0040539:toxicity [Qualitative Concept]
   760   C0600688:Toxicity [Injury or Poisoning]

Phrase: "we"

Phrase: "purchased"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0869011:purchased [Activity]

Phrase: "kinetin from an independent source"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "(Sigma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1719918:Sigma [Intellectual Product]

Phrase: ")"

Phrase: "dissolved in water."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   790   C0599638:WATER [Substance]
   790   C1550678:Water [Inorganic Chemical]
   756   C1549535:Dissolve [Functional Concept]
   718 E C0443350:Watery [Qualitative Concept]
Processing 00000000.tx.64: Real-time quantitative PCR analysis showed that the WT:MU IKBKAP mRNA ratio increased steadily from 1:1 in untreated cells to 12:1 in cells treated with 400M kinetin, the maximum dose tested due to the appearance of some cellular toxicity (Fig.2C). 

Phrase: "Real-time quantitative PCR analysis"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   888   C1709846:Real-Time PCR [Molecular Biology Research Technique]
   884   C2733022:Quantitative PCR analysis [Laboratory Procedure]
   840   C0200931:PCR analysis [Laboratory Procedure]
   804   C0002778:Analysis [Laboratory Procedure]
   804   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   804   C0677874:pCR [Finding]
   804   C0936012:Analysis [Research Activity]
   804   C1524024:analysis [Functional Concept]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that"

Phrase: "the WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "MU IKBKAP mRNA ratio"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0456603:Ratio [Quantitative Concept]
   812   C1547037:Ratio [Intellectual Product]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "steadily from 1"

Phrase: ":"

Phrase: "1 in untreated cells"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   770   C0007634:Cells [Cell]
   770   C0332155:untreated [Finding]
   770   C2827734:1+ [Quantitative Concept]
   770   C2981698:1+ [Classification]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "to 12"

Phrase: ":"

Phrase: "1 in cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   790   C0007634:Cells [Cell]
   790   C2827734:1+ [Quantitative Concept]
   790   C2981698:1+ [Classification]
   790   C3282337:Cells [Cell]
   756 E C1269647:Cell [Cell]
   756 E C1704653:Cell [Medical Device]
   756 E C1948049:Cell [Spatial Concept]

Phrase: "treated with 400M kinetin,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
   770   C1522326:Treated [Functional Concept]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "the maximum dose"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   861   C0178602:Dose [Quantitative Concept]
   861   C0806909:Maximum [Quantitative Concept]
   861   C0869039:Dose [Quantitative Concept]
   861   C1114758:Dose # [Clinical Attribute]
   861   C1552615:maximum [Quantitative Concept]
   861   C2826546:MAXIMUM [Quantitative Concept]
   789 E C0205289:Maximal [Qualitative Concept]

Phrase: "tested due to the appearance of some cellular toxicity"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   764   C0678226:Due to [Functional Concept]
           due
   745   C0242890:Toxicity Test [Diagnostic Procedure]
   742   C0007634:Cellular [Cell]
   742   C0040539:toxicity [Qualitative Concept]
   742   C0178539:Cellular [Functional Concept]
   742   C0233426:Appearance [Organism Attribute]
   742   C0392366:tested [Intellectual Product]
   742   C0600688:Toxicity [Injury or Poisoning]
   742   C0700364:Appearance [Qualitative Concept]
   742   C3146286:Due [Idea or Concept]
   708 E C0022885:Test [Laboratory Procedure]
   708 E C0039593:Test [Functional Concept]

Phrase: "(Fig.2C"

Phrase: ")."
Processing 00000000.tx.65: By contrast, total IKBKAP mRNA was relatively unaffected, with a slight increase (1.5-fold) being detected only at doses higher than 50M (data not shown). 

Phrase: "By contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "total IKBKAP mRNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "relatively unaffected,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986417:Unaffected [Conceptual Entity]

Phrase: "with a slight increase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0442805:Increase [Functional Concept]

Phrase: "(1.5-fold"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0332462:Fold [Spatial Concept]
   827   C1880834:FOLD [Phenomenon or Process]
   734   C0450316:1/5 [Quantitative Concept]

Phrase: ")"

Phrase: "being"

Phrase: "detected"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0442726:Detected [Finding]
  1000   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: "only at doses"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   790   C0178602:Doses [Quantitative Concept]
   790   C0205171:Only [Quantitative Concept]
   790   C1720467:Only [Intellectual Product]
   756 E C0869039:Dose [Quantitative Concept]
   756 E C1114758:Dose # [Clinical Attribute]
   756 E C1428722:DOS [Gene or Genome]

Phrase: "higher than 50M"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   756   C0205250:High [Qualitative Concept]
   756   C1299351:High [Qualitative Concept]
   756   C2700149:HIGH [Intellectual Product]
   706 E C0489786:Height [Organism Attribute]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.66: View larger version (53K): [in this window] [in a new window]  Figure 2. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(53K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 2."
Processing 00000000.tx.67: The action of kinetin on IKBKAP splicing is dose and time dependent and results in an increase of IKAP protein in FD lymphoblast cell lines. 

Phrase: "The action of kinetin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0441472:Action [Functional Concept]
   770   C3266814:Action [Activity]

Phrase: "on IKBKAP splicing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0035687:Splicing [Genetic Function]
   861   C2610186:splicing [Genetic Function]

Phrase: "is"

Phrase: "dose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0178602:Dose [Quantitative Concept]
  1000   C0869039:Dose [Quantitative Concept]
  1000   C1114758:Dose # [Clinical Attribute]

Phrase: "and"

Phrase: "time dependent"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   861   C0040223:Time [Temporal Concept]
   861   C0851827:Dependent [Qualitative Concept]
   861   C1701901:Dependent [Qualitative Concept]
   861   C3244310:dependent [Functional Concept]
   861   C3541383:Time [Temporal Concept]
   805 E C0442043:Temporal [Spatial Concept]
   805 E C2362314:Temporal [Temporal Concept]
   777 E C1632851:Times [Quantitative Concept]

Phrase: "and"

Phrase: "results in an increase of IKAP protein"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   748   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0442805:Increase [Functional Concept]
   748   C1274040:Result [Functional Concept]
   748   C1416379:IKAP [Gene or Genome]
   748   C1546471:Result [Idea or Concept]
   748   C2825142:Result [Finding]

Phrase: "in FD lymphoblast cell lines."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   840   C0007600:Cell lines [Cell]
   804   C0007634:Cell [Cell]
   804   C0205132:lines [Spatial Concept]
   804   C1269647:Cell [Cell]
   804   C1704653:Cell [Medical Device]
   804   C1948049:Cell [Spatial Concept]
   771 E C1550648:Line [Substance]
   771 E C1552960:Line [Quantitative Concept]
Processing 00000000.tx.68: (A) RTPCR demonstrating increasing WT:MU IKBKAP ratios as a result of increased kinetin concentration. 

Phrase: "(A) RTPCR"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0599161:RT-PCR [Molecular Biology Research Technique]

Phrase: "demonstrating"

Phrase: "increasing WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C1883559:Wild Type [Organism Attribute]
   827   C0332307:Type [Qualitative Concept]
   827   C0445392:Wild [Intellectual Product]
   827   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "MU IKBKAP ratios as a result of increased kinetin concentration."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   739   C0456603:Ratios [Quantitative Concept]
   739   C1610540:*Ratios [Quantitative Concept]
   706 E C1547037:Ratio [Intellectual Product]
Processing 00000000.tx.69: Sizes of the WT and MU bands are shown on the right, and the IDV ratios are shown beneath each lane. 

Phrase: "Sizes of the WT"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0456389:SIZES [Spatial Concept]

Phrase: "and"

Phrase: "MU bands"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0175723:Bands [Medical Device]
   827 E C0439645:Band [Spatial Concept]
   827 E C1521913:band [Cell Component]

Phrase: "are"

Phrase: "shown on the right,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205090:Right [Spatial Concept]
   737   C1547282:Show [Intellectual Product]

Phrase: "and"

Phrase: "the IDV ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   812   C0456603:Ratios [Quantitative Concept]
   812   C1610540:*Ratios [Quantitative Concept]
   779 E C1547037:Ratio [Intellectual Product]

Phrase: "are"

Phrase: "shown beneath each lane."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1708639:Lane [Spatial Concept]
   737   C1547282:Show [Intellectual Product]
Processing 00000000.tx.70: Adjacent lanes under each treatment represent two independent FD cell lines. 

Phrase: "Adjacent lanes under each treatment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   726   C1708639:Lane [Spatial Concept]

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "two independent FD cell lines."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   827   C0007600:Cell lines [Cell]
   799   C0007634:Cell [Cell]
   799   C0205132:lines [Spatial Concept]
   799   C1269647:Cell [Cell]
   799   C1704653:Cell [Medical Device]
   799   C1948049:Cell [Spatial Concept]
   766 E C1550648:Line [Substance]
   766 E C1552960:Line [Quantitative Concept]
Processing 00000000.tx.71: (B) Western blot probed with an IKAP monoclonal antibody showing that increasing concentrations of kinetin result in an increase in IKAP protein production in FD cells. 

Phrase: "(B) Western blot"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   901   C0949466:Western Blot [Laboratory Procedure]
   827   C1705493:Western [Spatial Concept]

Phrase: "probed with an IKAP monoclonal antibody"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   790   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   753   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   753   C0746619:monoclonal [Finding]
   753   C1416379:IKAP [Gene or Genome]
   719   C0182400:Probe [Medical Device]
   719   C1704681:Probe [Gene or Genome]
   719   C2347609:Probe [Chemical Viewed Functionally]
   719   C3536729:Probe [Manufactured Object]

Phrase: "showing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that increasing concentrations of kinetin result"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0086045:Concentrations [Mental Process]
   719 E C1446561:Concentration [Quantitative Concept]

Phrase: "in an increase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]

Phrase: "in IKAP protein production"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0033268:production [Occupational Activity]

Phrase: "in FD cells."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
Processing 00000000.tx.72: The lower panel shows the same blot probed with an IDE antibody as a protein loading control. 

Phrase: "The lower panel"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0441833:Panel [Idea or Concept]
   861   C1999270:Panel [Intellectual Product]
   861   C3537156:Panel [Manufactured Object]

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "the same blot"

Phrase: "probed with an IDE antibody"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   814   C0021669:Insulin-Degrading Enzyme [Amino Acid, Peptide, or Protein,Enzyme]
   814   C1415875:INSULIN-DEGRADING ENZYME [Gene or Genome]
   774   C0021644:Insulin antibody [Immunologic Factor]
   748   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   748   C0014442:Enzyme [Enzyme,Organic Chemical]
   748   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   748   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1579433:Insulin [Pharmacologic Substance]
   714   C0182400:Probe [Medical Device]
   714   C1704681:Probe [Gene or Genome]
   714   C2347609:Probe [Chemical Viewed Functionally]
   714   C3536729:Probe [Manufactured Object]

Phrase: "as a protein loading control."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0243148:control [Qualitative Concept]
   827   C1550141:Control [Substance]
   827   C1882979:Control [Conceptual Entity]
   827   C2587213:Control [Functional Concept]
   827   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.73: (C) Graph of WT:MU IKBKAP ratios at increasing kinetin concentrations determined by QPCR of FD cells (treated with kinetin in water in duplicate and each amplified in triplicate) showing that higher doses of kinetin continue to increase WT:MU IKBKAP. 

Phrase: "(C) Graph of WT"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0681493:Graph [Intellectual Product]
   760   C2698021:Graph [Conceptual Entity]

Phrase: ":"

Phrase: "MU IKBKAP ratios at increasing kinetin concentrations"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   748   C0456603:Ratios [Quantitative Concept]
   748   C1610540:*Ratios [Quantitative Concept]
   714 E C1547037:Ratio [Intellectual Product]

Phrase: "determined by QPCR of FD cells"
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   770   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   744   C0007634:Cells [Cell]
   744   C0013363:Dysautonomia [Disease or Syndrome]
   744   C0015576:familial [Family Group]
   744   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   744   C0241888:Familial [Functional Concept]
   744   C0392762:Quantitative [Quantitative Concept]
   744   C0677874:pCR [Finding]
   744   C1145628:dysautonomia [Disease or Syndrome]
   744   C3282337:Cells [Cell]
   711 E C1269647:Cell [Cell]
   711 E C1704653:Cell [Medical Device]
   711 E C1948049:Cell [Spatial Concept]

Phrase: "("

Phrase: "treated with kinetin"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "in water"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
  1000   C0599638:WATER [Substance]
  1000   C1550678:Water [Inorganic Chemical]
   928 E C0443350:Watery [Qualitative Concept]

Phrase: "in duplicate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205173:Duplicate [Functional Concept]
  1000   C3539942:Duplicate [Intellectual Product]

Phrase: "and"

Phrase: "each"

Phrase: "amplified in triplicate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205174:Triplicate [Quantitative Concept]

Phrase: ")"

Phrase: "showing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that higher doses of kinetin"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   773   C0444956:High dose [Quantitative Concept]
   760   C0178602:Doses [Quantitative Concept]
   726 E C0869039:Dose [Quantitative Concept]
   726 E C1114758:Dose # [Clinical Attribute]
   726 E C1428722:DOS [Gene or Genome]

Phrase: "continue"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549178:Continue [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "MU IKBKAP."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1416379:IKBKAP [Gene or Genome]
Processing 00000000.tx.74: Examination of (A) shows that at kinetin concentrations of 100M the MU band is barely discernable using densitometry, therefore QPCR was used for this study. 

Phrase: "Examination of ("

Phrase: "A)"

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "that at kinetin concentrations of 100M"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
   753   C0086045:Concentrations [Mental Process]
   719 E C1446561:Concentration [Quantitative Concept]

Phrase: "the MU band"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0175723:Band [Medical Device]
   861   C0439645:Band [Spatial Concept]
   861   C1521913:band [Cell Component]

Phrase: "is"

Phrase: "barely discernable"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205396:Discernible [Qualitative Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "densitometry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0011321:Densitometry [Laboratory Procedure]

Phrase: "therefore QPCR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0677874:pCR [Finding]

Phrase: "was"

Phrase: "used for this study."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   802   C0869040:study use [Research Activity]
   770   C0557651:Study [Manufactured Object]
   770   C1273517:used [Finding]
   770   C2603343:Study [Research Activity]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.75: (D) Graph of WT:MU ratios generated using IDV values following culturing of FD cells in 50M kinetin for increasing lengths of time. 

Phrase: "("

Phrase: "D)"

Phrase: "Graph of WT"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0681493:Graph [Intellectual Product]
   770   C2698021:Graph [Conceptual Entity]

Phrase: ":"

Phrase: "MU ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0456603:Ratios [Quantitative Concept]
   861   C1610540:*Ratios [Quantitative Concept]
   827 E C1547037:Ratio [Intellectual Product]

Phrase: "generated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3146294:Generated [Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "IDV values"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0042295:Values [Qualitative Concept]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "culturing of FD cells"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   781   C0007585:cells culture [Laboratory Procedure]
   781   C0007635:cell culturing [Cell]
   726   C0010453:Culture [Idea or Concept]
   726   C0220814:culture [Functional Concept]
   726   C0430400:Culture [Laboratory Procedure]
   726   C2242979:Culture [Laboratory Procedure]

Phrase: "in 50M kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "for increasing lengths"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   861   C1444754:Lengths [Quantitative Concept]
   827 E C1706316:LENGTH [Research Activity]
   777 E C0205166:Long [Qualitative Concept]
   777 E C1522425:Longest [Qualitative Concept]
   777 E C1706317:Long [Qualitative Concept]

Phrase: "of time."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0040223:Time [Temporal Concept]
  1000   C3541383:Time [Temporal Concept]
   944 E C0442043:Temporal [Spatial Concept]
   944 E C2362314:Temporal [Temporal Concept]
   916 E C1632851:Times [Quantitative Concept]
Processing 00000000.tx.76: All treatments were performed in duplicate and average data points are plotted.  

Phrase: "All treatments"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0087111:Treatments [Therapeutic or Preventive Procedure]
   966 E C0039798:treatment [Functional Concept]
   966 E C1522326:Treatment [Functional Concept]
   966 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   966 E C1705169:Treatment [Conceptual Entity]
   966 E C3538994:TREATMENT [Research Activity]

Phrase: "were"

Phrase: "performed in duplicate"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0205173:Duplicate [Functional Concept]
   790   C0884358:Performed [Functional Concept]
   790   C3539942:Duplicate [Intellectual Product]
   756 E C2947996:Perform [Pharmacologic Substance]

Phrase: "and"

Phrase: "average data points"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   901   C3176122:Data points [Clinical Attribute]
   884 E C1511726:Data Point [Idea or Concept]
   793   C1552961:Point [Quantitative Concept]
   793   C2347617:point [Quantitative Concept]

Phrase: "are"

Phrase: "plotted."
Processing 00000000.tx.77: Kinetin belongs to the family of N6-substituted adenine derivatives known as cytokinins, or plant growth factors, that also includes zeatin, benzyladenine and 2iP (Fig.1B). 

Phrase: "Kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "belongs to the family of N6-substituted adenine derivatives"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   745   C0680049:family substitute [Social Behavior]
   742   C0001407:Adenine [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   742   C0015576:Family [Family Group]
   742   C0243072:derivatives [Chemical Viewed Structurally]
   742   C0442786:N6 [Finding]
   742   C1704727:Family [Conceptual Entity]
   708 E C1527240:Derivative [Functional Concept]

Phrase: "known as cytokinins,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0010815:Cytokinins [Biologically Active Substance]
   790   C0205309:Known [Qualitative Concept]

Phrase: "or"

Phrase: "plant growth factors,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   901   C0018284:Growth Factors [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   901   C0597252:plant growth [Organism Function]
   827   C0018270:'growth' NOS [Organism Function]
   827   C0220844:growth [Physiologic Function]
   827   C1621966:Growth [Organ or Tissue Function]
   827   C2911660:Growth [Activity]
   793   C1521761:Factor [Functional Concept]
   793   C2827422:Factor [Conceptual Entity]

Phrase: "that also"

Phrase: "includes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:Includes [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "zeatin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043456:Zeatin [Biologically Active Substance,Organic Chemical]

Phrase: "benzyladenine"

Phrase: "and"

Phrase: "2iP"

Phrase: "(Fig.1B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450345:1B [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.78: In our FD lymphoblast assay, neither zeatin nor 2iP had any effect on WT:MU IKBKAP ratio. 

Phrase: "In our FD lymphoblast assay,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0005507:Assay [Laboratory Procedure]
   812   C0243073:assay [Qualitative Concept]
   812   C1510438:Assay [Laboratory Procedure]

Phrase: "neither zeatin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043456:Zeatin [Biologically Active Substance,Organic Chemical]

Phrase: "nor"

Phrase: "2iP"

Phrase: "had"

Phrase: "any effect on WT"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: ":"

Phrase: "MU IKBKAP ratio."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0456603:Ratio [Quantitative Concept]
   827   C1547037:Ratio [Intellectual Product]
Processing 00000000.tx.79: Benzyladenine did enhance inclusion of exon 20 in the IKBKAP transcripts 2-fold by 100M, a less dramatic effect than kinetin (data not shown). 

Phrase: "Benzyladenine"

Phrase: "did"

Phrase: "enhance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhance [Activity]

Phrase: "inclusion of exon 20"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1512693:Inclusion [Qualitative Concept]

Phrase: "in the IKBKAP transcripts 2-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0332462:Fold [Spatial Concept]
   812   C1880834:FOLD [Phenomenon or Process]

Phrase: "by 100M,"

Phrase: "a less dramatic effect than kinetin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.80: The fact that only kinetin and benzyladenine alter IKBKAP splicing suggests that the nature of the adenine N6-linked modification plays a role in this function. 

Phrase: "The fact"

Phrase: "that only kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "and"

Phrase: "benzyladenine"

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "IKBKAP splicing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0035687:Splicing [Genetic Function]
   861   C2610186:splicing [Genetic Function]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the nature of the adenine N6-linked modification"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0349590:Nature [Idea or Concept]
   744   C1262865:Nature [Functional Concept]

Phrase: "plays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:Plays [Finding]

Phrase: "a role in this function."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   762   C1705810:Functional Role [Conceptual Entity]
           Role
   760   C0035820:Role [Social Behavior]
Processing 00000000.tx.81: The experiments described above were all performed after 72h of treatment with kinetin. 

Phrase: "The experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0681814:Experiments [Research Activity]
   966 E C1706386:Experiment [Conceptual Entity]
   916 E C1517586:Experimental [Qualitative Concept]

Phrase: "described above"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C1552738:described [Idea or Concept]

Phrase: "were"

Phrase: "all"

Phrase: "performed after 72h of treatment"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0884358:Performed [Functional Concept]
   760   C1292423:72H [Temporal Concept]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]
   726 E C2947996:Perform [Pharmacologic Substance]

Phrase: "with kinetin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
Processing 00000000.tx.82: In order to define how quickly kinetin alters IKBKAP splicing, we performed a time-course at 50M kinetin (Fig.2D). 

Phrase: "In order to"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C1705175:Order [Intellectual Product]
   861   C1705176:Order [Qualitative Concept]
   861   C1705177:Order [Classification]
   861   C1705178:Order [Activity]
   861   C1882348:Order [Qualitative Concept]

Phrase: "define"

Phrase: "how quickly kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "alters"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "IKBKAP splicing,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0035687:Splicing [Genetic Function]
   861   C2610186:splicing [Genetic Function]

Phrase: "we"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "a time-course at 50M kinetin"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0449247:Time course [Temporal Concept]
   753   C0040223:Time [Temporal Concept]
   753   C0750729:Course [Temporal Concept]
   753   C3541383:Time [Temporal Concept]

Phrase: "(Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]

Phrase: "2D"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1705052:2D [Spatial Concept]
  1000   C2986796:2D [Functional Concept]

Phrase: ")."
Processing 00000000.tx.83: The increase in the WT:MU ratio was seen at 1h, was maximal by 8h, and was maintained for at least 72h in culture without kinetin replenishment. 

Phrase: "The increase in the WT"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0442805:Increase [Functional Concept]

Phrase: ":"

Phrase: "MU ratio"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0456603:Ratio [Quantitative Concept]
   861   C1547037:Ratio [Intellectual Product]

Phrase: "was"

Phrase: "seen at 1h,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0205397:Seen [Qualitative Concept]
   790   C1442450:1H [Temporal Concept]
   756 E C0042789:see [Organism Function]
   756 E C1947903:See [Activity]

Phrase: "was"

Phrase: "maximal by 8h,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0205289:Maximal [Qualitative Concept]
   790   C0806909:Maximal [Quantitative Concept]
   718 E C1552615:maximum [Quantitative Concept]
   718 E C2826546:MAXIMUM [Quantitative Concept]

Phrase: "and"

Phrase: "was"

Phrase: "maintained for"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   833   C1314677:Maintained [Functional Concept]
   799 E C0024501:Maintain [Activity]

Phrase: "at least 72h"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1292423:72H [Temporal Concept]

Phrase: "in culture"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0010453:Culture [Idea or Concept]
  1000   C0220814:culture [Functional Concept]
  1000   C0430400:Culture [Laboratory Procedure]
  1000   C2242979:Culture [Laboratory Procedure]

Phrase: "without kinetin replenishment."
Processing 00000000.tx.84: The consistency of the effect was tested by treating lymphoblast lines from nine FD patients with 50M kinetin for 24h. 

Phrase: "The consistency of the effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0332529:Consistency [Qualitative Concept]
   760   C1547017:Consistency [Quantitative Concept]

Phrase: "was"

Phrase: "tested by treating lymphoblast lines"
Meta Candidates (Total=10; Excluded=5; Pruned=0; Remaining=5)
   760   C0205132:lines [Spatial Concept]
   760   C0229613:lymphoblast [Cell]
   760   C0332293:treating [Therapeutic or Preventive Procedure]
   760   C0392366:tested [Intellectual Product]
   760   C1522326:Treating [Functional Concept]
   726 E C0022885:Test [Laboratory Procedure]
   726 E C0039593:Test [Functional Concept]
   726 E C1292734:TREAT [Functional Concept]
   726 E C1550648:Line [Substance]
   726 E C1552960:Line [Quantitative Concept]

Phrase: "from nine FD patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0030705:Patients [Patient or Disabled Group]

Phrase: "with 50M kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "for 24h."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0456696:/24h [Temporal Concept]
  1000   C1442770:24H [Temporal Concept]
Processing 00000000.tx.85: All nine lines showed an increase in WT IKBKAP mRNA with WT:MU ratios ranging from 1.3 to 1.9 in untreated cells to 5.68.6 in kinetin treated cells. 

Phrase: "All nine lines"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0205132:lines [Spatial Concept]
   827 E C1550648:Line [Substance]
   827 E C1552960:Line [Quantitative Concept]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "an increase in WT IKBKAP mRNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0442805:Increase [Functional Concept]

Phrase: "with WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "MU ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0456603:Ratios [Quantitative Concept]
   861   C1610540:*Ratios [Quantitative Concept]
   827 E C1547037:Ratio [Intellectual Product]

Phrase: "ranging from 1.3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   737   C1514721:Range [Quantitative Concept]
   737   C2348147:Range [Quantitative Concept]
   737   C3542016:Range [Intellectual Product]

Phrase: "to 1.9"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: "in untreated cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "to 5.68.6"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0442749:5 6 [Finding]
   827   C0439084:>5 [Quantitative Concept]
   827   C0450387:68 [Intellectual Product]
   827   C0728893:+5 [Quantitative Concept]

Phrase: "in kinetin treated cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.86: Kinetin was also effective in FD fibroblast lines which exhibited a dose-dependent increase in WT:MU IKBKAP ratio similar to that seen in lymphoblasts (data not shown). 

Phrase: "Kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "was"

Phrase: "also effective in FD fibroblast lines"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280519:effective [Qualitative Concept]
   748   C1704419:Effective [Qualitative Concept]

Phrase: "which"

Phrase: "exhibited"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0015272:Exhibit [Intellectual Product]

Phrase: "a dose-dependent increase in WT"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0442805:Increase [Functional Concept]

Phrase: ":"

Phrase: "MU IKBKAP ratio"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0456603:Ratio [Quantitative Concept]
   827   C1547037:Ratio [Intellectual Product]

Phrase: "similar to that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2348205:Similar [Qualitative Concept]

Phrase: "seen in lymphoblasts"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0205397:Seen [Qualitative Concept]
   790   C0229613:Lymphoblasts [Cell]
   790   C1167770:Lymphoblasts [Laboratory Procedure]
   756 E C0042789:see [Organism Function]
   756 E C1947903:See [Activity]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.87: To explore whether the effect of kinetin was specific to IKBKAP exon 20 or generally increased inclusion of alternatively spliced exons, we assayed splicing of the MYO5A gene (Fig.3A). 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "explore"

Phrase: "whether"

Phrase: "the effect of kinetin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1280500:Effect [Qualitative Concept]
   770   C2348382:Effect [Qualitative Concept]

Phrase: "was"

Phrase: "specific to IKBKAP exon 20"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0205369:Specific [Qualitative Concept]
   760   C1552740:specific [Intellectual Product]

Phrase: "or"

Phrase: "generally increased inclusion of alternatively spliced exons,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1512693:Inclusion [Qualitative Concept]

Phrase: "we"

Phrase: "assayed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0005507:Assay [Laboratory Procedure]
   966   C0243073:assay [Qualitative Concept]
   966   C1510438:Assay [Laboratory Procedure]

Phrase: "splicing of the MYO5A gene"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   797   C0017365:gene splicing [Gene or Genome]
   797   C0017387:Gene Splicing [Molecular Biology Research Technique]
   760   C0035687:Splicing [Genetic Function]
   760   C2610186:splicing [Genetic Function]

Phrase: "(Fig.3A"

Phrase: ")."
Processing 00000000.tx.88: MYO5A expresses multiple isoforms in fibroblasts and lymphoblasts, one of which is generated by skipping of exon 31 (25). 

Phrase: "MYO5A"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1417565:MYO5A [Gene or Genome]

Phrase: "expresses"

Phrase: "multiple isoforms in fibroblasts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0597298:Isoforms [Amino Acid, Peptide, or Protein]

Phrase: "and"

Phrase: "lymphoblasts,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0229613:Lymphoblasts [Cell]
  1000   C1167770:Lymphoblasts [Laboratory Procedure]

Phrase: "one of which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205447:One [Quantitative Concept]

Phrase: "is"

Phrase: "generated by skipping of exon 31"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0450355:31 [Intellectual Product]
   753   C0560435:skipping [Finding]
   753   C3146294:Generated [Activity]

Phrase: "(25"

Phrase: ")."
Processing 00000000.tx.89: We designed primers flanking exon 31 and examined the ratio of the two MYO5A isoforms in nine FD lymphoblast cell lines following treatment with 50M kinetin for 72h. 

Phrase: "We"

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "flanking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0230171:flanking [Body Location or Region]

Phrase: "exon 31"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0450355:31 [Intellectual Product]

Phrase: "and"

Phrase: "examined"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332128:Examined [Finding]

Phrase: "the ratio of the two MYO5A isoforms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0456603:Ratio [Quantitative Concept]
   748   C1547037:Ratio [Intellectual Product]

Phrase: "in nine FD lymphoblast cell lines"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   827   C0007600:Cell lines [Cell]
   799   C0007634:Cell [Cell]
   799   C0205132:lines [Spatial Concept]
   799   C1269647:Cell [Cell]
   799   C1704653:Cell [Medical Device]
   799   C1948049:Cell [Spatial Concept]
   766 E C1550648:Line [Substance]
   766 E C1552960:Line [Quantitative Concept]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "treatment with 50M kinetin"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "for 72h."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292423:72H [Temporal Concept]
Processing 00000000.tx.90: No significant difference was observed in the ratio of the two isoforms between the treated and untreated samples, with average transcript ratios of 2.33 and 2.46, respectively (Fig.3B). 

Phrase: "No significant difference"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C1705241:*Difference [Quantitative Concept]
   861   C1705242:Difference [Qualitative Concept]
   789 E C0443199:Differential [Qualitative Concept]

Phrase: "was"

Phrase: "observed in the ratio of the two isoforms"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0205448:Two [Quantitative Concept]
   744   C0456603:Ratio [Quantitative Concept]
   744   C0597298:Isoforms [Amino Acid, Peptide, or Protein]
   744   C1441672:Observed [Functional Concept]
   744   C1547037:Ratio [Intellectual Product]

Phrase: "between the treated"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332293:treated [Therapeutic or Preventive Procedure]
  1000   C1522326:Treated [Functional Concept]
   966 E C1292734:TREAT [Functional Concept]

Phrase: "and"

Phrase: "untreated samples,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0370003:Sample [Substance]
   827   C2347026:Sample [Conceptual Entity]

Phrase: "with average transcript ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0456603:Ratios [Quantitative Concept]
   827   C1610540:*Ratios [Quantitative Concept]
   793 E C1547037:Ratio [Intellectual Product]

Phrase: "of 2.33"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0740116:+2 [Quantitative Concept]
   861   C2827735:2+ [Quantitative Concept]
   861   C2981700:2+ [Classification]

Phrase: "and"

Phrase: "2.46,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0740116:+2 [Quantitative Concept]
   861   C2827735:2+ [Quantitative Concept]
   861   C2981700:2+ [Classification]

Phrase: "respectively"

Phrase: "(Fig.3B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450365:3b [Intellectual Product]
   861   C1706097:3B [Research Activity]

Phrase: ")."
Processing 00000000.tx.91: View larger version (45K): [in this window] [in a new window]  Figure 3. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(45K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 3."
Processing 00000000.tx.92: Kinetin has no effect on incorporation of exon 31 in the alternatively spliced MYO5A gene. 

Phrase: "Kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "has"

Phrase: "no effect on incorporation of exon 31"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C1301751:No effect [Qualitative Concept]
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "in the alternatively spliced MYO5A gene."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1417565:MYO5A gene [Gene or Genome]
   812   C0017337:Gene [Gene or Genome]
Processing 00000000.tx.93: (A) Schematic diagram illustrating two of the alternative transcripts produced by MYO5A. 

Phrase: "(A) Schematic diagram illustrating two of the alternative transcripts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0205448:Two [Quantitative Concept]

Phrase: "produced by MYO5A."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1417565:MYO5A [Gene or Genome]
Processing 00000000.tx.94: The primers used for amplification are illustrated by arrows indicated on each isoform. 

Phrase: "The primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "used for amplification"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   790   C1273517:used [Finding]
   790   C1517480:Amplification [Molecular Biology Research Technique]
   790   C1521871:Amplification [Phenomenon or Process]
   790   C1705759:Amplification [Cell or Molecular Dysfunction]
   756 E C0042153:use [Functional Concept]
   756 E C0457083:Use [Functional Concept]
   756 E C1947944:Use [Intellectual Product]

Phrase: "are"

Phrase: "illustrated by arrows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0336721:arrows [Manufactured Object]

Phrase: "indicated on each isoform."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0597298:Isoform [Amino Acid, Peptide, or Protein]
   770   C1444656:Indicated [Finding]
Processing 00000000.tx.95: (B) Representative example of MYO5A RTPCR from FD lymphoblast cells showing no change in the ratio of MYO5A isoforms by kinetin treatment. 

Phrase: "(B) Representative example of MYO5A RTPCR"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1707959:Example [Conceptual Entity]

Phrase: "from FD lymphoblast cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]

Phrase: "showing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "no change in the ratio of MYO5A isoforms"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0442739:No change [Finding]
   770   C1548568:No change [Intellectual Product]
   744   C0392747:Change [Functional Concept]
   744   C0443172:change [Quantitative Concept]
   744   C1705241:Change [Quantitative Concept]

Phrase: "by kinetin treatment."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.96: Nine independent cell lines were tested.  

Phrase: "Nine independent cell lines"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   861   C0007600:Cell lines [Cell]
   812   C0007634:Cell [Cell]
   812   C0205132:lines [Spatial Concept]
   812   C1269647:Cell [Cell]
   812   C1704653:Cell [Medical Device]
   812   C1948049:Cell [Spatial Concept]
   779 E C1550648:Line [Substance]
   779 E C1552960:Line [Quantitative Concept]

Phrase: "were"

Phrase: "tested."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]
Processing 00000000.tx.97: The IVS20+6TC mutation in IKBKAP leads to a frameshift and a premature termination codon in exon 21, which is expected to target the mutant message for decay via the nonsense-mediated mRNA decay (NMD) pathway (26). 

Phrase: "The IVS20+6TC mutation in IKBKAP"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0026882:Mutation [Genetic Function]
   753   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "leads to a frameshift"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   770   C0079380:Frameshift [Cell or Molecular Dysfunction]
   770   C0181586:leads [Medical Device]
   770   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   770   C1522538:Lead [Functional Concept]
   770   C2348269:Lead [Element, Ion, or Isotope]
   770   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "a premature termination codon in exon 21,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   814   C0242612:Codon, Termination, Premature [Nucleotide Sequence]
   778   C0242611:Codon, Termination [Nucleotide Sequence]
   748   C0009221:Codon [Nucleotide Sequence]
   748   C0205252:Premature [Temporal Concept]
   748   C1095825:Codon [Plant]
   748   C1549081:Termination [Intellectual Product]
   748   C1692758:termination [Idea or Concept]

Phrase: "which"

Phrase: "is"

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "target"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1521840:Target [Functional Concept]
  1000   C2986546:TARGET [Diagnostic Procedure]

Phrase: "the mutant message for decay"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0470166:Message [Intellectual Product]

Phrase: "via the nonsense-mediated mRNA decay (NMD) pathway"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C1704259:Pathway [Molecular Function]
   804   C1705987:Pathway [Conceptual Entity]
   771   C1158013:Nonsense Mediated mRNA Decay [Genetic Function]
           Nonsense-Mediated Decay

Phrase: "(26"

Phrase: ")."
Processing 00000000.tx.98: While we hypothesize that kinetin is acting directly on IKBKAP splicing, it is possible that an increase in NMD of the mutant transcript could result in the observed changes in WT:MU transcript. 

Phrase: "While"

Phrase: "we"

Phrase: "hypothesize"

Phrase: "that kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "is"

Phrase: "acting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0079613:ACT [Therapeutic or Preventive Procedure]

Phrase: "directly on IKBKAP splicing,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0035687:Splicing [Genetic Function]
   770   C1416379:IKBKAP [Gene or Genome]
   770   C1947931:Directly [Qualitative Concept]
   770   C2610186:splicing [Genetic Function]

Phrase: "it"

Phrase: "is"

Phrase: "possible"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332149:Possible [Qualitative Concept]
  1000   C1705910:Possible [Qualitative Concept]
  1000   C2362652:Possible [Qualitative Concept]

Phrase: "that"

Phrase: "an increase in NMD of the mutant transcript"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0442805:Increase [Functional Concept]

Phrase: "could"

Phrase: "result in the observed changes"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0392747:changes [Functional Concept]
   760   C0443172:changes [Quantitative Concept]
   760   C1274040:Result [Functional Concept]
   760   C1441672:Observed [Functional Concept]
   760   C1546471:Result [Idea or Concept]
   760   C2825142:Result [Finding]
   726 E C1705241:Change [Quantitative Concept]

Phrase: "in WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "MU transcript."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcript [Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.99: Therefore, we exposed kinetin-treated FD cells to cycloheximide, a translation inhibitor, in order to halt NMD of the mutant transcript (27). 

Phrase: "Therefore,"

Phrase: "we"

Phrase: "exposed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332157:Exposed [Clinical Attribute]

Phrase: "kinetin-treated FD cells to cycloheximide,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   748   C0007634:Cells [Cell]
   748   C3282337:Cells [Cell]
   714 E C1269647:Cell [Cell]
   714 E C1704653:Cell [Medical Device]
   714 E C1948049:Cell [Spatial Concept]

Phrase: "a translation inhibitor,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1999216:Inhibitor [Qualitative Concept]

Phrase: "in order"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1705175:Order [Intellectual Product]
  1000   C1705176:Order [Qualitative Concept]
  1000   C1705177:Order [Classification]
  1000   C1705178:Order [Activity]
  1000   C1882348:Order [Qualitative Concept]

Phrase: "to halt NMD"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   937   C1158013:Nonsense Mediated mRNA Decay [Genetic Function]
           Nonsense-Mediated Decay
   840   C1257758:mRNA Decay [Genetic Function]
   804   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   804   C0086597:mediated [Social Behavior]
   804   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]
   804   C0746939:nonsense [Idea or Concept]
   804   C1265875:Decay [Acquired Abnormality]
   804   C2700592:Decay [Phenomenon or Process]

Phrase: "of the mutant transcript"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcript [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(27"

Phrase: ")."
Processing 00000000.tx.100: As shown in Figure 4, cycloheximide increases the MU transcript and decreases the WT:MU ratio as expected. 

Phrase: "As"

Phrase: "shown in Figure 4,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C1547282:Show [Intellectual Product]

Phrase: "cycloheximide"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0010572:Cycloheximide [Antibiotic,Organic Chemical]
   944 E C0947670:Actidione [Antibiotic,Organic Chemical]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "the MU transcript"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcript [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and"

Phrase: "decreases"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0392756:Decrease [Qualitative Concept]
  1000   C0547047:Decrease [Quantitative Concept]

Phrase: "the WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "MU ratio"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0456603:Ratio [Quantitative Concept]
   861   C1547037:Ratio [Intellectual Product]

Phrase: "as"

Phrase: "expected."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]
Processing 00000000.tx.101: However, kinetin significantly alters the WT:MU ratio even when the NMD pathway is inhibited, an observation consistent with the hypothesis that kinetin is acting on IKBKAP splicing. 

Phrase: "However,"

Phrase: "kinetin significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "alters"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "the WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "MU ratio even"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0456603:Ratio [Quantitative Concept]
   827   C1547037:Ratio [Intellectual Product]

Phrase: "when"

Phrase: "the NMD pathway"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C1704259:Pathway [Molecular Function]
   804   C1705987:Pathway [Conceptual Entity]
   771   C1158013:Nonsense Mediated mRNA Decay [Genetic Function]
           Nonsense-Mediated Decay

Phrase: "is"

Phrase: "inhibited"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0311403:Inhibited [Qualitative Concept]
   928 E C0018790:arrested [Disease or Syndrome]
   928 E C0237477:Arrest [Temporal Concept]
   928 E C0392351:arrest [Governmental or Regulatory Activity]
   928 E C0521111:Retarded [Qualitative Concept]
   907 E C3463820:Inhibiting [Activity]

Phrase: ","

Phrase: "an observation"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0302523:Observation [Research Activity]
  1000   C0700325:observation [Health Care Activity]
  1000   C1964257:Observation [Diagnostic Procedure]
   928 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: "consistent with the hypothesis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "that kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "is"

Phrase: "acting on IKBKAP splicing."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0035687:Splicing [Genetic Function]
   770   C1416379:IKBKAP [Gene or Genome]
   770   C2610186:splicing [Genetic Function]
   737   C0079613:ACT [Therapeutic or Preventive Procedure]
Processing 00000000.tx.102: View larger version (39K): [in this window] [in a new window]  Figure 4. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(39K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 4."
Processing 00000000.tx.103: Kinetin increases WT:MU IKBKAP in the presence of cycloheximide, which inhibits nonsense mediated decay. 

Phrase: "Kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "MU IKBKAP in the presence of cycloheximide,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1416379:IKBKAP [Gene or Genome]

Phrase: "which"

Phrase: "inhibits"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "nonsense mediated decay."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C1158013:Nonsense-Mediated Decay [Genetic Function]
   827   C0086597:mediated [Social Behavior]
   827   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]
   827   C0746939:nonsense [Idea or Concept]
   827   C1265875:Decay [Acquired Abnormality]
   827   C2700592:Decay [Phenomenon or Process]
Processing 00000000.tx.104: Two FD cell lines were treated as follows: U=untreated; 

Phrase: "Two FD cell lines"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   840   C0007600:Cell lines [Cell]
   804   C0007634:Cell [Cell]
   804   C0205132:lines [Spatial Concept]
   804   C1269647:Cell [Cell]
   804   C1704653:Cell [Medical Device]
   804   C1948049:Cell [Spatial Concept]
   771 E C1550648:Line [Substance]
   771 E C1552960:Line [Quantitative Concept]

Phrase: "were"

Phrase: "treated"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332293:treated [Therapeutic or Preventive Procedure]
  1000   C1522326:Treated [Functional Concept]
   966 E C1292734:TREAT [Functional Concept]

Phrase: "as"

Phrase: "follows"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]

Phrase: ":"

Phrase: "U"

Phrase: "=untreated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332155:untreated [Finding]

Phrase: ";"
Processing 00000000.tx.105: C=50g/ml cycloheximide; 

Phrase: "C=50g/ml cycloheximide"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0010572:Cycloheximide [Antibiotic,Organic Chemical]
   756 E C0947670:Actidione [Antibiotic,Organic Chemical]

Phrase: ";"
Processing 00000000.tx.106: K=100M kinetin; 

Phrase: "K=100M kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.107: C+K=cycloheximide and kinetin.  

Phrase: "C+K=cycloheximide"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0010572:Cycloheximide [Antibiotic,Organic Chemical]
   771 E C0947670:Actidione [Antibiotic,Organic Chemical]

Phrase: "and"

Phrase: "kinetin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
Processing 00000000.tx.108: In order to better understand the mechanism of action of kinetin on IKBKAP splicing, we created both FD and WT minigene constructs containing the genomic sequence spanning exons 1921 (Fig.5A). 

Phrase: "In order to better"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   827   C0332272:Better [Qualitative Concept]
   827   C1705175:Order [Intellectual Product]
   827   C1705176:Order [Qualitative Concept]
   827   C1705177:Order [Classification]
   827   C1705178:Order [Activity]
   827   C1882348:Order [Qualitative Concept]
   793 E C0205170:Well [Qualitative Concept]
   793 E C3146287:Well [Manufactured Object]

Phrase: "understand"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0162340:Understand [Mental Process]

Phrase: "the mechanism of action of kinetin"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0031327:mechanism of action [Physiologic Function]
   833   C1524059:mechanism of action [Functional Concept]
   753   C0441712:Mechanism [Functional Concept]
   753   C1706376:Mechanism [Manufactured Object]

Phrase: "on IKBKAP splicing,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0035687:Splicing [Genetic Function]
   861   C2610186:splicing [Genetic Function]

Phrase: "we"

Phrase: "created"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1706214:Created [Activity]
   966 E C3244320:create [Functional Concept]

Phrase: "both FD"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]

Phrase: "and"

Phrase: "WT minigene constructs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   779   C2827421:Construct [Classification]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "the genomic sequence spanning exons 1921"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   804   C0004793:Sequence [Nucleotide Sequence]
   804   C0015295:Exons [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   804   C0017428:Genomic [Gene or Genome]
   804   C0162326:Sequence [Nucleotide Sequence]
   804   C0162327:Sequence [Nucleotide Sequence]
   804   C0887950:genomic [Biomedical Occupation or Discipline]
   804   C1519249:Sequence [Functional Concept]
   771   C1711300:Span [Conceptual Entity]
   771   C2700613:Span [Quantitative Concept]
   733 E C1548958:Sequential [Idea or Concept]
   733 E C1705294:Sequential [Qualitative Concept]

Phrase: "(Fig.5A"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1553637:5a [Medical Device]

Phrase: ")."
Processing 00000000.tx.109: These constructs were transfected into HEK293 cells and RNA amplified using vector-specific primers to avoid amplification of the endogenous IKBKAP message. 

Phrase: "These constructs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2827421:Construct [Classification]

Phrase: "were"

Phrase: "transfected into HEK293 cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   833   C2936239:HEK293 Cells [Cell]
   770   C0007634:Cells [Cell]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "RNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "amplified"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "vector-specific primers to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   779   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "avoid"

Phrase: "amplification of the endogenous IKBKAP message."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1517480:Amplification [Molecular Biology Research Technique]
   753   C1521871:Amplification [Phenomenon or Process]
   753   C1705759:Amplification [Cell or Molecular Dysfunction]
Processing 00000000.tx.110: Evaluation of the transcripts produced from the WT construct showed that although the WT transcript is the predominant product, trace levels of exon 20 skipping do occur even in the absence of the FD mutation. 

Phrase: "Evaluation of the transcripts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0220825:Evaluation [Functional Concept]
   770   C1261322:Evaluation [Health Care Activity]

Phrase: "produced from the WT construct"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C1883559:Wild Type [Organism Attribute]
   753   C0332307:Type [Qualitative Concept]
   753   C0445392:Wild [Intellectual Product]
   753   C1547052:*Type [Quantitative Concept]
   753   C2827421:Construct [Classification]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that"

Phrase: "although"

Phrase: "the WT transcript"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1519595:Transcript [Nucleic Acid, Nucleoside, or Nucleotide]
   734   C1883559:Wild Type [Organism Attribute]

Phrase: "is"

Phrase: "the predominant product,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]

Phrase: "trace levels of exon 20 skipping"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   753   C0441889:Levels [Qualitative Concept]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]

Phrase: "do"

Phrase: "occur"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1709305:Occur [Activity]
  1000   C2745955:OCCUR [Temporal Concept]

Phrase: "even in the absence of the FD mutation."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   764   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   742   C0013363:Dysautonomia [Disease or Syndrome]
   742   C0015576:familial [Family Group]
   742   C0026882:Mutation [Genetic Function]
   742   C0241888:Familial [Functional Concept]
   742   C0332197:absence [Quantitative Concept]
   742   C1145628:dysautonomia [Disease or Syndrome]
   742   C1689985:Absence [Anatomical Abnormality]
   742   C1705285:Mutation [Cell or Molecular Dysfunction]
Processing 00000000.tx.111: Introduction of the FD mutation into the construct increased exon 20 skipping as predicted. 

Phrase: "Introduction of the FD mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1293116:Introduction [Health Care Activity]
   753   C1875307:INTRODUCTION [Manufactured Object]

Phrase: "into the construct"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2827421:Construct [Classification]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "exon 20 skipping"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0560435:skipping [Finding]

Phrase: "as"

Phrase: "predicted."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681842:Predicted [Idea or Concept]
  1000   C1882327:%{Predicted} [Quantitative Concept]
Processing 00000000.tx.112: Interestingly, treatment with kinetin enhanced inclusion of exon 20 not only in the FD construct, but also in the WT construct (Fig.5B). 

Phrase: "Interestingly,"

Phrase: "treatment with kinetin"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0039798:treatment [Functional Concept]
   790   C0087111:Treatment [Therapeutic or Preventive Procedure]
   790   C1522326:Treatment [Functional Concept]
   790   C1533734:Treatment [Therapeutic or Preventive Procedure]
   790   C1705169:Treatment [Conceptual Entity]
   790   C3538994:TREATMENT [Research Activity]

Phrase: "enhanced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhanced [Activity]

Phrase: "inclusion of exon 20"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1512693:Inclusion [Qualitative Concept]

Phrase: "not only in the FD construct,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   778   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   748   C0013363:Dysautonomia [Disease or Syndrome]
   748   C0015576:familial [Family Group]
   748   C0205171:Only [Quantitative Concept]
   748   C0241888:Familial [Functional Concept]
   748   C1145628:dysautonomia [Disease or Syndrome]
   748   C1518422:Not [Functional Concept]
   748   C1720467:Only [Intellectual Product]
   748   C2827421:Construct [Classification]

Phrase: "but"

Phrase: "also in the WT construct"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C1883559:Wild Type [Organism Attribute]
   753   C0332307:Type [Qualitative Concept]
   753   C0445392:Wild [Intellectual Product]
   753   C1547052:*Type [Quantitative Concept]
   753   C2827421:Construct [Classification]

Phrase: "(Fig.5B"

Phrase: ")."
Processing 00000000.tx.113: In fact, a MU-specific PCR assay that utilizes a primer spanning the junction of exons 19 and 21 (23) revealed that exon 20 skipping is completely corrected by kinetin treatment in transcripts generated from the WT construct (Fig.5C). 

Phrase: "In fact,"

Phrase: "a MU-specific PCR assay"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   812   C0005507:Assay [Laboratory Procedure]
   812   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   812   C0243073:assay [Qualitative Concept]
   812   C0677874:pCR [Finding]
   812   C1510438:Assay [Laboratory Procedure]

Phrase: "that"

Phrase: "utilizes"

Phrase: "a primer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "spanning"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1711300:Span [Conceptual Entity]
   966   C2700613:Span [Quantitative Concept]

Phrase: "the junction of exons 19"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0205144:Junction [Spatial Concept]
   760   C1706311:Junction [Medical Device]

Phrase: "and"

Phrase: "21"

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")"

Phrase: "revealed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:Revealed [Qualitative Concept]

Phrase: "that exon 20 skipping"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0560435:skipping [Finding]

Phrase: "is"

Phrase: "completely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Completely [Qualitative Concept]

Phrase: "corrected by kinetin treatment"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   770   C0039798:treatment [Functional Concept]
   770   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C0205202:Corrected [Qualitative Concept]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]
   737 E C2349182:Correct [Qualitative Concept]

Phrase: "in transcripts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "generated from the WT construct"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C1883559:Wild Type [Organism Attribute]
   753   C0332307:Type [Qualitative Concept]
   753   C0445392:Wild [Intellectual Product]
   753   C1547052:*Type [Quantitative Concept]
   753   C2827421:Construct [Classification]
   753   C3146294:Generated [Activity]

Phrase: "(Fig.5C"

Phrase: ")."
Processing 00000000.tx.114: These findings indicate that kinetin's ability to enhance splicing efficiency is not dependent on either the presence of the FD mutation or the wider regulation of IKBKAP transcription or IKAP protein production, and is likely due to specific sequence elements in the region of exon 20 that function to regulate splicing of this particular exon. 

Phrase: "These findings"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C2607943:findings [Functional Concept]
  1000   C2926606:Findings [Clinical Attribute]
  1000   C3539655:Findings [Intellectual Product]
   966 E C0037088:Finding [Sign or Symptom]
   966 E C0243095:Finding [Finding]
   966 E C2825141:Finding [Finding]

Phrase: "indicate"

Phrase: "that kinetin's ability to"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0085732:Ability [Organism Attribute]
   755 E C1299581:Able [Finding]

Phrase: "enhance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhance [Activity]

Phrase: "splicing efficiency"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0013682:Efficiency [Quantitative Concept]
   789 E C0442799:Efficient [Qualitative Concept]

Phrase: "is"

Phrase: "not dependent on either"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0851827:Dependent [Qualitative Concept]
   770   C1701901:Dependent [Qualitative Concept]
   770   C3244310:dependent [Functional Concept]

Phrase: "the presence of the FD mutation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "or"

Phrase: "the wider regulation of IKBKAP transcription"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C1158770:Transcription Regulation [Genetic Function]
   753   C0851285:Regulation [Governmental or Regulatory Activity]
   753   C1327622:Regulation [Biologic Function]

Phrase: "or"

Phrase: "IKAP protein production,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0033268:production [Occupational Activity]

Phrase: "and"

Phrase: "is"

Phrase: "likely due to specific sequence elements"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   790   C0678226:Due to [Functional Concept]
           due
   753   C0004793:Sequence [Nucleotide Sequence]
   753   C0013879:Elements [Element, Ion, or Isotope]
   753   C0162326:Sequence [Nucleotide Sequence]
   753   C0162327:Sequence [Nucleotide Sequence]
   753   C0205369:Specific [Qualitative Concept]
   753   C0332148:Likely [Qualitative Concept]
   753   C0750492:Likely [Idea or Concept]
   753   C1519249:Sequence [Functional Concept]
   753   C1552740:specific [Intellectual Product]
   753   C3146286:Due [Idea or Concept]
   719 E C1705248:Element [Conceptual Entity]

Phrase: "in the region"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0017446:Region [Geographic Area]
  1000   C0205147:Region [Spatial Concept]
   928 E C0205276:Regional [Spatial Concept]
   928 E C1947913:Regional [Spatial Concept]

Phrase: "of exon 20"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "that"

Phrase: "function"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "regulate"

Phrase: "splicing of this particular exon."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0035687:Splicing [Genetic Function]
   760   C2610186:splicing [Genetic Function]
Processing 00000000.tx.115: View larger version (37K): [in this window] [in a new window]  Figure 5. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(37K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 5."
Processing 00000000.tx.116: Kinetin enhances inclusion of exon 20 in both the MU and WT IKBKAP minigene. 

Phrase: "Kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "enhances"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhance [Activity]

Phrase: "inclusion of exon 20"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1512693:Inclusion [Qualitative Concept]

Phrase: "in both"

Phrase: "the MU"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "and"

Phrase: "WT IKBKAP minigene."
Processing 00000000.tx.117: (A) Schematic diagram illustrating the minigene constructs and the location of the IVS20+6TC mutation. 

Phrase: "(A) Schematic diagram"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0681494:Diagram [Intellectual Product]

Phrase: "illustrating"

Phrase: "the minigene constructs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2827421:Construct [Classification]

Phrase: "and"

Phrase: "the location of the IVS20+6TC mutation."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0450429:Location [Spatial Concept]
   748   C1515974:Location [Body Location or Region]
Processing 00000000.tx.118: Vector specific primers used for RTPCR analysis are shown. 

Phrase: "Vector specific primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "used for RTPCR analysis"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   770   C0002778:Analysis [Laboratory Procedure]
   770   C0599161:RT-PCR [Molecular Biology Research Technique]
   770   C0936012:Analysis [Research Activity]
   770   C1273517:used [Finding]
   770   C1524024:analysis [Functional Concept]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]

Phrase: "are"

Phrase: "shown."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]
Processing 00000000.tx.119: (B) RTPCR of MU and WT minigene RNA isolated from HEK293 cells following transfection and treatment with kinetin. 

Phrase: "(B) RTPCR of MU"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0599161:RT-PCR [Molecular Biology Research Technique]

Phrase: "and"

Phrase: "WT minigene RNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "isolated from HEK293 cells"
Meta Candidates (Total=10; Excluded=5; Pruned=0; Remaining=5)
   833   C2936239:HEK293 Cells [Cell]
   770   C0007634:Cells [Cell]
   770   C0205409:Isolated [Functional Concept]
   770   C1548221:Isolated [Idea or Concept]
   770   C3282337:Cells [Cell]
   737 E C0370215:Isolate [Substance]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1875400:ISOLATE [Pharmacologic Substance]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "transfection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040669:Transfection [Genetic Function,Molecular Biology Research Technique]

Phrase: "and"

Phrase: "treatment with kinetin."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0039798:treatment [Functional Concept]
   790   C0087111:Treatment [Therapeutic or Preventive Procedure]
   790   C1522326:Treatment [Functional Concept]
   790   C1533734:Treatment [Therapeutic or Preventive Procedure]
   790   C1705169:Treatment [Conceptual Entity]
   790   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.120: PCR was performed using the primers T7 and BGHR. 

Phrase: "PCR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
  1000   C0677874:pCR [Finding]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the primers T7"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1179691:T7 [Body Location or Region]

Phrase: "and"

Phrase: "BGHR."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0520815:bGHr [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
Processing 00000000.tx.121: Trace amounts of MU IKBKAP can be seen in the untreated WT lanes. 

Phrase: "Trace amounts of MU IKBKAP"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0442822:trace amount [Quantitative Concept]
   760   C1265611:amounts [Quantitative Concept]

Phrase: "can"

Phrase: "be"

Phrase: "seen in the untreated WT lanes."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   778   C1883559:Wild Type [Organism Attribute]
   748   C0205397:Seen [Qualitative Concept]
   748   C0332155:untreated [Finding]
   748   C0332307:Type [Qualitative Concept]
   748   C0445392:Wild [Intellectual Product]
   748   C1547052:*Type [Quantitative Concept]
   714 E C0042789:see [Organism Function]
   714   C1708639:Lane [Spatial Concept]
   714 E C1947903:See [Activity]
Processing 00000000.tx.122: PCR fragment sizes of the two spliced products are shown on the left. 

Phrase: "PCR fragment sizes of the two spliced products"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0456389:SIZES [Spatial Concept]

Phrase: "are"

Phrase: "shown on the left."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205091:Left [Spatial Concept]
   770   C1552822:left [Functional Concept]
   737   C1547282:Show [Intellectual Product]
Processing 00000000.tx.123: (C) RTPCR of the same RNA in (B) using T7 and a primer that spans the 1921 exon junction known to specifically amplify the MU band (23), showing absence of MU transcript in the WT lane following kinetin treatment. 

Phrase: "(C) RTPCR of the same RNA in (B)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0599161:RT-PCR [Molecular Biology Research Technique]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "T7"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1179691:T7 [Body Location or Region]

Phrase: "and"

Phrase: "a primer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "that"

Phrase: "spans"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1711300:Span [Conceptual Entity]
  1000   C2700613:Span [Quantitative Concept]

Phrase: "the 1921 exon junction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205144:Junction [Spatial Concept]
   827   C1706311:Junction [Medical Device]

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to specifically"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1883351:To [Qualitative Concept]

Phrase: "amplify"

Phrase: "the MU band"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0175723:Band [Medical Device]
   861   C0439645:Band [Spatial Concept]
   861   C1521913:band [Cell Component]

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "showing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "absence of MU transcript"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0332197:absence [Quantitative Concept]
   770   C1689985:Absence [Anatomical Abnormality]

Phrase: "in the WT lane"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1708639:Lane [Spatial Concept]
   734   C1883559:Wild Type [Organism Attribute]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "kinetin treatment."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.124: The size of this fragment is shown on the left.   

Phrase: "The size of this fragment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0456389:size [Spatial Concept]

Phrase: "is"

Phrase: "shown on the left."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205091:Left [Spatial Concept]
   770   C1552822:left [Functional Concept]
   737   C1547282:Show [Intellectual Product]
Processing 00000000.tx.125: DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  Mutations in the splice donor site that alter either the fifth or sixth base position, and might therefore be expected to lead to variable exon skipping, have been reported for over 30 different genetic disorders. 

Phrase: "DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Mutations in the splice donor site"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   803   C1519478:Splice-Site Mutation [Genetic Function]
   753   C0026882:Mutations [Genetic Function]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "either"

Phrase: "the fifth"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205439:Fifth [Quantitative Concept]

Phrase: "or"

Phrase: "sixth base position,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0733755:Position [Spatial Concept]
   755 E C0240795:POSITIONAL [Finding]

Phrase: "and"

Phrase: "might"

Phrase: "therefore"

Phrase: "be"

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "lead to variable exon skipping,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   760   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0439828:Variable [Qualitative Concept]
   760   C0560435:skipping [Finding]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "have"

Phrase: "been"

Phrase: "reported for over 30 different genetic disorders."
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   778   C0019247:Genetic Disorders [Disease or Syndrome]
   778   C2924406:Genetic disorders [Laboratory Procedure]
   751 E C0242354:birth disorders [Congenital Abnormality,Disease or Syndrome]
   748   C0012634:Disorders [Disease or Syndrome]
   748   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   748   C0314603:Genetic [Functional Concept]
   748   C0684224:Reported [Intellectual Product]
   748   C0700287:Reported [Health Care Activity]
   748   C1705242:Different [Qualitative Concept]
   748   C3496591:Reported [Clinical Attribute]
   737 E C0178829:Genital Disorders [Disease or Syndrome]
   714 E C3273238:Report [Intellectual Product]
   711   C2919603:Original report [Intellectual Product]
Processing 00000000.tx.126: FD is unusual among the common Ashkenazi Jewish disorders in that it is caused by only three mutations, the most frequent of which accounts for >99.5% of all FD chromosomes. 

Phrase: "FD"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]

Phrase: "is"

Phrase: "unusual among the common Ashkenazi Jewish disorders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C2700116:Unusual [Qualitative Concept]

Phrase: "in"

Phrase: "that"

Phrase: "it"

Phrase: "is"

Phrase: "caused by only three mutations,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0026882:Mutations [Genetic Function]
   760   C0205171:Only [Quantitative Concept]
   760   C0205449:Three [Quantitative Concept]
   760   C1720467:Only [Intellectual Product]
   726   C0015127:cause [Functional Concept]
   726   C1524003:Cause [Conceptual Entity]
   726 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "the most frequent of which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0332183:Frequent [Temporal Concept]

Phrase: "accounts for"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1551359:account [Idea or Concept]
   833   C2741673:Account # [Clinical Attribute]
   833   C2981730:Account [Classification]

Phrase: ">99.5% of all FD chromosomes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   757   C0008668:Chromosome 5 [Cell Component]
   748   C0008633:Chromosomes [Cell Component]
   748   C0013363:Dysautonomia [Disease or Syndrome]
   748   C0015576:familial [Family Group]
   748   C0241888:Familial [Functional Concept]
   748   C1145628:dysautonomia [Disease or Syndrome]
Processing 00000000.tx.127: This IVS20+6TC mutation is present on at least one chromosome in all FD patients identified to date. 

Phrase: "This IVS20+6TC mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0026882:Mutation [Genetic Function]
   827   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "is"

Phrase: "present on"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0150312:Present [Quantitative Concept]
   833   C0449450:Present [Idea or Concept]

Phrase: "at least one chromosome"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0008633:Chromosome [Cell Component]

Phrase: "in all FD patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]

Phrase: "identified to date."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0011008:Date [Temporal Concept]
   790   C0205396:Identified [Qualitative Concept]
   790   C1550043:Identified [Finding]
   790   C1551388:Identified [Functional Concept]
   790   C2348077:Date [Food]
Processing 00000000.tx.128: Given that FD is universally associated with one particular partial splicing mutation that results in subtle variability in IKAP levels suggests that tissue-specific splicing regulation underlies the development of the FD phenotype. 

Phrase: "Given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "that FD"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]

Phrase: "is"

Phrase: "universally"

Phrase: "associated with one particular partial splicing mutation"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   778   C0332281:Associated with [Qualitative Concept]
           Associated
   748   C0026882:Mutation [Genetic Function]
   748   C0035687:Splicing [Genetic Function]
   748   C0205447:One [Quantitative Concept]
   748   C0728938:Partial [Quantitative Concept]
   748   C1550516:partial [Idea or Concept]
   748   C1705285:Mutation [Cell or Molecular Dysfunction]
   748   C2610186:splicing [Genetic Function]
   714 E C0750490:Associate [Idea or Concept]
   714 E C1706221:Associate [Professional or Occupational Group]

Phrase: "that results in subtle variability"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   726   C1274040:Result [Functional Concept]
   726   C1546471:Result [Idea or Concept]
   726   C2825142:Result [Finding]

Phrase: "in IKAP levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that tissue-specific splicing regulation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0851285:Regulation [Governmental or Regulatory Activity]
   812   C1327622:Regulation [Biologic Function]
   756   C1519517:Tissue-Specific Splicing [Genetic Function]

Phrase: "underlies"

Phrase: "the development of the FD phenotype."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0243107:development [Physiologic Function]
   748   C0678723:Development [Organism Function]
   748   C1527148:Development [Functional Concept]
Processing 00000000.tx.129: In this study we demonstrate that kinetin can significantly increase the level of full-length IKAP protein in FD cells. 

Phrase: "In this study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "we"

Phrase: "demonstrate"

Phrase: "that kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "can"

Phrase: "significantly"

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "the level of full-length IKAP protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   774   C0428479:Protein level [Laboratory or Test Result]
   748   C0441889:Level [Qualitative Concept]
   748   C0456079:Level [Classification]
   748   C1547707:Level [Geographic Area]
   748   C2946261:Level [Pharmacologic Substance]

Phrase: "in FD cells."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
Processing 00000000.tx.130: This is exciting since even subtle changes in the level of functional protein have been shown to have a drastic effect on phenotype. 

Phrase: "This"

Phrase: "is"

Phrase: "exciting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0549255:Excite [Activity]

Phrase: "since even subtle changes in the level of functional protein"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   739   C0392747:changes [Functional Concept]
   739   C0443172:changes [Quantitative Concept]
   706 E C1705241:Change [Quantitative Concept]

Phrase: "have"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "a drastic effect on phenotype."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.131: For example, mutations in ATP7A are responsible for both Menkes disease (MD), a lethal disorder of copper metabolism, and occipital horn syndrome (OHS), a milder disorder characterized by connective tissue abnormalities. 

Phrase: "For example,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707959:Example [Conceptual Entity]

Phrase: "mutations in ATP7A"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0026882:Mutations [Genetic Function]
   756 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "responsible for both Menkes disease (MD),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1273518:Responsible [Finding]

Phrase: "a lethal disorder of copper metabolism,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   882   C0012714:Disorder of copper metabolism [Disease or Syndrome]
           copper metabolism disorder
           Copper disorder
   820   C0025517:Disorder of metabolism NOS [Disease or Syndrome]
           Metabolism disorder NOS
   753   C0012634:Disorder [Disease or Syndrome]

Phrase: "and"

Phrase: "occipital horn syndrome (OHS),"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0268353:Occipital horn syndrome [Congenital Abnormality]
   827   C0019939:Horn [Body Part, Organ, or Organ Component]
   827   C0039082:Syndrome [Disease or Syndrome]
   827   C1184145:Occipital [Body Location or Region]

Phrase: "a milder disorder"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   983   C3280118:Mild disorder [Finding]
   861   C0012634:Disorder [Disease or Syndrome]

Phrase: "characterized by connective tissue abnormalities."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0009780:Connective Tissue [Tissue]
   760   C0000768:Abnormalities [Congenital Abnormality]
   760   C0000769:abnormalities [Functional Concept]
   760   C0040300:Tissue [Tissue]
   760   C1547928:Tissue [Intellectual Product]
   760   C1880022:Characterized [Activity]
   726 E C1704258:Abnormality [Finding]
Processing 00000000.tx.132: MD is caused by mutations in the invariant donor splice site of exon 6 that lead to complete exon skipping, while OHS is the result of a mutation at bp 6 of the same donor splice site that leads to incomplete exon skipping, resulting in the milder phenotype (28). 

Phrase: "MD"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0022716:Menkes' Disease [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "is"

Phrase: "caused by mutations"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0026882:Mutations [Genetic Function]
   756   C0015127:cause [Functional Concept]
   756   C1524003:Cause [Conceptual Entity]
   756 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "in the invariant donor splice site"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   875   C1444716:Donor site [Body Location or Region]
   812   C0205145:Site [Spatial Concept]
   812   C1515974:Site [Body Location or Region]
   812   C2825164:Site [Spatial Concept]

Phrase: "of exon 6"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "that"

Phrase: "lead"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
  1000   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
  1000   C1522538:Lead [Functional Concept]
  1000   C2348269:Lead [Element, Ion, or Isotope]
  1000   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "complete"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Complete [Qualitative Concept]

Phrase: "exon skipping,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0560435:skipping [Finding]

Phrase: "while"

Phrase: "OHS"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0268353:Occipital horn syndrome [Congenital Abnormality]
   827   C0019939:Horn [Body Part, Organ, or Organ Component]
   827   C0039082:Syndrome [Disease or Syndrome]
   827   C1184145:Occipital [Body Location or Region]

Phrase: "is"

Phrase: "the result of a mutation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C1274040:Result [Functional Concept]
   760   C1546471:Result [Idea or Concept]
   760   C2825142:Result [Finding]

Phrase: "at bp 6"

Phrase: "of the same donor splice site"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   875   C1444716:Donor site [Body Location or Region]
   812   C0205145:Site [Spatial Concept]
   812   C1515974:Site [Body Location or Region]
   812   C2825164:Site [Spatial Concept]

Phrase: "that"

Phrase: "leads to incomplete exon skipping,"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   760   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0181586:leads [Medical Device]
   760   C0205257:Incomplete [Quantitative Concept]
   760   C0560435:skipping [Finding]
   760   C0728938:incomplete [Quantitative Concept]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C1548386:incomplete [Idea or Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "resulting in the milder phenotype"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   806   C0332294:Resulting in [Functional Concept]
   790   C1855585:Mild phenotype [Finding]
   760   C0031437:Phenotype [Organism Attribute]
   760   C0678226:resulting [Functional Concept]
   760   C1285572:Phenotype [Laboratory Procedure]
   726 E C1274040:Result [Functional Concept]
   726 E C1546471:Result [Idea or Concept]
   726 E C2825142:Result [Finding]
   726   C2945599:Mild [Qualitative Concept]

Phrase: "(28"

Phrase: ")."
Processing 00000000.tx.133: The level of functional protein in OHS is only 25% of normal, but sufficient to significantly alter the resulting phenotype. 

Phrase: "The level of functional protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   797   C0428479:Protein level [Laboratory or Test Result]
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1547707:Level [Geographic Area]
   760   C2946261:Level [Pharmacologic Substance]

Phrase: "in OHS"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0268353:Occipital horn syndrome [Congenital Abnormality]
   827   C0019939:Horn [Body Part, Organ, or Organ Component]
   827   C0039082:Syndrome [Disease or Syndrome]
   827   C1184145:Occipital [Body Location or Region]

Phrase: "is"

Phrase: "only 25% of normal,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0205171:Only [Quantitative Concept]
   770   C0205307:Normal [Qualitative Concept]
   770   C0439166:% normal [Quantitative Concept]
   770   C1720467:Only [Intellectual Product]
   770   C2347086:% Normal [Quantitative Concept]

Phrase: "but"

Phrase: "sufficient to significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205410:Sufficient [Qualitative Concept]

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "the resulting phenotype."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031437:Phenotype [Organism Attribute]
   861   C1285572:Phenotype [Laboratory Procedure]
Processing 00000000.tx.134: The same is true for Scn8a, a voltage-gated sodium channel that when mutated causes movement disorders, ataxia, and dystonia in mice. 

Phrase: "The same"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0445247:Same [Qualitative Concept]

Phrase: "is"

Phrase: "true for Scn8a,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205238:True [Qualitative Concept]

Phrase: "a voltage-gated sodium channel"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   923   C0597675:voltage gated channel [Physiologic Function]
   861   C0037492:Sodium Channel [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0037473:Sodium [Biologically Active Substance,Element, Ion, or Isotope]
   812   C0439799:Channel [Spatial Concept]
   812   C0597484:Sodium+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1706095:Channel [Conceptual Entity]

Phrase: "that"

Phrase: "when"

Phrase: "mutated"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1705285:Mutated [Cell or Molecular Dysfunction]
   966 E C1513776:Mutate [Genetic Function]

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "movement disorders,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0026650:Movement Disorders [Disease or Syndrome]
   861   C0012634:Disorders [Disease or Syndrome]
   861   C0026649:Movement [Organism Function]

Phrase: "ataxia,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0004134:Ataxia [Sign or Symptom]
   928 E C0234366:Ataxic [Sign or Symptom]

Phrase: "and"

Phrase: "dystonia in mice."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0013421:Dystonia [Sign or Symptom]
   790   C0393593:Dystonia [Disease or Syndrome]
Processing 00000000.tx.135: Scn8a null alleles produce progressive paralysis and death, while the Scn8amedJ allele, which has a splice donor mutation in intron 3 that leads to exon skipping, results in a milder phenotype (29). 

Phrase: "Scn8a null alleles"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   884   C2985437:Null Allele [Cell or Molecular Dysfunction]
   827   C0002085:Alleles [Gene or Genome]

Phrase: "produce"

Phrase: "progressive paralysis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205858:PARALYSIS, PROGRESSIVE [Disease or Syndrome]
   861   C0522224:Paralysis [Finding]

Phrase: "and"

Phrase: "death,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011065:Death [Organism Function]
  1000   C1306577:Death, NOS [Finding]

Phrase: "while"

Phrase: "the Scn8amedJ allele,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0002085:Allele [Gene or Genome]

Phrase: "which"

Phrase: "has"

Phrase: "a splice donor mutation in intron 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C1881250:Intron Mutation [Genetic Function]
   748   C0026882:Mutation [Genetic Function]
   748   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "leads to exon skipping,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   770   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   770   C0181586:leads [Medical Device]
   770   C0560435:skipping [Finding]
   770   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   770   C1522538:Lead [Functional Concept]
   770   C2348269:Lead [Element, Ion, or Isotope]
   770   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "results in a milder phenotype"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C1855585:Mild phenotype [Finding]
   760   C0031437:Phenotype [Organism Attribute]
   760   C1274040:Result [Functional Concept]
   760   C1285572:Phenotype [Laboratory Procedure]
   760   C1546471:Result [Idea or Concept]
   760   C2825142:Result [Finding]
   726   C2945599:Mild [Qualitative Concept]

Phrase: "(29"

Phrase: ")."
Processing 00000000.tx.136: Scn8a exon skipping is modulated by Scnm1, whereby homozygosity for the Scnm1 B allele reduces the level of correctly spliced transcripts from 12 to 6% and results in a lethal phenotype (29,30). 

Phrase: "Scn8a exon skipping"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0560435:skipping [Finding]

Phrase: "is"

Phrase: "modulated by Scnm1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0443264:Modulated [Spatial Concept]
   790   C1427938:SCNM1 [Gene or Genome]

Phrase: "whereby homozygosity for the Scnm1 B allele"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0019904:Homozygosity [Organism Attribute]

Phrase: "reduces"

Phrase: "the level of correctly spliced transcripts"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0441889:Level [Qualitative Concept]
   753   C0456079:Level [Classification]
   753   C1547707:Level [Geographic Area]
   753   C2946261:Level [Pharmacologic Substance]

Phrase: "from 12"

Phrase: "to 6%"

Phrase: "and"

Phrase: "results in a lethal phenotype"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0031437:Phenotype [Organism Attribute]
   760   C1274040:Result [Functional Concept]
   760   C1285572:Phenotype [Laboratory Procedure]
   760   C1546471:Result [Idea or Concept]
   760   C2825142:Result [Finding]
   760   C3151529:Lethal [Finding]

Phrase: "(29,"

Phrase: "30"

Phrase: ")."
Processing 00000000.tx.137: These studies suggest that even a modest increase in the amount of functional IKAP in FD cells might prove effective in preventing the continued neuronal degeneration that occurs throughout life in persons with FD. 

Phrase: "These studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that even"

Phrase: "a modest increase in the amount of functional IKAP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0442805:Increase [Functional Concept]

Phrase: "in FD cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]

Phrase: "might"

Phrase: "prove"

Phrase: "effective in preventing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280519:effective [Qualitative Concept]
   790   C1704419:Effective [Qualitative Concept]

Phrase: "the continued neuronal degeneration"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   865   C0027746:Neuron Degeneration [Cell or Molecular Dysfunction]
   827   C0011164:Degeneration [Pathologic Function]
   827   C1880269:Degeneration [Functional Concept]

Phrase: "that"

Phrase: "occurs throughout life"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0376558:Life [Idea or Concept]
   790   C1709305:Occur [Activity]
   790   C2745955:OCCUR [Temporal Concept]
   706 E C0595998:lives [Finding]

Phrase: "in persons"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0027361:Persons [Population Group]
   966 E C2347489:Person [Group]
   916 E C1519021:Personal [Organism Attribute]

Phrase: "with FD."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]
Processing 00000000.tx.138: Methods aimed at increasing correctly spliced transcripts in a few disorders that result from exon skipping have been reported, perhaps most notably in spinal muscular atrophy. 

Phrase: "Methods"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "aimed at increasing correctly spliced transcripts"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   753   C0442808:Increasing [Functional Concept]
   753   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]
   719 E C0442805:Increase [Functional Concept]
   719   C1947946:Aim [Idea or Concept]
   719   C2948600:Aim [Pharmacologic Substance]
   719   C3540471:AIM [Gene or Genome]
   719   C3540472:AIM [Functional Concept]

Phrase: "in a few disorders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012634:Disorders [Disease or Syndrome]

Phrase: "that"

Phrase: "result from exon skipping"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   770   C0560435:skipping [Finding]
   770   C1274040:Result [Functional Concept]
   770   C1546471:Result [Idea or Concept]
   770   C2825142:Result [Finding]

Phrase: "have"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: ","

Phrase: "perhaps most notably in spinal muscular atrophy."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   814   C0026847:Spinal Muscular Atrophy [Disease or Syndrome]
   778   C0026846:Muscular Atrophy [Disease or Syndrome]
   748   C0026845:Muscular [Tissue]
   748   C0333641:Atrophy [Pathologic Function]
   748   C0442025:Muscular [Spatial Concept]
   748   C0521329:Spinal [Spatial Concept]
Processing 00000000.tx.139: Sodium butyrate, aclarubicin, sodium vanadate, valproic acid and Htra2--1 have all been shown to promote the inclusion of exon 7 in the SMN2 transcript (1014). 

Phrase: "Sodium butyrate,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0142812:Sodium Butyrate [Lipid,Pharmacologic Substance]
   861   C0006521:butyrate [Lipid]
   861   C0037473:Sodium [Biologically Active Substance,Element, Ion, or Isotope]
   861   C0220802:butyrate [Lipid]
   861   C0597484:Sodium+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "aclarubicin,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0001143:Aclarubicin [Antibiotic,Organic Chemical]
  1000   C0771002:Aclarubicin [Antibiotic,Organic Chemical]

Phrase: "sodium vanadate,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0037568:Sodium Vanadate [Inorganic Chemical,Pharmacologic Substance]
   861   C0042305:Vanadate [Inorganic Chemical]

Phrase: "valproic acid"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042291:Valproic Acid [Organic Chemical,Pharmacologic Substance]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "and"

Phrase: "Htra2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1825553:HTRA2 [Gene or Genome]

Phrase: "--"

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "have"

Phrase: "all"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "promote"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "the inclusion of exon 7"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1512693:Inclusion [Qualitative Concept]

Phrase: "in the SMN2 transcript"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1519595:Transcript [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(1014"

Phrase: ")."
Processing 00000000.tx.140: Aclarubicin was tested on FD cells as part of our original screen and had no effect on IKBKAP splicing. 

Phrase: "Aclarubicin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0001143:Aclarubicin [Antibiotic,Organic Chemical]
  1000   C0771002:Aclarubicin [Antibiotic,Organic Chemical]

Phrase: "was"

Phrase: "tested on FD cells"
Meta Candidates (Total=13; Excluded=5; Pruned=0; Remaining=8)
   806   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   760   C0007634:Cells [Cell]
   760   C0013363:Dysautonomia [Disease or Syndrome]
   760   C0015576:familial [Family Group]
   760   C0241888:Familial [Functional Concept]
   760   C0392366:tested [Intellectual Product]
   760   C1145628:dysautonomia [Disease or Syndrome]
   760   C3282337:Cells [Cell]
   726 E C0022885:Test [Laboratory Procedure]
   726 E C0039593:Test [Functional Concept]
   726 E C1269647:Cell [Cell]
   726 E C1704653:Cell [Medical Device]
   726 E C1948049:Cell [Spatial Concept]

Phrase: "as part"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0449719:Part [Spatial Concept]
  1000   C1709471:Part [Quantitative Concept]

Phrase: "of our original screen"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0220908:screen [Health Care Activity]
   861   C1305399:screen [Functional Concept]
   861   C1705053:Screen [Medical Device]

Phrase: "and"

Phrase: "had"

Phrase: "no effect on IKBKAP splicing."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C1301751:No effect [Qualitative Concept]
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.141: Similarly, kinetin has no effect on exon 7 inclusion in SMN2 (Jianhua Zhou, personal communication), and neither of these drugs promotes inclusion of alternatively spliced exons in MYO5A (12). 

Phrase: "Similarly,"

Phrase: "kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "has"

Phrase: "no effect on exon 7 inclusion"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1301751:No effect [Qualitative Concept]
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "in SMN2"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   861   C0026609:Motor neuron [Cell]
   812   C0027882:Neuron [Cell]
   812   C0038952:Survival [Activity]
   812   C0220921:survival [Functional Concept]
   812   C1513492:Motor [Functional Concept]
   812   C1705994:Motor [Manufactured Object]
   741 E C0521390:Neuronal [Immunologic Factor]

Phrase: "(Jianhua Zhou,"

Phrase: "personal communication"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0086792:Personal Communication [Social Behavior]
   861   C0009452:Communication [Social Behavior]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "neither of these drugs"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0013227:Drugs [Pharmacologic Substance]
   770   C3274651:Neither [Qualitative Concept]
   737 E C1254351:Drug [Pharmacologic Substance]

Phrase: "promotes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "inclusion of alternatively spliced exons"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1512693:Inclusion [Qualitative Concept]

Phrase: "in MYO5A"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1417565:MYO5A [Gene or Genome]

Phrase: "(12"

Phrase: ")."
Processing 00000000.tx.142: Taken together, these studies clearly indicate that there are multiple distinct mechanisms that contribute to exon choice during pre-mRNA splicing in both normal and disease situations. 

Phrase: "Taken"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883727:Taken [Conceptual Entity]
   966 E C1515187:Take [Health Care Activity]

Phrase: "together,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883357:Together [Qualitative Concept]

Phrase: "these studies clearly"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "indicate"

Phrase: "that there"

Phrase: "are"

Phrase: "multiple distinct mechanisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0441712:Mechanisms [Functional Concept]
   793 E C1706376:Mechanism [Manufactured Object]

Phrase: "that"

Phrase: "contribute to exon choice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0008300:choice [Individual Behavior]
   770   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   770   C1707391:Choice [Activity]
   770   C1880177:Contribute [Activity]

Phrase: "during pre-mRNA splicing"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C1622990:pre-mRNA splicing [Genetic Function]
   901   C0086934:mRNA splicing [Genetic Function]
   827   C0035687:Splicing [Genetic Function]
   827   C2610186:splicing [Genetic Function]
   734   C0026661:Pre-mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   734   C0035695:Pre-mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "in both normal"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205307:Normal [Qualitative Concept]
  1000   C0439166:% normal [Quantitative Concept]
  1000   C2347086:% Normal [Quantitative Concept]

Phrase: "and"

Phrase: "disease situations."
Processing 00000000.tx.143: SR proteins and hnRNPs are known to play a crucial role in pre-mRNA splicing, and changes in their cellular distribution, expression or activation can mediate both constitutive and alternative splicing (8,9,31,32). 

Phrase: "SR proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "hnRNPs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0123538:hnRNP [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "are"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "play"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:play [Finding]

Phrase: "a crucial role in pre-mRNA splicing,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035820:Role [Social Behavior]
   748   C1705810:Role [Conceptual Entity]

Phrase: "and"

Phrase: "changes in their cellular distribution,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0007634:Cellular [Cell]
   760   C0178539:Cellular [Functional Concept]
   760   C0392747:Change [Functional Concept]
   760   C0443172:change [Quantitative Concept]
   760   C0520511:distribution [Idea or Concept]
   760   C1704711:Distribution [Functional Concept]
   760   C1705241:Change [Quantitative Concept]

Phrase: "expression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "or"

Phrase: "activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "can"

Phrase: "mediate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediate [Social Behavior]

Phrase: "both constitutive"

Phrase: "and"

Phrase: "alternative splicing"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0002345:Alternative Splicing [Genetic Function]
   861   C0035687:Splicing [Genetic Function]
   861   C2610186:splicing [Genetic Function]

Phrase: "(8,"

Phrase: "9,"

Phrase: "31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "32"

Phrase: ")."
Processing 00000000.tx.144: Their direct positive effect on exon inclusion when disease-causing mutations are present has been shown for both CFTR and SMN2 transcripts (9,10). 

Phrase: "Their direct positive effect on exon inclusion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "when"

Phrase: "disease-causing mutations"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   988   C2985434:Disease-causing Mutation [Cell or Molecular Dysfunction]
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]
   717   C1314792:disease cause [Functional Concept]

Phrase: "are"

Phrase: "present"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0150312:Present [Quantitative Concept]
  1000   C0449450:Present [Idea or Concept]

Phrase: "has"

Phrase: "been"

Phrase: "shown for both CFTR"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0056889:CFTR [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C1413365:CFTR [Gene or Genome]
   737   C1547282:Show [Intellectual Product]

Phrase: "and"

Phrase: "SMN2 transcripts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(9,"

Phrase: "10"

Phrase: ")."
Processing 00000000.tx.145: In addition, immunofluorescence experiments demonstrate that aclarubicin induces a redistribution of SR proteins (12). 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "immunofluorescence experiments"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]

Phrase: "demonstrate"

Phrase: "that aclarubicin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0001143:Aclarubicin [Antibiotic,Organic Chemical]
  1000   C0771002:Aclarubicin [Antibiotic,Organic Chemical]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "a redistribution of SR proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0332620:Redistribution [Functional Concept]

Phrase: "(12"

Phrase: ")."
Processing 00000000.tx.146: Very recently, it has been reported that ()-epigallocatechin gallate (EGCG) can increase correct IKBKAP splicing in FD cells (33). 

Phrase: "Very recently,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332185:Recently [Temporal Concept]
   861   C0442824:Very [Qualitative Concept]

Phrase: "it"

Phrase: "has"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "that"

Phrase: "("

Phrase: ")-"

Phrase: "epigallocatechin gallate (EGCG)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0059438:epigallo-catechin gallate [Organic Chemical,Pharmacologic Substance]
   861   C0061012:epigallocatechin [Organic Chemical]
   861   C2348459:Epigallocatechin [Organic Chemical]

Phrase: "can"

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "correct IKBKAP splicing in FD cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035687:Splicing [Genetic Function]
   748   C2610186:splicing [Genetic Function]

Phrase: "(33"

Phrase: ")."
Processing 00000000.tx.147: EGCG, an antioxidant found in green tea, is known to down-regulate the expression of hnRNP A2/B1 (34), which may explain its effect on IKBKAP splicing. 

Phrase: "EGCG,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0059438:epigallo-catechin gallate [Organic Chemical,Pharmacologic Substance]
   861   C0061012:epigallocatechin [Organic Chemical]
   861   C2348459:Epigallocatechin [Organic Chemical]

Phrase: "an antioxidant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003402:Antioxidant [Pharmacologic Substance]

Phrase: "found in green tea,"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   833   C1384640:Green tea [Food]
   791 E C1704263:green teas [Organic Chemical,Pharmacologic Substance]
   770   C0039400:Tea [Food]
   770   C0150312:Found [Quantitative Concept]
   770   C0332583:Green [Qualitative Concept]
   737 E C0243095:Find [Finding]
   715 E C0543468:Thea [Plant]
   715 E C1825834:THEA [Gene or Genome]

Phrase: "is"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "down-regulate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   805   C0423866:Lanugo [Body Part, Organ, or Organ Component]
   805   C2626739:Lanugo [Eukaryote]

Phrase: "the expression of hnRNP A2/B1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0185117:Expression [Therapeutic or Preventive Procedure]
   703   C0209851:Heterogeneous Nuclear Ribonucleoprotein A2/B1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   703   C1415636:HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2/B1 [Gene or Genome]

Phrase: "(34"

Phrase: ")"

Phrase: ","

Phrase: "which"

Phrase: "may"

Phrase: "explain"

Phrase: "its effect on IKBKAP splicing."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.148: Kinetin is currently marketed as an anti-aging ingredient in skin treatments due to its ability to ameliorate aging characteristics in cultured human fibroblasts (35), possibly through anti-oxidant activity (36). 

Phrase: "Kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "is"

Phrase: "currently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521116:Currently [Temporal Concept]

Phrase: "marketed as an anti-aging ingredient"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   753   C0001811:Ageing [Organism Function]
   753   C1550600:Ingredient [Chemical Viewed Functionally]
   719 E C0001779:Age [Organism Attribute]
   719   C1318228:Market [Geographic Area]

Phrase: "in skin treatments"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
  1000   C1718338:Skin treatments [Therapeutic or Preventive Procedure]
   861   C0087111:Treatments [Therapeutic or Preventive Procedure]
   827 E C0039798:treatment [Functional Concept]
   827 E C1522326:Treatment [Functional Concept]
   827 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   827 E C1705169:Treatment [Conceptual Entity]
   827 E C3538994:TREATMENT [Research Activity]

Phrase: "due to its ability to"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0085732:Ability [Organism Attribute]
   789 E C1299581:Able [Finding]

Phrase: "ameliorate"

Phrase: "aging characteristics in cultured human fibroblasts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C0870672:Human Characteristics [Group Attribute]
   753   C1521970:Characteristics [Qualitative Concept]

Phrase: "(35"

Phrase: ")"

Phrase: ","

Phrase: "possibly through anti-oxidant activity"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0085403:oxidant [Chemical Viewed Functionally]
   760   C0205177:Activity [Functional Concept]
   760   C0439167:% activity [Quantitative Concept]
   760   C0441655:Activity [Activity]
   760   C1561536:*Activity [Idea or Concept]
   760   C2362652:Possibly [Qualitative Concept]

Phrase: "(36"

Phrase: ")."
Processing 00000000.tx.149: Our demonstration that kinetin can increase correct splicing of the control IKBKAP minigene construct suggests that its function is not dependant on the IVS+6 mutation, but rather linked to particular sequence elements that control IKBKAP exon 20 splicing. 

Phrase: "Our demonstration"

Phrase: "that kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "can"

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "correct splicing of the control IKBKAP minigene construct"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035687:Splicing [Genetic Function]
   744   C2610186:splicing [Genetic Function]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "its function"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]
   928 E C0205245:Functional [Functional Concept]
   928 E C2700217:Functional [Conceptual Entity]

Phrase: "is"

Phrase: "not dependant on the IVS+6 mutation,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0851827:Dependent [Qualitative Concept]
   748   C1701901:Dependent [Qualitative Concept]
   748   C3244310:dependent [Functional Concept]

Phrase: "but"

Phrase: "rather"

Phrase: "linked to particular sequence elements"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   760   C0004793:Sequence [Nucleotide Sequence]
   760   C0013879:Elements [Element, Ion, or Isotope]
   760   C0162326:Sequence [Nucleotide Sequence]
   760   C0162327:Sequence [Nucleotide Sequence]
   760   C1519249:Sequence [Functional Concept]
   726   C1517892:Link [Intellectual Product]
   726   C1704666:Link [Intellectual Product]
   726 E C1705248:Element [Conceptual Entity]

Phrase: "that"

Phrase: "control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "IKBKAP exon 20 splicing."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0035687:Splicing [Genetic Function]
   812   C2610186:splicing [Genetic Function]
Processing 00000000.tx.150: This finding, combined with the studies cited above, suggests that kinetin likely influences the activation or cellular localization of specific spliceosomal proteins. 

Phrase: "This finding,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0037088:Finding [Sign or Symptom]
  1000   C0243095:Finding [Finding]
  1000   C2825141:Finding [Finding]

Phrase: "combined with the studies"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0205195:Combined [Qualitative Concept]
   770   C0947630:studies [Laboratory Procedure]
   737 E C0336789:Combine [Manufactured Object]
   737 E C0557651:Study [Manufactured Object]
   737 E C2603343:Study [Research Activity]

Phrase: "cited"

Phrase: "above,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1282910:Above [Spatial Concept]
  1000   C1552828:above [Idea or Concept]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that kinetin likely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "influences"

Phrase: "the activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "or"

Phrase: "cellular localization of specific spliceosomal proteins."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   803   C2612729:cellular protein localisation [Cell Function]
   790   C1660642:cellular localisation [Cell Function]
   767   C0597704:protein localisation [Cell Function]
   767   C1159772:Protein Localization [Cell Function]
   753   C0475264:Localisation [Functional Concept]
   753   C1744691:localisation [Biologic Function]
Processing 00000000.tx.151: The effect of EGCG on WT IKBKAP expression and cellular IKAP levels is not as dramatic as that of kinetin, but it will be interesting to compare their activities directly and assess their therapeutic value when used together. 

Phrase: "The effect of EGCG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "on WT IKBKAP expression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "cellular IKAP levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]

Phrase: "is"

Phrase: "not as dramatic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1518422:Not [Functional Concept]

Phrase: "as that"

Phrase: "of kinetin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "but"

Phrase: "it"

Phrase: "will"

Phrase: "be"

Phrase: "interesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0543488:interesting [Mental Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "compare"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compare [Activity]

Phrase: "their activities directly"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441655:Activities [Activity]
   827 E C0205177:Activity [Functional Concept]
   827 E C0439167:% activity [Quantitative Concept]
   827 E C1561536:*Activity [Idea or Concept]

Phrase: "and"

Phrase: "assess"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assess [Activity]

Phrase: "their therapeutic value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1522609:Value [Quantitative Concept]

Phrase: "when"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "together."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883357:Together [Qualitative Concept]
Processing 00000000.tx.152: Further studies into the mechanism of action of these compounds will no doubt lead to a better understanding of a fundamental regulatory process controlling tissue-specific gene expression. 

Phrase: "Further studies into the mechanism of action of these compounds"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   741   C2986485:Action Study [Research Activity]
   739   C0947630:studies [Laboratory Procedure]
   722   C2698671:MECHANISTIC STUDIES [Regulation or Law]
   706 E C0557651:Study [Manufactured Object]
   706 E C2603343:Study [Research Activity]

Phrase: "will"

Phrase: "no doubt"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0870444:doubt [Mental Process]
   928 E C0750558:Doubtful [Conceptual Entity]

Phrase: "lead to a better understanding"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0162340:Understanding [Mental Process]
   760   C0332272:Better [Qualitative Concept]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "of a fundamental regulatory process controlling tissue-specific gene expression."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   864   C0017362:Regulatory Gene [Gene or Genome]
   861   C1519516:Tissue-Specific Gene Expression [Genetic Function]
   812   C0017262:Gene Expression [Genetic Function]
   793   C0017337:Gene [Gene or Genome]
   793   C0185117:Expression [Therapeutic or Preventive Procedure]
Processing 00000000.tx.153: In the meantime, they may be useful not only in the treatment of FD, but also of many other disorders caused by splicing mutations under similar regulatory control.  

Phrase: "In the meantime,"

Phrase: "they"

Phrase: "may"

Phrase: "be"

Phrase: "useful"

Phrase: "not only in the treatment of FD,"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   770   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   744   C0013363:Dysautonomia [Disease or Syndrome]
   744   C0015576:familial [Family Group]
   744   C0039798:treatment [Functional Concept]
   744   C0087111:Treatment [Therapeutic or Preventive Procedure]
   744   C0205171:Only [Quantitative Concept]
   744   C0241888:Familial [Functional Concept]
   744   C1145628:dysautonomia [Disease or Syndrome]
   744   C1518422:Not [Functional Concept]
   744   C1522326:Treatment [Functional Concept]
   744   C1533734:Treatment [Therapeutic or Preventive Procedure]
   744   C1705169:Treatment [Conceptual Entity]
   744   C1720467:Only [Intellectual Product]
   744   C3538994:TREATMENT [Research Activity]

Phrase: "but"

Phrase: "also of many"

Phrase: "other disorders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012634:Disorders [Disease or Syndrome]

Phrase: "caused by splicing mutations"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   770   C0026882:Mutations [Genetic Function]
   770   C0035687:Splicing [Genetic Function]
   770   C2610186:splicing [Genetic Function]
   737   C0015127:cause [Functional Concept]
   737   C1524003:Cause [Conceptual Entity]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "under similar regulatory control."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   827   C0220905:regulatory [Regulation or Law]
   827   C0243148:control [Qualitative Concept]
   827   C1550141:Control [Substance]
   827   C1704735:Regulatory [Conceptual Entity]
   827   C1882979:Control [Conceptual Entity]
   827   C2587213:Control [Functional Concept]
   827   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.154: MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  Patient cell lines Patient lymphoblast cell lines previously established in our laboratory by EBV transformation were utilized in this study (20,37). 

Phrase: "MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Patient cell lines Patient lymphoblast cell lines previously"

Phrase: "established in our laboratory"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0022877:Laboratory [Manufactured Object,Organization]
   770   C0443211:Established [Qualitative Concept]
   770   C1272684:Established [Qualitative Concept]
   770   C3244292:laboratory [Functional Concept]

Phrase: "by EBV transformation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0040682:Transformation [Cell Function]
   861   C1510411:Transformation [Pathologic Function]
   861   C1705163:Transformation [Research Activity]

Phrase: "were"

Phrase: "utilized in this study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]

Phrase: "(20,"

Phrase: "37"

Phrase: ")."
Processing 00000000.tx.155: We have current Institutional Review Board approval for the establishment and use of these lines through New York University Medical Center, Massachusetts General Hospital, and Harvard Medical School. 

Phrase: "We"

Phrase: "have"

Phrase: "current Institutional Review Board approval for the establishment"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   833   C2346499:Institutional Review Board Approval [Regulation or Law]
   800   C0086911:Review Board, Institutional [Professional or Occupational Group]
   744   C0205540:Approval [Qualitative Concept]
   744   C0282443:Review [Intellectual Product]
   744   C0972401:board [Medical Device]
   744   C1552617:Review [Idea or Concept]
   744   C1948070:Board [Organization]
   744   C2346845:Approval [Intellectual Product]

Phrase: "and"

Phrase: "use of these lines"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C1524063:Use of [Functional Concept]
   770   C0042153:use [Functional Concept]
   770   C0457083:Use [Functional Concept]
   770   C1947944:Use [Intellectual Product]

Phrase: "through New York University Medical Center,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   884   C0000872:University Medical Center [Health Care Related Organization,Manufactured Object]
   840   C0027976:New York [Geographic Area]
   840   C0565990:Medical center [Health Care Related Organization,Manufactured Object]
   840   C1552471:Medical Center [Health Care Related Organization,Manufactured Object]
   804   C0041740:University [Manufactured Object,Organization]
   804   C0205099:Center [Spatial Concept]
   804   C0205314:New [Temporal Concept]
   804   C0205476:Medical [Functional Concept]

Phrase: "Massachusetts General Hospital,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   901   C0020008:general hospital [Health Care Related Organization,Manufactured Object]
   827   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   827   C0205246:General [Spatial Concept]
   827   C1510665:Hospital [Qualitative Concept]
   827   C1553889:General [Idea or Concept]
   743 E C1609061:Hospitals [Intellectual Product]

Phrase: "and"

Phrase: "Harvard Medical School."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0036378:School, Medical [Health Care Related Organization,Manufactured Object]
   827   C0036375:School [Manufactured Object,Organization]
Processing 00000000.tx.156: Two fibroblast cell lines were used in the current study, GUS12829 was established in our laboratory and GM02343 was purchased from the Coriell Cell Repository. 

Phrase: "Two fibroblast cell lines"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   890   C0682524:fibroblast cell line [Cell]
   861   C0007600:Cell lines [Cell]
   861   C0016030:fibroblast cell [Cell]
           Fibroblast
   812   C0007634:Cell [Cell]
   812   C0205132:lines [Spatial Concept]
   812   C1269647:Cell [Cell]
   812   C1704653:Cell [Medical Device]
   812   C1948049:Cell [Spatial Concept]
   779 E C1550648:Line [Substance]
   779 E C1552960:Line [Quantitative Concept]

Phrase: "were"

Phrase: "used in the current study,"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   781   C0869040:study use [Research Activity]
   760   C0521116:Current [Temporal Concept]
   760   C0557651:Study [Manufactured Object]
   760   C1273517:used [Finding]
   760   C1705970:Current [Natural Phenomenon or Process]
   760   C2603343:Study [Research Activity]
   726 E C0042153:use [Functional Concept]
   726 E C0457083:Use [Functional Concept]
   726 E C1947944:Use [Intellectual Product]

Phrase: "GUS12829"

Phrase: "was"

Phrase: "established in our laboratory"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0022877:Laboratory [Manufactured Object,Organization]
   770   C0443211:Established [Qualitative Concept]
   770   C1272684:Established [Qualitative Concept]
   770   C3244292:laboratory [Functional Concept]

Phrase: "and"

Phrase: "GM02343"

Phrase: "was"

Phrase: "purchased from the Coriell Cell Repository."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0007634:Cell [Cell]
   753   C0869011:purchased [Activity]
   753   C0872261:Repository [Manufactured Object]
   753   C1269647:Cell [Cell]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]
Processing 00000000.tx.157: Drug screen The panel of 1040 independent compounds used was specifically designed for the NINDS sponsored Neurodegeneration Drug Screening Consortium (MicroSource Discovery Systems). 

Phrase: "Drug"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0013227:Drug [Pharmacologic Substance]
  1000   C1254351:Drug [Pharmacologic Substance]
   944 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   944 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   907 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "screen"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0220908:screen [Health Care Activity]
  1000   C1305399:screen [Functional Concept]
  1000   C1705053:Screen [Medical Device]

Phrase: "The panel of 1040 independent compounds"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0441833:Panel [Idea or Concept]
   753   C1999270:Panel [Intellectual Product]
   753   C3537156:Panel [Manufactured Object]

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "was"

Phrase: "specifically"

Phrase: "designed for the NINDS sponsored Neurodegeneration Drug Screening Consortium"
Meta Candidates (Total=22; Excluded=3; Pruned=0; Remaining=19)
   764   C0013206:Drug Screening [Research Activity]
   764   C0373483:drug screening [Laboratory Procedure]
   748 E C0038577:Drug Screen [Laboratory Procedure]
   745   C0013171:Drug Design [Occupation or Discipline]
   745   C2347936:Drug Sponsor [Organization]
   742   C0013227:Drug [Pharmacologic Substance]
   742   C0027746:Neurodegeneration [Cell or Molecular Dysfunction]
   742   C0220908:Screening [Health Care Activity]
   742   C0220909:screening [Functional Concept]
   742   C1254351:Drug [Pharmacologic Substance]
   742   C1513822:Consortium [Professional or Occupational Group]
   742   C1698960:screening [Intellectual Product]
   742   C1710031:Screening [Diagnostic Procedure]
   742   C1710477:SCREENING [Research Activity]
   742   C1880171:Consortium [Professional or Occupational Group]
   742   C2350584:NINDS [Health Care Related Organization]
   708 E C1305399:screen [Functional Concept]
   708 E C1705053:Screen [Medical Device]
   708   C1707689:Design [Activity]
   708   C1711305:Sponsor [Human]
   708   C2347796:SPONSOR [Organization]
   708   C2983265:DESIGN [Intellectual Product]

Phrase: "(MicroSource Discovery Systems"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   793   C0449913:System [Functional Concept]
   793   C1553451:System [Manufactured Object]
   793   C1704459:System [Medical Device]
   743 E C0205373:Systemic [Functional Concept]

Phrase: ")."
Processing 00000000.tx.158: A single FD lymphoblast cell line was cultured in 24-well format and treated with 10M compound dissolved in DMSO for 72h. 

Phrase: "A single FD lymphoblast cell line"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   827   C0007600:Cell Line [Cell]
   799   C0007634:Cell [Cell]
   799   C0205132:Line [Spatial Concept]
   799   C1269647:Cell [Cell]
   799   C1550648:Line [Substance]
   799   C1552960:Line [Quantitative Concept]
   799   C1704653:Cell [Medical Device]
   799   C1948049:Cell [Spatial Concept]

Phrase: "was"

Phrase: "cultured in 24-well"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0205170:Well [Qualitative Concept]
   770   C3146287:Well [Manufactured Object]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "format"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1301627:Format [Intellectual Product]

Phrase: "and"

Phrase: "treated with 10M compound"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0205198:Compound [Qualitative Concept]
   770   C1442446:10M [Temporal Concept]
   770   C1522326:Treated [Functional Concept]
   770   C1706082:Compound [Chemical]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "dissolved in DMSO"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]
   756   C1549535:Dissolve [Functional Concept]

Phrase: "for 72h."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292423:72H [Temporal Concept]
Processing 00000000.tx.159: RNA was extracted using Tri-ReagentTM (Molecular Research Center) and reverse transcription and IKBKAP PCR was performed as previously described (23). 

Phrase: "RNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "extracted"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0185115:Extracted [Therapeutic or Preventive Procedure]
  1000   C3541890:EXTRACTED [Finding]
   966 E C2828366:Extract [Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "Tri-ReagentTM"

Phrase: "(Molecular Research Center"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0683939:research center [Manufactured Object,Organization]
   827   C0205099:Center [Spatial Concept]

Phrase: ")"

Phrase: "and"

Phrase: "reverse transcription"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0035380:Reverse Transcription [Genetic Function]
   861   C0040649:Transcription [Genetic Function]
   861   C1555029:Reverse [Idea or Concept]

Phrase: "and"

Phrase: "IKBKAP PCR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   861   C0677874:pCR [Finding]

Phrase: "was"

Phrase: "performed as previously"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0884358:Performed [Functional Concept]
   756 E C2947996:Perform [Pharmacologic Substance]

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.160: Cell culture and treatment FD lymphoblast lines were grown in RPMI-1640 and primary fibroblast lines in Dulbecco's modified Eagle's media (DMEM) with Earle's balanced salts. 

Phrase: "Cell culture"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0007585:Cell Culture [Laboratory Procedure]
   861   C0007634:Cell [Cell]
   861   C0010453:Culture [Idea or Concept]
   861   C0220814:culture [Functional Concept]
   861   C0430400:Culture [Laboratory Procedure]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]
   861   C2242979:Culture [Laboratory Procedure]

Phrase: "and"

Phrase: "treatment FD lymphoblast lines"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   804   C0205132:lines [Spatial Concept]
   771 E C1550648:Line [Substance]
   771 E C1552960:Line [Quantitative Concept]

Phrase: "were"

Phrase: "grown in RPMI-1640"

Phrase: "and"

Phrase: "primary fibroblast lines in Dulbecco's modified Eagle's media"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   744   C0205132:lines [Spatial Concept]
   711 E C1550648:Line [Substance]
   711 E C1552960:Line [Quantitative Concept]

Phrase: "(DMEM"

Phrase: ")"

Phrase: "with Earle's balanced salts."
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   827   C0036140:Salts [Chemical Viewed Structurally]
   793 E C0037494:Salt [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   793 E C0206136:Salt [Food,Inorganic Chemical]
   743 E C1537053:salty [Qualitative Concept]
   721 E C0678584:saltiness [Qualitative Concept]
Processing 00000000.tx.161: Both media were supplemented with 2mML-glutamine and 1% penicillin/streptomycin and either 10% (lymphoblast) or 20% (fibroblast) fetal bovine serum (Invitrogen). 

Phrase: "Both media"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0009458:Media [Intellectual Product]
  1000   C0162867:Media [Tissue]
  1000   C1254021:Media [Tissue]
   966 E C0439536:Medium [Quantitative Concept]
   966 E C1705217:Medium [Substance]
   966 E C3244283:medium [Intellectual Product]

Phrase: "were"

Phrase: "supplemented with 2mML-glutamine"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0017797:Glutamine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   737   C0242295:Supplement [Food]
   737   C1947943:Supplement [Intellectual Product]
   737   C2348609:Supplement [Functional Concept]

Phrase: "and"

Phrase: "1% penicillin/streptomycin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0038425:Streptomycin [Antibiotic,Carbohydrate]

Phrase: "and"

Phrase: "either 10%"

Phrase: "(lymphoblast"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0229613:lymphoblast [Cell]

Phrase: ")"

Phrase: "or"

Phrase: "20%"

Phrase: "(fibroblast"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016030:Fibroblast [Cell]

Phrase: ")"

Phrase: "fetal bovine serum"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   827   C0007452:Bovine [Mammal]
   827   C0015965:Fetal [Embryonic Structure]
   827   C0229671:Serum [Body Substance]
   827   C0521457:Fetal [Functional Concept]
   827   C1140701:bovine [Mammal]
   827   C1546774:Serum [Intellectual Product]
   827   C1550100:Serum [Body Substance]

Phrase: "(Invitrogen"

Phrase: ")."
Processing 00000000.tx.162: Kinetin was obtained from both MicroSource Discovery Systems and Sigma and dissolved at 10mM in either DMSO or water. 

Phrase: "Kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "was"

Phrase: "obtained from both MicroSource Discovery Systems"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   753   C1301820:Obtained [Functional Concept]
   753   C1880355:Discovery [Activity]
   719   C0449913:System [Functional Concept]
   719   C1553451:System [Manufactured Object]
   719   C1704459:System [Medical Device]
   719 E C1706701:Obtain [Activity]

Phrase: "and"

Phrase: "Sigma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1719918:Sigma [Intellectual Product]

Phrase: "and"

Phrase: "dissolved at 10mM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1549535:Dissolve [Functional Concept]

Phrase: "in either DMSO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]

Phrase: "or"

Phrase: "water."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
  1000   C0599638:WATER [Substance]
  1000   C1550678:Water [Inorganic Chemical]
   928 E C0443350:Watery [Qualitative Concept]
Processing 00000000.tx.163: FD cells were cultured in the presence of kinetin for 72h except where noted. 

Phrase: "FD cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]

Phrase: "were"

Phrase: "cultured in the presence of kinetin"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
   753   C0392148:Presence [Therapeutic or Preventive Procedure]
   719   C0010453:Culture [Idea or Concept]
   719   C0220814:culture [Functional Concept]
   719   C0430400:Culture [Laboratory Procedure]
   719   C2242979:Culture [Laboratory Procedure]

Phrase: "for 72h"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292423:72H [Temporal Concept]

Phrase: "except where"

Phrase: "noted."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1316572:Note [Clinical Attribute]
   966   C1317574:Note [Intellectual Product]
   966   C1369612:Note [Clinical Attribute]
Processing 00000000.tx.164: Benzyladenine, zeatin, and 2iP were obtained from Sigma and dissolved in DMSO at 10mM. 

Phrase: "Benzyladenine,"

Phrase: "zeatin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043456:Zeatin [Biologically Active Substance,Organic Chemical]

Phrase: "and"

Phrase: "2iP"

Phrase: "were"

Phrase: "obtained from Sigma"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C1301820:Obtained [Functional Concept]
   790   C1719918:Sigma [Intellectual Product]
   756 E C1706701:Obtain [Activity]
   718 E C1517378:Gain [Quantitative Concept]

Phrase: "and"

Phrase: "dissolved in DMSO"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]
   756   C1549535:Dissolve [Functional Concept]

Phrase: "at 10mM."
Processing 00000000.tx.165: These compounds were tested at concentrations of 1, 10, 50 and 100M. 

Phrase: "These compounds"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0205198:Compound [Qualitative Concept]
   966   C1706082:Compound [Chemical]

Phrase: "were"

Phrase: "tested at concentrations of 1,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   760   C0086045:Concentrations [Mental Process]
   760   C0392366:tested [Intellectual Product]
   726 E C0022885:Test [Laboratory Procedure]
   726 E C0039593:Test [Functional Concept]
   726 E C1446561:Concentration [Quantitative Concept]

Phrase: "10,"

Phrase: "50"

Phrase: "and"

Phrase: "100M."
Processing 00000000.tx.166: Cycloheximide was obtained from Sigma and dissolved at 10mg/ml in DMSO. 

Phrase: "Cycloheximide"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0010572:Cycloheximide [Antibiotic,Organic Chemical]
   944 E C0947670:Actidione [Antibiotic,Organic Chemical]

Phrase: "was"

Phrase: "obtained from Sigma"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C1301820:Obtained [Functional Concept]
   790   C1719918:Sigma [Intellectual Product]
   756 E C1706701:Obtain [Activity]
   718 E C1517378:Gain [Quantitative Concept]

Phrase: "and"

Phrase: "dissolved at 10mg/ml"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0439526:/mL [Quantitative Concept]
   737   C1549535:Dissolve [Functional Concept]

Phrase: "in DMSO."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.167: Cells were treated with 100M kinetin for eight hours, then 50g/ml cycloheximide was added to the cultures for 4h (27). 

Phrase: "Cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "treated with 100M kinetin"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
   770   C1522326:Treated [Functional Concept]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "for eight hours,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439227:hours [Temporal Concept]
   827 E C0564385:/hour [Quantitative Concept]

Phrase: "then 50g/ml cycloheximide"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0010572:Cycloheximide [Antibiotic,Organic Chemical]
   756 E C0947670:Actidione [Antibiotic,Organic Chemical]

Phrase: "was"

Phrase: "added to the cultures"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   770   C0010453:Cultures [Idea or Concept]
   770   C1524062:Added [Functional Concept]
   737 E C0220814:culture [Functional Concept]
   737 E C0430400:Culture [Laboratory Procedure]
   737 E C1883712:Add [Functional Concept]
   737 E C2242979:Culture [Laboratory Procedure]

Phrase: "for 4h"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292426:4H [Temporal Concept]

Phrase: "(27"

Phrase: ")."
Processing 00000000.tx.168: Determination of IKBKAP transcript ratios The ratio of WT:MU IKBKAP transcripts was determined following amplification by fractionation on 1.5% agarose gels stained with ethidium bromide (23). 

Phrase: "Determination of IKBKAP transcript ratios"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1148554:determination [Laboratory Procedure]

Phrase: "The ratio of WT"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0456603:Ratio [Quantitative Concept]
   760   C1547037:Ratio [Intellectual Product]

Phrase: ":"

Phrase: "MU IKBKAP transcripts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "determined"

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "amplification by fractionation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1517480:Amplification [Molecular Biology Research Technique]
   790   C1521871:Amplification [Phenomenon or Process]
   790   C1705759:Amplification [Cell or Molecular Dysfunction]

Phrase: "on 1.5% agarose gels"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   844   C1706746:Agarose Gel [Research Device]
   812   C0017243:Gels [Biomedical or Dental Material]
   779 E C1382104:Gel [Substance]

Phrase: "stained with ethidium bromide"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   833   C0019873:Ethidium Bromide [Organic Chemical,Pharmacologic Substance]
   770   C0006222:Bromide [Inorganic Chemical]
   770   C0015008:Ethidium [Organic Chemical,Pharmacologic Substance]
   770   C2986582:Stained [Qualitative Concept]
   737 E C0038128:Stain [Indicator, Reagent, or Diagnostic Aid]

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.169: Each gel band was assessed using an Alpha 2000TM Image Analyzer and software coupled with automatic background subtraction (Alpha Innotech Corporation). 

Phrase: "Each gel band"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0175723:Band [Medical Device]
   861   C0439645:Band [Spatial Concept]
   861   C1521913:band [Cell Component]

Phrase: "was"

Phrase: "assessed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assessed [Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "an Alpha 2000TM Image Analyzer"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0179038:Analyzer [Medical Device]
   812   C1706246:Analyzer [Manufactured Object]

Phrase: "and"

Phrase: "software"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0037585:Software [Intellectual Product,Manufactured Object]

Phrase: "coupled with automatic background subtraction"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0205554:Automatic [Functional Concept]
   760   C1706907:Background [Conceptual Entity]
   760   C1948027:Coupled [Functional Concept]
   760   C2348589:Subtraction [Phenomenon or Process]
   726 E C0010222:couple [Family Group]

Phrase: "(Alpha Innotech Corporation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0683758:Corporation [Organization]

Phrase: ")."
Processing 00000000.tx.170: WT:MU ratios were obtained using the integrated density value (IDV) for each band (23). 

Phrase: "WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "MU ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0456603:Ratios [Quantitative Concept]
   861   C1610540:*Ratios [Quantitative Concept]
   827 E C1547037:Ratio [Intellectual Product]

Phrase: "were"

Phrase: "obtained"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C1301820:Obtained [Functional Concept]
   966 E C1706701:Obtain [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the integrated density value"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   827   C0178587:density [Quantitative Concept]
   827   C1522609:Value [Quantitative Concept]
   755 E C0439794:Dense [Qualitative Concept]
   755   C1158478:Integration [Genetic Function]
   755   C1705422:Integration [Machine Activity]

Phrase: "(IDV"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   827   C0178587:density [Quantitative Concept]
   827   C1522609:Value [Quantitative Concept]
   755 E C0439794:Dense [Qualitative Concept]
   755   C1158478:Integration [Genetic Function]
   755   C1705422:Integration [Machine Activity]

Phrase: ")"

Phrase: "for each band"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0175723:Band [Medical Device]
  1000   C0439645:Band [Spatial Concept]
  1000   C1521913:band [Cell Component]

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.171: Real-time quantitative PCR (QPCR) was performed as described using primers specific to WT IKBKAP, MU IKBKAP, and 18S ribosomal RNA (23). 

Phrase: "Real-time quantitative PCR (QPCR)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   923   C1709846:Real-Time PCR [Molecular Biology Research Technique]
   812   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   812   C0677874:pCR [Finding]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "specific to WT IKBKAP,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0205369:Specific [Qualitative Concept]
   760   C1552740:specific [Intellectual Product]

Phrase: "MU IKBKAP,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1416379:IKBKAP [Gene or Genome]

Phrase: "and"

Phrase: "18S ribosomal RNA (23"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   923   C0035703:RNA, Ribosomal, 18S [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
           18S RNA
   861   C0035701:Ribosomal RNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   861   C1622954:ribosomal RNA [Cell Component]
   812   C0035553:Ribosomal [Cell Component]
   812   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0450348:23 [Quantitative Concept]
   812   C1552132:18s [Body Part, Organ, or Organ Component]
   741 E C2984240:Ribosome [Functional Concept]

Phrase: ")."
Processing 00000000.tx.172: In order to assess total IKBKAP expression we used the following primers: EX3F5'-TCAGGACTTGCTGGATCAGGA; 

Phrase: "In order to"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C1705175:Order [Intellectual Product]
   861   C1705176:Order [Qualitative Concept]
   861   C1705177:Order [Classification]
   861   C1705178:Order [Activity]
   861   C1882348:Order [Qualitative Concept]

Phrase: "assess"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assess [Activity]

Phrase: "total IKBKAP expression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "we"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the following primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ":"

Phrase: "EX3F5'-TCAGGACTTGCTGGATCAGGA"

Phrase: ";"
Processing 00000000.tx.173: and EX4R5'-CCACTGGCTACACTCCCTTCT located in IKBKAP exons 3 and 4 and an exon 3 TaqMan probe: TCTGGAGACGTCATACTCTGCAGTCTCAGC. 

Phrase: "and"

Phrase: "EX4R5'-CCACTGGCTACACTCCCTTCT"

Phrase: "located in IKBKAP exons 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0015295:Exons [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   760   C1416379:IKBKAP [Gene or Genome]

Phrase: "and"

Phrase: "4"

Phrase: "and"

Phrase: "an exon 3 TaqMan probe"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0182400:Probe [Medical Device]
   812   C1704681:Probe [Gene or Genome]
   812   C2347609:Probe [Chemical Viewed Functionally]
   812   C3536729:Probe [Manufactured Object]

Phrase: ":"

Phrase: "TCTGGAGACGTCATACTCTGCAGTCTCAGC."
Processing 00000000.tx.174: For the Myosin VA assay, we designed primers that flank the alternatively spliced exon 31 in order to assess transcript levels of the two isoforms. 

Phrase: "For the Myosin VA assay,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0005507:Assay [Laboratory Procedure]
   827   C0243073:assay [Qualitative Concept]
   827   C1510438:Assay [Laboratory Procedure]
   734   C1417565:MYOSIN VA [Gene or Genome]

Phrase: "we"

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "that"

Phrase: "flank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0230171:Flank [Body Location or Region]

Phrase: "the alternatively spliced exon 31 in order to"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   744   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   744   C0450355:31 [Intellectual Product]
   744   C1705175:Order [Intellectual Product]
   744   C1705176:Order [Qualitative Concept]
   744   C1705177:Order [Classification]
   744   C1705178:Order [Activity]
   744   C1882348:Order [Qualitative Concept]

Phrase: "assess"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assess [Activity]

Phrase: "transcript levels of the two isoforms."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   753   C0441889:Levels [Qualitative Concept]
   753   C1519595:Transcript [Nucleic Acid, Nucleoside, or Nucleotide]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.175: Primer sequences were as follows: MYO-FGAA TAC AAT GAC AGA TTC CAC; 

Phrase: "Primer sequences"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   861   C0162326:Sequences [Nucleotide Sequence]
   827 E C0004793:Sequence [Nucleotide Sequence]
   827 E C0162327:Sequence [Nucleotide Sequence]
   827 E C1519249:Sequence [Functional Concept]
   777 E C1548958:Sequential [Idea or Concept]
   777 E C1705294:Sequential [Qualitative Concept]

Phrase: "were"

Phrase: "as"

Phrase: "follows"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]

Phrase: ":"

Phrase: "MYO-FGAA TAC AAT GAC AGA TTC CAC"

Phrase: ";"
Processing 00000000.tx.176: MYO-RCAG GCT GGC CTC AAT TGC. 

Phrase: "MYO-RCAG GCT GGC CTC AAT TGC."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C1420714:TGC [Gene or Genome]
Processing 00000000.tx.177: Following reverse-transcription and PCR, products were separated on a 1.5% agarose gel and IDV ratios determined as described above. 

Phrase: "Following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "reverse-transcription"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0035380:Reverse Transcription [Genetic Function]
   861   C0040649:Transcription [Genetic Function]
   861   C1555029:Reverse [Idea or Concept]

Phrase: "and"

Phrase: "PCR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
  1000   C0677874:pCR [Finding]

Phrase: "products"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1514468:Products [Entity]
   966 E C1704444:Product [Quantitative Concept]

Phrase: "were"

Phrase: "separated on a 1.5% agarose gel"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C1706746:Agarose Gel [Research Device]
   748   C0017243:Gel [Biomedical or Dental Material]
   748   C0036681:Agarose [Carbohydrate]
   748   C0086972:Separated [Finding]
   748   C0443299:separated [Spatial Concept]
   748   C0687118:Separated [Functional Concept]
   748   C1382104:Gel [Substance]

Phrase: "and"

Phrase: "IDV ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   812   C0456603:Ratios [Quantitative Concept]
   812   C1610540:*Ratios [Quantitative Concept]
   779 E C1547037:Ratio [Intellectual Product]

Phrase: "determined as described above."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1552738:described [Idea or Concept]
Processing 00000000.tx.178: Western blot analysis Patient lymphoblast cell lines were treated with increasing concentrations of kinetin for 72h. 

Phrase: "Western blot analysis Patient lymphoblast cell lines"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   818   C0007600:Cell lines [Cell]
   795   C0007634:Cell [Cell]
   795   C0205132:lines [Spatial Concept]
   795   C1269647:Cell [Cell]
   795   C1704653:Cell [Medical Device]
   795   C1948049:Cell [Spatial Concept]
   762 E C1550648:Line [Substance]
   762 E C1552960:Line [Quantitative Concept]

Phrase: "were"

Phrase: "treated with increasing concentrations of kinetin"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   790   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   753   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
   753   C0086045:Concentrations [Mental Process]
   753   C0442808:Increasing [Functional Concept]
   753   C1522326:Treated [Functional Concept]
   719 E C1292734:TREAT [Functional Concept]
   719 E C1446561:Concentration [Quantitative Concept]

Phrase: "for 72h."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292423:72H [Temporal Concept]
Processing 00000000.tx.179: Extracted protein was run on a 6% polyacrylamide gel. 

Phrase: "Extracted protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "was"

Phrase: "run on"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0035953:run [Daily or Recreational Activity]
   861   C0600140:run [Finding]
   861   C1704688:Run [Functional Concept]
   861   C2346414:Run [Finding]

Phrase: "a 6% polyacrylamide gel."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0071500:Polyacrylamide Gel [Biomedical or Dental Material,Pharmacologic Substance]
   827   C0017243:Gel [Biomedical or Dental Material]
   827   C0071499:polyacrylamide [Biomedical or Dental Material,Organic Chemical]
   827   C1382104:Gel [Substance]
Processing 00000000.tx.180: The samples were transferred to nitrocellulose and stained with Ponceau-S to visualize protein loading. 

Phrase: "The samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0370003:Sample [Substance]
   966   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "transferred"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0348011:transferred [Functional Concept]
   966 E C0040671:Transfer [Mental Process]
   966 E C1705822:Transfer [Activity]

Phrase: "to nitrocellulose"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0600190:Nitrocellulose [Biomedical or Dental Material,Organic Chemical,Pharmacologic Substance]
   777 E C0009357:Collodion Cotton [Biomedical or Dental Material,Pharmacologic Substance]

Phrase: "and"

Phrase: "stained with Ponceau-S to"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   827   C0071720:Ponceau S stain [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
           Ponceau S
   781   C0491958:STAIN, PONCEAU [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   760   C2986582:Stained [Qualitative Concept]
   726 E C0038128:Stain [Indicator, Reagent, or Diagnostic Aid]

Phrase: "visualize"

Phrase: "protein loading."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1708715:Loading [Activity]
Processing 00000000.tx.181: IKAP was detected using a monoclonal antibody raised against amino acids 7961008 of IKAP (BD Bioscience) that detects the 150kDa full-length IKAP protein. 

Phrase: "IKAP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416379:IKAP [Gene or Genome]

Phrase: "was"

Phrase: "detected"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0442726:Detected [Finding]
  1000   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a monoclonal antibody"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   861   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0746619:monoclonal [Finding]

Phrase: "raised against amino acids 7961008 of IKAP"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   778   C0002520:Amino Acids [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   748   C0001128:Acids [Chemical]
   748   C0442818:Raised [Quantitative Concept]
   748   C1416379:IKAP [Gene or Genome]
   745 E C2917660:Amino Acid [Pharmacologic Substance]
   714 E C0202406:Acid [Laboratory Procedure]

Phrase: "(BD Bioscience"

Phrase: ")"

Phrase: "that"

Phrase: "detects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442726:detect [Finding]

Phrase: "the 150kDa full-length IKAP protein."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.182: The same blot was probed with an antibody to insulin-degrading enzyme (IDE) as a protein loading control. 

Phrase: "The same blot"

Phrase: "was"

Phrase: "probed with an antibody"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   770   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   737   C0182400:Probe [Medical Device]
   737   C1704681:Probe [Gene or Genome]
   737   C2347609:Probe [Chemical Viewed Functionally]
   737   C3536729:Probe [Manufactured Object]

Phrase: "to insulin-degrading enzyme (IDE)"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0021669:Insulin-Degrading Enzyme [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415875:INSULIN-DEGRADING ENZYME [Gene or Genome]
   827   C0014442:Enzyme [Enzyme,Organic Chemical]
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C0014445:enzymes [Functional Concept]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "as a protein loading control."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0243148:control [Qualitative Concept]
   827   C1550141:Control [Substance]
   827   C1882979:Control [Conceptual Entity]
   827   C2587213:Control [Functional Concept]
   827   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.183: Bands were quantitated using an Alpha 2000TM Image Analyzer. 

Phrase: "Bands"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0175723:Bands [Medical Device]
   966 E C0439645:Band [Spatial Concept]
   966 E C1521913:band [Cell Component]

Phrase: "were"

Phrase: "quantitated"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "an Alpha 2000TM Image Analyzer."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0179038:Analyzer [Medical Device]
   812   C1706246:Analyzer [Manufactured Object]
Processing 00000000.tx.184: In vivo IKBKAP minigene splicing assay IKBKAP genomic DNA was amplified from an unaffected and an FD individual using primers in exon 19 and 21: EX19F5'-CATTACAGGCCGGCCTGAG; 

Phrase: "In vivo IKBKAP minigene splicing assay IKBKAP genomic DNA"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   807   C3272453:Genomic DNA [Nucleic Acid, Nucleoside, or Nucleotide]
   791   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   791   C0017428:Genomic [Gene or Genome]
   791   C0887950:genomic [Biomedical Occupation or Discipline]

Phrase: "was"

Phrase: "amplified from an unaffected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2986417:Unaffected [Conceptual Entity]

Phrase: "and"

Phrase: "an FD individual"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0027361:Individual [Population Group]
   827   C0237401:Individual [Human]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "primers in exon 19"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and"

Phrase: "21"

Phrase: ":"

Phrase: "EX19F5'-CATTACAGGCCGGCCTGAG"

Phrase: ";"
Processing 00000000.tx.185: and EX21R5'-CAGCTTAGAAAGTTACCTTAG. 

Phrase: "and"

Phrase: "EX21R5'-CAGCTTAGAAAGTTACCTTAG."
Processing 00000000.tx.186: The amplified products were cloned into pcDNA3.1/V5-His Topo (Invitrogen) and sequenced for verification. 

Phrase: "The amplified products"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1514468:Products [Entity]
   827 E C1704444:Product [Quantitative Concept]

Phrase: "were"

Phrase: "cloned into pcDNA3.1/V5-"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0009013:cloned [Cell]
   760   C2349105:V5+ [Element, Ion, or Isotope]
   726 E C1522642:Clone [Tissue]

Phrase: "His Topo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0077229:TOPO [Organophosphorus Compound,Pharmacologic Substance]
  1000   C0146224:TOPO [Organic Chemical,Pharmacologic Substance]

Phrase: "(Invitrogen"

Phrase: ")"

Phrase: "and"

Phrase: "sequenced for verification."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0237944:Verification [Research Activity]
   790   C1711411:Verification [Functional Concept]
   756   C0004793:Sequence [Nucleotide Sequence]
   756   C0162326:Sequence [Nucleotide Sequence]
   756   C0162327:Sequence [Nucleotide Sequence]
   756   C1519249:Sequence [Functional Concept]
Processing 00000000.tx.187: HEK293 cells were plated and kinetin was added to the tissue culture media 4 hours later. 

Phrase: "HEK293 cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C2936239:HEK293 Cells [Cell]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "plated"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0005971:Plate [Medical Device]
   966   C1139930:plate [Medical Device]
   966   C3537155:Plate [Manufactured Object]

Phrase: "and"

Phrase: "kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "was"

Phrase: "added to the tissue culture media 4 hours later."
Meta Candidates (Total=18; Excluded=5; Pruned=0; Remaining=13)
   764   C0010454:Culture Media [Indicator, Reagent, or Diagnostic Aid]
   764   C0040284:Tissue culture [Laboratory Procedure]
   742   C0009458:Media [Intellectual Product]
   742   C0010453:Culture [Idea or Concept]
   742   C0040300:Tissue [Tissue]
   742   C0162867:Media [Tissue]
   742   C0220814:culture [Functional Concept]
   742   C0430400:Culture [Laboratory Procedure]
   742   C0439227:hours [Temporal Concept]
   742   C1254021:Media [Tissue]
   742   C1524062:Added [Functional Concept]
   742   C1547928:Tissue [Intellectual Product]
   742   C2242979:Culture [Laboratory Procedure]
   708 E C0439536:Medium [Quantitative Concept]
   708 E C0564385:/hour [Quantitative Concept]
   708 E C1705217:Medium [Substance]
   708 E C1883712:Add [Functional Concept]
   708 E C3244283:medium [Intellectual Product]
Processing 00000000.tx.188: Minigene constructs were transiently transfected 12h later using Genejuice (Novagen) as directed by the manufacturer. 

Phrase: "Minigene constructs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2827421:Construct [Classification]

Phrase: "were"

Phrase: "transiently transfected 12h later"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0456695:/12h [Temporal Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "Genejuice"

Phrase: "(Novagen"

Phrase: ")"

Phrase: "as"

Phrase: "directed by the manufacturer."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0947322:Manufacturer [Intellectual Product]
   770   C1705426:Manufacturer [Population Group]
   737   C0439851:Direct [Qualitative Concept]
   737   C1947931:Direct [Qualitative Concept]
Processing 00000000.tx.189: After 48h RNA was isolated using the RNAeasy kit (Qiagen) and reverse transcribed using SuperscriptTM II reverse transcriptase (Invitrogen) as described (23). 

Phrase: "After 48h RNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "isolated"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0205409:Isolated [Functional Concept]
  1000   C1548221:Isolated [Idea or Concept]
   966 E C0370215:Isolate [Substance]
   966 E C1875400:ISOLATE [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the RNAeasy kit (Qiagen"

Phrase: ")"

Phrase: "and"

Phrase: "reverse"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1555029:Reverse [Idea or Concept]

Phrase: "transcribed"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "SuperscriptTM II reverse transcriptase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0035379:Reverse Transcriptase [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0040646:Transcriptase [Amino Acid, Peptide, or Protein,Enzyme]
   812   C1555029:Reverse [Idea or Concept]
   812   C2257077:transcriptase [Genetic Function]

Phrase: "(Invitrogen"

Phrase: ")"

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.190: PCR was performed using vector specific primers: T7 (TAATACGACTCACTATAGG) and BGHR (TAGAAGGCACAGTCGAGG), which amplify both WT and MU transcripts, or the MU-specific primer EX19/21F (CAAAGCTTGTATTACAGACT) and BGH-R to specifically amplify only MU transcripts. 

Phrase: "PCR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
  1000   C0677874:pCR [Finding]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "vector specific primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ":"

Phrase: "T7 (TAATACGACTCACTATAGG"

Phrase: ")"

Phrase: "and"

Phrase: "BGHR"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0520815:bGHr [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "(TAGAAGGCACAGTCGAGG"

Phrase: ")"

Phrase: ","

Phrase: "which"

Phrase: "amplify"

Phrase: "both WT"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1883559:Wild Type [Organism Attribute]
   861   C0332307:Type [Qualitative Concept]
   861   C0445392:Wild [Intellectual Product]
   861   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "MU transcripts,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "or"

Phrase: "the MU-specific primer EX19/21F"

Phrase: "(CAAAGCTTGTATTACAGACT"

Phrase: ")"

Phrase: "and"

Phrase: "BGH-R to specifically"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205090:R- [Spatial Concept]
   770   C0684010:R. [Professional or Occupational Group]
   770   C2603358:R' [Clinical Attribute]

Phrase: "amplify"

Phrase: "only MU transcripts."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.191: PCR was performed as follows: 26 cycles of (94C, 30s; 56C, 30s; 72C, 30s) and products resolved on a 1.5% agarose gel and visualized by ethidium bromide staining.  

Phrase: "PCR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
  1000   C0677874:pCR [Finding]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "as"

Phrase: "follows"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]

Phrase: ":"

Phrase: "26 cycles of (94C,"

Phrase: "30s"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0227073:30S [Body Part, Organ, or Organ Component]

Phrase: "; 56C,"

Phrase: "30s"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0227073:30S [Body Part, Organ, or Organ Component]

Phrase: "; 72C,"

Phrase: "30s"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0227073:30S [Body Part, Organ, or Organ Component]

Phrase: ")"

Phrase: "and"

Phrase: "products"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1514468:Products [Entity]
   966 E C1704444:Product [Quantitative Concept]

Phrase: "resolved on a 1.5% agarose gel"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C1706746:Agarose Gel [Research Device]
   748   C0017243:Gel [Biomedical or Dental Material]
   748   C0036681:Agarose [Carbohydrate]
   748   C1382104:Gel [Substance]
   748   C1514893:Resolved [Idea or Concept]
   748   C2699488:Resolved [Conceptual Entity]

Phrase: "and"

Phrase: "visualized by ethidium bromide staining."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0019873:Ethidium Bromide [Organic Chemical,Pharmacologic Substance]
   760   C0006222:Bromide [Inorganic Chemical]
   760   C0015008:Ethidium [Organic Chemical,Pharmacologic Substance]
   760   C0234621:Visualized [Functional Concept]
   760   C0487602:Staining [Laboratory Procedure]
   760   C1704680:Staining [Finding]
Processing 00000000.tx.192: ACKNOWLEDGEMENTS  We wish to thank all FD patients and their families for their continued participation in our studies. 

Phrase: "ACKNOWLEDGEMENTS"

Phrase: "We"

Phrase: "wish"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1423524:WISH [Gene or Genome]
  1000   C3273411:WISH [Gene or Genome]
  1000   C3273412:WISH [Amino Acid, Peptide, or Protein]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "thank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "all FD patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]

Phrase: "and"

Phrase: "their families for their continued participation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0015576:Families [Family Group]
   753   C1704727:Family [Conceptual Entity]

Phrase: "in our studies."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]
Processing 00000000.tx.193: This work was supported by grants from the Dysautonomia Foundation Inc. 

Phrase: "This work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "was"

Phrase: "supported by grants"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0018173:Grants [Quantitative Concept]
   790   C1521721:Supported [Conceptual Entity]
   756 E C0183683:Support [Medical Device]
   756 E C1548284:Grant [Idea or Concept]

Phrase: "from the Dysautonomia Foundation Inc."
Processing 00000000.tx.194: (S.A.S. and J.F.G.), the National Institute of Neurological Disorders and Stroke (S.A.S.), and the Harvard Center for Neurodegeneration and Repair (S.A.S.).  

Phrase: "(S.A.S."

Phrase: "and"

Phrase: "J.F.G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439267:g% [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "the National Institute of Neurological Disorders and Stroke"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
  1000   C2350584:National Institute of Neurological Disorders and Stroke [Health Care Related Organization]
   845   C0038454:Stroke, neurological [Disease or Syndrome]
           Stroke
   818   C0027765:Neurological Disorders [Disease or Syndrome]
   795   C0012634:Disorders [Disease or Syndrome]
   795   C0021622:institute [Organization]
   795   C0205494:Neurological [Qualitative Concept]
   795   C1272753:Institute [Idea or Concept]
   795   C2707261:Neurological [Clinical Attribute]
   795   C3245503:national [Intellectual Product]

Phrase: "(S.A."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2603362:S' [Clinical Attribute]

Phrase: "S."

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "the Harvard Center for Neurodegeneration"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0205099:Center [Spatial Concept]

Phrase: "and"

Phrase: "Repair"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0043240:Repair, NOS [Organism Function]
  1000   C0374711:Repair [Therapeutic or Preventive Procedure]

Phrase: "(S.A."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2603362:S' [Clinical Attribute]

Phrase: "S."

Phrase: ")."
Processing 00000000.tx.195: FOOTNOTES  * To whom correspondence should be addressed at: NRB Building Room 160C, 4 Blackfan Circle, Boston, MA 02115, USA. 

Phrase: "FOOTNOTES"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2825232:Footnote [Intellectual Product]

Phrase: "*"

Phrase: "To whom correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282413:Correspondence [Intellectual Product]

Phrase: "should"

Phrase: "be"

Phrase: "addressed at"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0376649:Address [Intellectual Product]
   799   C1442065:Address [Spatial Concept]

Phrase: ":"

Phrase: "NRB Building Room 160C,"

Phrase: "4 Blackfan Circle,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1282913:Circle [Spatial Concept]
   827   C1551714:Circle [Population Group]

Phrase: "Boston,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006037:Boston [Geographic Area]

Phrase: "MA 02115,"

Phrase: "USA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]
Processing 00000000.tx.196: Tel: +1 6175254558; 

Phrase: "Tel"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0254343:TEL [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C0796520:TEL [Gene or Genome]
  1000   C3272379:TEL [Intellectual Product]

Phrase: ":"

Phrase: "+1 6175254558"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: ";"
Processing 00000000.tx.197: Fax: +1 6175254533; 

Phrase: "Fax"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085205:Fax [Manufactured Object]
  1000   C1549619:FAX [Conceptual Entity]
  1000   C1880669:Fax [Manufactured Object]

Phrase: ":"

Phrase: "+1 6175254533"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: ";"
Processing 00000000.tx.198: Email: susan_slaugenhaupt{at}hms.harvard.edu  REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W. et al. 

Phrase: "Email"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]

Phrase: ":"

Phrase: "susan_slaugenhaupt{at}hms.harvard.edu"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0059804:EDU [Organic Chemical,Pharmacologic Substance]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Lander,"

Phrase: "E.S.,"

Phrase: "Linton,"

Phrase: "L.M.,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0439394:l's [Quantitative Concept]
   861   C0441923:M+ [Intellectual Product]
   861   C1706495:L- [Intellectual Product]
   861   C3642217:/L [Quantitative Concept]

Phrase: "Birren,"

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Nusbaum,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Zody,"

Phrase: "M.C.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Baldwin,"

Phrase: "J.,"

Phrase: "Devon,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0454849:Devon [Geographic Area]

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Dewar,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1707728:Dewar [Manufactured Object]
  1000   C1880296:Dewar [Quantitative Concept]

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Doyle,"

Phrase: "M."

Phrase: ","

Phrase: "FitzHugh,"

Phrase: "W. et al."
Processing 00000000.tx.199: (2001) Initial sequencing and analysis of the human genome. 

Phrase: "(2001"

Phrase: ")"

Phrase: "Initial sequencing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1553778:Sequencing [Intellectual Product]
   861   C1561491:Sequencing [Functional Concept]

Phrase: "and"

Phrase: "analysis of the human genome."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0002778:Analysis [Laboratory Procedure]
   760   C0936012:Analysis [Research Activity]
   760   C1524024:analysis [Functional Concept]
Processing 00000000.tx.200: Nature, 409, 860921.[CrossRef][ISI][Medline] Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., Yandell, M., Evans, C.A., Holt, R.A. et al. 

Phrase: "Nature,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0349590:Nature [Idea or Concept]
  1000   C1262865:Nature [Functional Concept]
   928 E C0205296:Natural [Functional Concept]

Phrase: "409,"

Phrase: "860921."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Venter,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0224086:Venter [Body Part, Organ, or Organ Component]

Phrase: "J.C., Adams,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0331762:Adams [Health Care Related Organization]

Phrase: "M.D.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1512018:M.D. [Intellectual Product]
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Myers,"

Phrase: "E.W., Li,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C3495095:Li+ [Element, Ion, or Isotope]

Phrase: "P.W., Mural,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0441995:Mural [Spatial Concept]

Phrase: "R.J.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Sutton,"

Phrase: "G.G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1319635:g/g [Quantitative Concept]

Phrase: "Smith,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0554249:Smith [Professional or Occupational Group]

Phrase: "H.O.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0455483:H/O: * NOS [Finding]

Phrase: "Yandell,"

Phrase: "M."

Phrase: ","

Phrase: "Evans,"

Phrase: "C."

Phrase: "A.,"

Phrase: "Holt,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "A. et al."
Processing 00000000.tx.201: (2001) The sequence of the human genome. 

Phrase: "(2001"

Phrase: ")"

Phrase: "The sequence of the human genome."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0004793:Sequence [Nucleotide Sequence]
   753   C0162326:Sequence [Nucleotide Sequence]
   753   C0162327:Sequence [Nucleotide Sequence]
   753   C1519249:Sequence [Functional Concept]
Processing 00000000.tx.202: Science, 291, 13041351.[Abstract/Free FullText] Nissim-Rafinia, M. and Kerem, B. 

Phrase: "Science,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0036397:Science [Occupation or Discipline]

Phrase: "291,"

Phrase: "13041351."

Phrase: "[Abstract/Free FullText"

Phrase: "] Nissim-Rafinia,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Kerem,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.203: (2002) Splicing regulation as a potential genetic modifier. 

Phrase: "(2002"

Phrase: ")"

Phrase: "Splicing regulation as a potential genetic modifier."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C0017263:genetic regulation [Genetic Function]
   748   C0851285:Regulation [Governmental or Regulatory Activity]
   748   C1327622:Regulation [Biologic Function]
Processing 00000000.tx.204: Trends Genet., 18, 123127.[CrossRef][ISI][Medline] Will, C.L. and Luhrmann, R. 

Phrase: "Trends"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040833:trends [Temporal Concept]
  1000   C1521798:Trends [Temporal Concept]

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "18,"

Phrase: "123127."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "Will"

Phrase: ","

Phrase: "C.L."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1553033:[c] [Quantitative Concept]

Phrase: "and"

Phrase: "Luhrmann,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.205: (2001) Spliceosomal UsnRNP biogenesis, structure and function. 

Phrase: "(2001"

Phrase: ")"

Phrase: "Spliceosomal UsnRNP biogenesis,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0005495:Biogenesis [Natural Phenomenon or Process]
   827   C0220781:Biogenesis [Biologic Function]

Phrase: "structure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678594:Structure [Spatial Concept]

Phrase: "and"

Phrase: "function."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]
   928 E C0205245:Functional [Functional Concept]
   928 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.206: Curr. 

Phrase: "Curr."
Processing 00000000.tx.207: Opin. 

Phrase: "Opin."
Processing 00000000.tx.208: Cell Biol., 13, 290301.[CrossRef][ISI][Medline] Reed, R. 

Phrase: "Cell Biol.,"

Phrase: "13,"

Phrase: "290301."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Reed,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.209: (2000) Mechanisms of fidelity in pre-mRNA splicing. 

Phrase: "(2000"

Phrase: ")"

Phrase: "Mechanisms of fidelity"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0441712:Mechanisms [Functional Concept]
   756 E C1706376:Mechanism [Manufactured Object]

Phrase: "in pre-mRNA splicing."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C1622990:pre-mRNA splicing [Genetic Function]
   901   C0086934:mRNA splicing [Genetic Function]
   827   C0035687:Splicing [Genetic Function]
   827   C2610186:splicing [Genetic Function]
   734   C0026661:Pre-mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   734   C0035695:Pre-mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.210: Curr. 

Phrase: "Curr."
Processing 00000000.tx.211: Opin. 

Phrase: "Opin."
Processing 00000000.tx.212: Cell Biol., 12, 340345.[CrossRef][ISI][Medline] Graveley, B.R. 

Phrase: "Cell Biol.,"

Phrase: "12,"

Phrase: "340345."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Graveley,"

Phrase: "B.R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.213: (2000) Sorting out the complexity of SR protein functions. 

Phrase: "(2000"

Phrase: ")"

Phrase: "Sorting"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237886:Sorting [Mental Process]
  1000   C0700314:sorting [Cell Function]
  1000   C1947906:Sorting [Activity]

Phrase: "out"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439787:Out [Spatial Concept]
  1000   C0849355:Out [Qualitative Concept]

Phrase: "the complexity of SR protein functions."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1180347:Protein complex [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C1523872:protein complex [Cell Component]
Processing 00000000.tx.214: RNA, 6, 11971211.[Free FullText] Jiang, Z.H., Zhang, W.J., Rao, Y. and Wu, J.Y. 

Phrase: "RNA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "6,"

Phrase: "11971211."

Phrase: "[Free FullText"

Phrase: "] Jiang,"

Phrase: "Z.H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Zhang,"

Phrase: "W.J.,"

Phrase: "Rao,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1412430:RAO [Gene or Genome]

Phrase: "Y."

Phrase: "and"

Phrase: "Wu,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1431628:wu [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "J.Y."
Processing 00000000.tx.215: (1998) Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. 

Phrase: "(1998"

Phrase: ")"

Phrase: "Regulation of Ich-1 pre-mRNA alternative splicing"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   842   C1327271:regulation of pre-mRNA splicing [Genetic Function]
   744   C0851285:Regulation [Governmental or Regulatory Activity]
   744   C1327622:Regulation [Biologic Function]

Phrase: "and"

Phrase: "apoptosis by mammalian splicing factors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162638:Apoptosis [Cell Function]
Processing 00000000.tx.216: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.217: Natl Acad. 

Phrase: "Natl Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268596:ACAD [Disease or Syndrome]
   861   C2700624:ACAD [Cell Function]
Processing 00000000.tx.218: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.219: USA, 95, 91559160.[Abstract/Free FullText] Mayeda, A., Helfman, D.M. and Krainer, A.R. 

Phrase: "USA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: "95,"

Phrase: "91559160."

Phrase: "[Abstract/Free FullText"

Phrase: "] Mayeda,"

Phrase: "A.,"

Phrase: "Helfman,"

Phrase: "D."

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Krainer,"

Phrase: "A.R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.220: (1993) Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF. 

Phrase: "(1993"

Phrase: ")"

Phrase: "Modulation of exon skipping"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0443264:Modulation [Spatial Concept]

Phrase: "and"

Phrase: "inclusion by heterogeneous nuclear ribonucleoprotein A1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C1366904:Nuclear Inclusion [Cell Component]
   753   C1512693:Inclusion [Qualitative Concept]
   716   C1415634:HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1 [Gene or Genome]

Phrase: "and"

Phrase: "pre-mRNA splicing factor SF2/ASF."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0001752:ASF [Disease or Syndrome]
   799   C1419989:ASF [Gene or Genome]
Processing 00000000.tx.221: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.222: Cell. 

Phrase: "Cell."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0007634:Cell [Cell]
  1000   C1269647:Cell [Cell]
  1000   C1704653:Cell [Medical Device]
  1000   C1948049:Cell [Spatial Concept]
Processing 00000000.tx.223: Biol., 13, 29933001.[Abstract] Nissim-Rafinia, M., Chiba-Falek, O., Sharon, G., Boss, A. and Kerem, B. 

Phrase: "Biol.,"

Phrase: "13,"

Phrase: "29933001."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Nissim-Rafinia,"

Phrase: "M."

Phrase: ","

Phrase: "Chiba-Falek,"

Phrase: "O.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]

Phrase: "Sharon,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Boss,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0265514:BOS [Disease or Syndrome]
  1000   C1265540:Bos [Mammal]

Phrase: "A."

Phrase: "and"

Phrase: "Kerem,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.224: (2000) Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. 

Phrase: "(2000"

Phrase: ")"

Phrase: "Cellular"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0007634:Cellular [Cell]
  1000   C0178539:Cellular [Functional Concept]
   928 E C1516377:Cellularity [Qualitative Concept]

Phrase: "and"

Phrase: "viral splicing factors"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0035687:Splicing [Genetic Function]
   827   C2610186:splicing [Genetic Function]
   793   C1521761:Factor [Functional Concept]
   793   C2827422:Factor [Conceptual Entity]

Phrase: "can"

Phrase: "modify"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392747:MODIFY [Functional Concept]

Phrase: "the splicing pattern of CFTR transcripts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0449774:Pattern [Spatial Concept]

Phrase: "carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206243:Carrying [Activity]
   966 E C0699809:carry [Finding]

Phrase: "splicing mutations."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0026882:Mutations [Genetic Function]
   827 E C1705285:Mutation [Cell or Molecular Dysfunction]
Processing 00000000.tx.225: Hum. 

Phrase: "Hum."
Processing 00000000.tx.226: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.227: Genet., 9, 17711778.[Abstract/Free FullText] Hofmann, Y., Lorson, C.L., Stamm, S., Androphy, E.J. and Wirth, B. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "9,"

Phrase: "17711778."

Phrase: "[Abstract/Free FullText"

Phrase: "] Hofmann,"

Phrase: "Y.,"

Phrase: "Lorson,"

Phrase: "C.L.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1553033:[c] [Quantitative Concept]

Phrase: "Stamm,"

Phrase: "S."

Phrase: ","

Phrase: "Androphy,"

Phrase: "E.J."

Phrase: "and"

Phrase: "Wirth,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.228: (2000) Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). 

Phrase: "(2000"

Phrase: ")"

Phrase: "Htra2-beta 1"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1419990:Htra2-beta [Gene or Genome]
   827   C0330390:Beta [Plant]
   827   C0439096:Beta [Intellectual Product]
   827   C1825553:HTRA2 [Gene or Genome]
   827   C2004068:Beta [Qualitative Concept]

Phrase: "stimulates"

Phrase: "an exonic splicing enhancer"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0035687:Splicing [Genetic Function]
   827   C0086222:Enhancer [Nucleic Acid, Nucleoside, or Nucleotide]
   827   C2610186:splicing [Genetic Function]
   755   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and"

Phrase: "can"

Phrase: "restore"

Phrase: "full-length SMN expression to survival motor neuron 2 (SMN2)."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0185117:Expression [Therapeutic or Preventive Procedure]
Processing 00000000.tx.229: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.230: Natl Acad. 

Phrase: "Natl Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268596:ACAD [Disease or Syndrome]
   861   C2700624:ACAD [Cell Function]
Processing 00000000.tx.231: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.232: USA, 97, 96189623.[Abstract/Free FullText] Chang, J.G., Hsieh-Li, H.M., Jong, Y.J., Wang, N.M., Tsai, C.H. and Li, H. 

Phrase: "USA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: "97,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439073:97 [Intellectual Product]
  1000   C0439082:>97 [Quantitative Concept]

Phrase: "96189623."

Phrase: "[Abstract/Free FullText"

Phrase: "] Chang,"

Phrase: "J.G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Hsieh-Li,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3495095:Li+ [Element, Ion, or Isotope]

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "M."

Phrase: ","

Phrase: "Jong,"

Phrase: "Y.J.,"

Phrase: "Wang,"

Phrase: "N.M.,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C2347350:N/m [Quantitative Concept]
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C0441923:M+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "Tsai,"

Phrase: "C.H."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]
   861   C1553033:[c] [Quantitative Concept]

Phrase: "and"

Phrase: "Li,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3495095:Li+ [Element, Ion, or Isotope]

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.233: (2001) Treatment of spinal muscular atrophy by sodium butyrate. 

Phrase: "(2001"

Phrase: ")"

Phrase: "Treatment of spinal muscular atrophy"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "by sodium butyrate."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0142812:Sodium Butyrate [Lipid,Pharmacologic Substance]
   861   C0006521:butyrate [Lipid]
   861   C0037473:Sodium [Biologically Active Substance,Element, Ion, or Isotope]
   861   C0220802:butyrate [Lipid]
   861   C0597484:Sodium+ [Element, Ion, or Isotope,Pharmacologic Substance]
Processing 00000000.tx.234: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.235: Natl Acad. 

Phrase: "Natl Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268596:ACAD [Disease or Syndrome]
   861   C2700624:ACAD [Cell Function]
Processing 00000000.tx.236: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.237: USA, 98, 98089813.[Abstract/Free FullText] Andreassi, C., Jarecki, J., Zhou, J., Coovert, D.D., Monani, U.R., Chen, X., Whitney, M., Pollok, B., Zhang, M., Androphy, E. et al. 

Phrase: "USA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: "98,"

Phrase: "98089813."

Phrase: "[Abstract/Free FullText"

Phrase: "] Andreassi,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Jarecki,"

Phrase: "J.,"

Phrase: "Zhou,"

Phrase: "J.,"

Phrase: "Coovert,"

Phrase: "D.D.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0112081:D-D [Hazardous or Poisonous Substance,Organic Chemical]
   861   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Monani,"

Phrase: "U.R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Chen,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0999213:Chen [Bird]

Phrase: "X.,"

Phrase: "Whitney,"

Phrase: "M."

Phrase: ","

Phrase: "Pollok,"

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Zhang,"

Phrase: "M."

Phrase: ","

Phrase: "Androphy,"

Phrase: "E. et al."
Processing 00000000.tx.238: (2001) Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. 

Phrase: "(2001"

Phrase: ")"

Phrase: "Aclarubicin treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]

Phrase: "restores"

Phrase: "SMN levels to cells"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   770   C0441889:Levels [Qualitative Concept]
   737 E C0456079:Level [Classification]
   737 E C1547707:Level [Geographic Area]
   737 E C2946261:Level [Pharmacologic Substance]

Phrase: "derived from type I spinal muscular atrophy patients."
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   869   C0043116:Type I Spinal Muscular Atrophy [Disease or Syndrome]
   800   C0026847:Spinal Muscular Atrophy [Disease or Syndrome]
   770   C0026846:Muscular Atrophy [Disease or Syndrome]
   770   C0441729:Type I [Classification]
   750   C1550335:Patient type [Classification]
   744   C0021966:I- [Inorganic Chemical]
   744   C0026845:Muscular [Tissue]
   744   C0030705:Patients [Patient or Disabled Group]
   744   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   744   C0332307:Type [Qualitative Concept]
   744   C0333641:Atrophy [Pathologic Function]
   744   C0442025:Muscular [Spatial Concept]
   744   C0521329:Spinal [Spatial Concept]
   744   C1441547:Derived [Qualitative Concept]
   744   C1547052:*Type [Quantitative Concept]
   744   C3245521:derived [Idea or Concept]
Processing 00000000.tx.239: Hum. 

Phrase: "Hum."
Processing 00000000.tx.240: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.241: Genet., 10, 28412849.[Abstract/Free FullText] Zhang, M.L., Lorson, C.L., Androphy, E.J. and Zhou, J. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "10,"

Phrase: "28412849."

Phrase: "[Abstract/Free FullText"

Phrase: "] Zhang,"

Phrase: "M.L.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Lorson,"

Phrase: "C.L.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1553033:[c] [Quantitative Concept]

Phrase: "Androphy,"

Phrase: "E.J."

Phrase: "and"

Phrase: "Zhou,"

Phrase: "J."
Processing 00000000.tx.242: (2001) An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. 

Phrase: "(2001"

Phrase: ")"

Phrase: "An in vivo reporter system for measuring increased inclusion of exon 7"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   736   C0449913:System [Functional Concept]
   736   C1553451:System [Manufactured Object]
   736   C1704459:System [Medical Device]

Phrase: "in SMN2 mRNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ":"

Phrase: "potential therapy of SMA."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0039798:therapy [Functional Concept]
   753   C0087111:Therapy [Therapeutic or Preventive Procedure]
   753   C1363945:Therapy [Finding]
Processing 00000000.tx.243: Gene Ther., 8, 15321538.[CrossRef][ISI][Medline] Sumner, C.J., Huynh, T.N., Markowitz, J.A., Perhac, J.S., Hill, B., Coovert, D.D., Schussler, K., Chen, X., Jarecki, J., Burghes, A.H. et al. 

Phrase: "Gene Ther.,"

Phrase: "8,"

Phrase: "15321538."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Sumner,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0444759:Sumner [Intellectual Product]

Phrase: "C.J.,"

Phrase: "Huynh,"

Phrase: "T.N.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2986835:T/N [Quantitative Concept]
   861   C2603360:T' [Clinical Attribute]

Phrase: "Markowitz,"

Phrase: "J."

Phrase: "A.,"

Phrase: "Perhac,"

Phrase: "J.S.,"

Phrase: "Hill,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442532:Hill [Spatial Concept]

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Coovert,"

Phrase: "D.D.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0112081:D-D [Hazardous or Poisonous Substance,Organic Chemical]
   861   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Schussler,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Chen,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0999213:Chen [Bird]

Phrase: "X.,"

Phrase: "Jarecki,"

Phrase: "J.,"

Phrase: "Burghes,"

Phrase: "A.H. et al."
Processing 00000000.tx.244: (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. 

Phrase: "(2003"

Phrase: ")"

Phrase: "Valproic acid"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042291:Valproic Acid [Organic Chemical,Pharmacologic Substance]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "SMN levels in spinal muscular atrophy patient cells."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   744   C0441889:Levels [Qualitative Concept]
   711 E C0456079:Level [Classification]
   711 E C1547707:Level [Geographic Area]
   711 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.245: Ann. 

Phrase: "Ann."
Processing 00000000.tx.246: Neurol., 54, 647654.[CrossRef][ISI][Medline] Brichta, L., Hofmann, Y., Hahnen, E., Siebzehnrubl, F.A., Raschke, H., Blumcke, I., Eyupoglu, I.Y. and Wirth, B. 

Phrase: "Neurol.,"

Phrase: "54,"

Phrase: "647654."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Brichta,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Hofmann,"

Phrase: "Y.,"

Phrase: "Hahnen,"

Phrase: "E.,"

Phrase: "Siebzehnrubl,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "A.,"

Phrase: "Raschke,"

Phrase: "H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Blumcke,"

Phrase: "I.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Eyupoglu,"

Phrase: "I.Y."

Phrase: "and"

Phrase: "Wirth,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.247: (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. 

Phrase: "(2003"

Phrase: ")"

Phrase: "Valproic acid"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042291:Valproic Acid [Organic Chemical,Pharmacologic Substance]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "the SMN2 protein level"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   858   C1179106:Motor protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0428479:Protein level [Laboratory or Test Result]
   799   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0441889:Level [Qualitative Concept]
   799   C0456079:Level [Classification]
   799   C1547707:Level [Geographic Area]
   799   C2946261:Level [Pharmacologic Substance]

Phrase: ":"

Phrase: "a well-known drug as a potential therapy"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   767   C0013216:Drug Therapy [Therapeutic or Preventive Procedure]
   767   C0013217:drug therapy [Functional Concept]
   744   C0013227:Drug [Pharmacologic Substance]
   744   C1254351:Drug [Pharmacologic Substance]

Phrase: "for spinal muscular atrophy."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0026847:Spinal Muscular Atrophy [Disease or Syndrome]
   901   C0026846:Muscular Atrophy [Disease or Syndrome]
   827   C0026845:Muscular [Tissue]
   827   C0333641:Atrophy [Pathologic Function]
   827   C0442025:Muscular [Spatial Concept]
   827   C0521329:Spinal [Spatial Concept]
   755 E C0151514:Atrophic [Disease or Syndrome]
   755 E C1995013:Muscles [Body Part, Organ, or Organ Component]
Processing 00000000.tx.248: Hum. 

Phrase: "Hum."
Processing 00000000.tx.249: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.250: Genet., 12, 24812489.[Abstract/Free FullText] Maayan, C., Kaplan, E., Shachar, S., Peleg, O. and Godfrey, S. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "12,"

Phrase: "24812489."

Phrase: "[Abstract/Free FullText"

Phrase: "] Maayan,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Kaplan,"

Phrase: "E.,"

Phrase: "Shachar,"

Phrase: "S."

Phrase: ","

Phrase: "Peleg,"

Phrase: "O."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]

Phrase: "and"

Phrase: "Godfrey,"

Phrase: "S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.251: (1987) Incidence of familial dysautonomia in Israel 19771981. 

Phrase: "(1987"

Phrase: ")"

Phrase: "Incidence of familial dysautonomia"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0021149:Incidence [Quantitative Concept]
   770   C0220856:incidence [Functional Concept]

Phrase: "in Israel 19771981."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022271:Israel [Geographic Area]
Processing 00000000.tx.252: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.253: Genet., 32, 106108.[ISI][Medline] Axelrod, F.B. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "32,"

Phrase: "106108."

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Axelrod,"

Phrase: "F.B."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.254: (1995) Familial Dysautonomia. 

Phrase: "(1995"

Phrase: ")"

Phrase: "Familial Dysautonomia."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]
Processing 00000000.tx.255: In Robertson, D. and Biaggioni, I. 

Phrase: "In Robertson,"

Phrase: "D."

Phrase: "and"

Phrase: "Biaggioni,"

Phrase: "I."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.256: (eds), Disorders of the Autonomic Nervous System. 

Phrase: "(eds"

Phrase: ")"

Phrase: ","

Phrase: "Disorders of the Autonomic Nervous System."
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C1145628:Disorders of the Autonomic Nervous System [Disease or Syndrome]
           Disorders of autonomic nervous system
           Autonomic nervous system disorders
           AUTONOMIC NERVOUS DISORDERS
           autonomic disorders
   901   C0549469:disorders of the nervous system [Disease or Syndrome]
   846   C0027765:Disorder of nervous system [Disease or Syndrome]
           Nervous System Disorders
           NERVOUS DISORDERS
   809   C1298233:Disorder of system [Functional Concept]
           disorders system
   767 E C0851241:nervous disorder [Mental or Behavioral Dysfunction]
   753   C0012634:Disorders [Disease or Syndrome]
   731 E C0442893:Systemic Disorder [Disease or Syndrome]
Processing 00000000.tx.257: Harwood Academic, Luxembourg, pp. 

Phrase: "Harwood Academic, Luxembourg,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0024176:Luxemborg [Geographic Area]

Phrase: "pp."
Processing 00000000.tx.258: 217231. 

Phrase: "217231."
Processing 00000000.tx.259: Anderson, S.L., Coli, R., Daly, I.W., Kichula, E.A., Rork, M.J., Volpi, S.A., Ekstein, J. and Rubin, B.Y. 

Phrase: "Anderson,"

Phrase: "S.L.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439394:s l [Quantitative Concept]
   861   C2603362:S' [Clinical Attribute]

Phrase: "Coli,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Daly,"

Phrase: "I.W., Kichula,"

Phrase: "E.A.,"

Phrase: "Rork,"

Phrase: "M."

Phrase: "J.,"

Phrase: "Volpi,"

Phrase: "S.A.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2603362:S' [Clinical Attribute]

Phrase: "Ekstein,"

Phrase: "J."

Phrase: "and"

Phrase: "Rubin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0252873:rubin's [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "B.Y."
Processing 00000000.tx.260: (2001) Familial dysautonomia is caused by mutations of the IKAP gene. 

Phrase: "(2001"

Phrase: ")"

Phrase: "Familial dysautonomia"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]

Phrase: "is"

Phrase: "caused by mutations of the IKAP gene."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   774   C0596611:gene mutations [Genetic Function]
   748   C0017337:Gene [Gene or Genome]
   748   C0026882:Mutations [Genetic Function]
   748   C1416379:IKAP [Gene or Genome]
   714   C0015127:cause [Functional Concept]
   714   C1524003:Cause [Conceptual Entity]
   714 E C1705285:Mutation [Cell or Molecular Dysfunction]
Processing 00000000.tx.261: Am. 

Phrase: "Am."
Processing 00000000.tx.262: J. 

Phrase: "J."
Processing 00000000.tx.263: Hum. 

Phrase: "Hum."
Processing 00000000.tx.264: Genet., 68, 753758.[CrossRef][ISI][Medline] Leyne, M., Mull, J., Gill, S.P., Cuajungco, M.P., Oddoux, C., Blumenfeld, A., Maayan, C., Gusella, J.F., Axelrod, F.B., Slaugenhaupt, S.A. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "68,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450387:68 [Intellectual Product]

Phrase: "753758."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Leyne,"

Phrase: "M."

Phrase: ","

Phrase: "Mull"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0454936:Mull [Geographic Area]

Phrase: ","

Phrase: "J.,"

Phrase: "Gill,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017558:Gill [Body Part, Organ, or Organ Component]
  1000   C1552935:gill [Quantitative Concept]

Phrase: "S.P.,"

Phrase: "Cuajungco,"

Phrase: "M."

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Oddoux,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Blumenfeld,"

Phrase: "A.,"

Phrase: "Maayan,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Gusella,"

Phrase: "J.F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Axelrod,"

Phrase: "F.B.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Slaugenhaupt,"

Phrase: "S.A."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.265: (2003) Identification of the first non-Jewish mutation in Familial Dysautonomia. 

Phrase: "(2003"

Phrase: ")"

Phrase: "Identification of the first non-Jewish mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0020792:Identification [Mental Process]
   748   C0205396:Identification [Qualitative Concept]

Phrase: "in Familial Dysautonomia."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]
Processing 00000000.tx.266: Am. 

Phrase: "Am."
Processing 00000000.tx.267: J. 

Phrase: "J."
Processing 00000000.tx.268: Med. 

Phrase: "Med."
Processing 00000000.tx.269: Genet., 118A, 305308.[CrossRef][Medline] Slaugenhaupt, S.A., Blumenfeld, A., Gill, S.P., Leyne, M., Mull, J., Cuajungco, M.P., Liebert, C.B., Chadwick, B., Idelson, M., Reznik, L. et al. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "118A,"

Phrase: "305308."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Slaugenhaupt,"

Phrase: "S.A.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2603362:S' [Clinical Attribute]

Phrase: "Blumenfeld,"

Phrase: "A.,"

Phrase: "Gill,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017558:Gill [Body Part, Organ, or Organ Component]
  1000   C1552935:gill [Quantitative Concept]

Phrase: "S.P.,"

Phrase: "Leyne,"

Phrase: "M."

Phrase: ","

Phrase: "Mull"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0454936:Mull [Geographic Area]

Phrase: ","

Phrase: "J.,"

Phrase: "Cuajungco,"

Phrase: "M."

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Liebert,"

Phrase: "C.B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1553033:[c] [Quantitative Concept]

Phrase: "Chadwick,"

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Idelson,"

Phrase: "M."

Phrase: ","

Phrase: "Reznik,"

Phrase: "L. et al."
Processing 00000000.tx.270: (2001) Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. 

Phrase: "(2001"

Phrase: ")"

Phrase: "Tissue-specific expression of a splicing mutation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "in the IKBKAP gene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1416379:IKBKAP gene [Gene or Genome]
   861   C0017337:Gene [Gene or Genome]

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "familial dysautonomia."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]
Processing 00000000.tx.271: Am. 

Phrase: "Am."
Processing 00000000.tx.272: J. 

Phrase: "J."
Processing 00000000.tx.273: Hum. 

Phrase: "Hum."
Processing 00000000.tx.274: Genet., 68, 598605.[CrossRef][ISI][Medline] Hawkes, N.A., Otero, G., Winkler, G.S., Marshall, N., Dahmus, M.E., Krappmann, D., Scheidereit, C., Thomas, C.L., Schiavo, G., Erdjument-Bromage, H. et al. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "68,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450387:68 [Intellectual Product]

Phrase: "598605."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Hawkes,"

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "A.,"

Phrase: "Otero,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Winkler,"

Phrase: "G.S.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0086903:G S [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C2827790:g/s [Quantitative Concept]
   861   C0439267:g% [Quantitative Concept]

Phrase: "Marshall,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1551881:Marshall [Population Group]

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Dahmus,"

Phrase: "M."

Phrase: "E.,"

Phrase: "Krappmann,"

Phrase: "D."

Phrase: ","

Phrase: "Scheidereit,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Thomas,"

Phrase: "C.L.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1553033:[c] [Quantitative Concept]

Phrase: "Schiavo,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Erdjument-Bromage,"

Phrase: "H. et al."
Processing 00000000.tx.275: (2002) Purification and characterization of the human elongator complex. 

Phrase: "(2002"

Phrase: ")"

Phrase: "Purification"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0243114:purification [Functional Concept]
  1000   C1998793:Purification [Functional Concept]

Phrase: "and"

Phrase: "characterization of the human elongator complex."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1880022:Characterization [Activity]
Processing 00000000.tx.276: J. 

Phrase: "J."
Processing 00000000.tx.277: Biol. 

Phrase: "Biol."
Processing 00000000.tx.278: Chem., 277, 30473052.[Abstract/Free FullText] Holmberg, C., Katz, S., Lerdrup, M., Herdegen, T., Jaattela, M., Aronheim, A. and Kallunki, T. 

Phrase: "Chem.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]

Phrase: "277,"

Phrase: "30473052."

Phrase: "[Abstract/Free FullText"

Phrase: "] Holmberg,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Katz,"

Phrase: "S."

Phrase: ","

Phrase: "Lerdrup,"

Phrase: "M."

Phrase: ","

Phrase: "Herdegen,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Jaattela,"

Phrase: "M."

Phrase: ","

Phrase: "Aronheim,"

Phrase: "A."

Phrase: "and"

Phrase: "Kallunki,"

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]
Processing 00000000.tx.279: (2002) A novel specific role for I-kappa B kinase complex-associated protein in cytosolic stress signaling. 

Phrase: "(2002"

Phrase: ")"

Phrase: "A novel specific role for I-kappa B kinase complex-associated protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   736   C0035820:Role [Social Behavior]
   736   C1705810:Role [Conceptual Entity]

Phrase: "in cytosolic stress signaling."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0037083:Signaling [Cell Function]
   827   C3537152:signaling [Biologic Function]
Processing 00000000.tx.280: J. 

Phrase: "J."
Processing 00000000.tx.281: Biol. 

Phrase: "Biol."
Processing 00000000.tx.282: Chem., 277, 3191831928.[Abstract/Free FullText] Cuajungco, M.P., Leyne, M., Mull, J., Gill, S.P., Lu, W., Zagzag, D., Axelrod, F.B., Maayan, C., Gusella, J.F. and Slaugenhaupt, S.A. 

Phrase: "Chem.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]

Phrase: "277,"

Phrase: "3191831928."

Phrase: "[Abstract/Free FullText"

Phrase: "] Cuajungco,"

Phrase: "M."

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Leyne,"

Phrase: "M."

Phrase: ","

Phrase: "Mull"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0454936:Mull [Geographic Area]

Phrase: ","

Phrase: "J.,"

Phrase: "Gill,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017558:Gill [Body Part, Organ, or Organ Component]
  1000   C1552935:gill [Quantitative Concept]

Phrase: "S.P.,"

Phrase: "Lu,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024171:LU [Body System]
  1000   C0024176:LU [Geographic Area]
  1000   C2697939:LU [Quantitative Concept]

Phrase: "W.,"

Phrase: "Zagzag,"

Phrase: "D."

Phrase: ","

Phrase: "Axelrod,"

Phrase: "F.B.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Maayan,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Gusella,"

Phrase: "J.F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "and"

Phrase: "Slaugenhaupt,"

Phrase: "S.A."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.283: (2003) Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. 

Phrase: "(2003"

Phrase: ")"

Phrase: "Tissue-specific reduction in splicing efficiency of IKBKAP"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0301630:Reduction [Natural Phenomenon or Process]
   744   C0392756:Reduction [Qualitative Concept]
   744   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "due to the major mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "associated with familial dysautonomia."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   833   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0013363:Dysautonomia [Disease or Syndrome]
   770   C0015576:familial [Family Group]
   770   C0241888:Familial [Functional Concept]
   770   C1145628:dysautonomia [Disease or Syndrome]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.284: Am. 

Phrase: "Am."
Processing 00000000.tx.285: J. 

Phrase: "J."
Processing 00000000.tx.286: Hum. 

Phrase: "Hum."
Processing 00000000.tx.287: Genet., 72, 749758.[CrossRef][ISI][Medline] Heemskerk, J., Tobin, A.J. and Bain, L.J. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "72,"

Phrase: "749758."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Heemskerk,"

Phrase: "J.,"

Phrase: "Tobin,"

Phrase: "A.J."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1510707:A/J [Mammal]

Phrase: "and"

Phrase: "Bain,"

Phrase: "L.J."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439394:l's [Quantitative Concept]
   861   C1706495:L- [Intellectual Product]
   861   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.288: (2002) Teaching old drugs new tricks. 

Phrase: "(2002"

Phrase: ")"

Phrase: "Teaching old drugs new tricks."
Processing 00000000.tx.289: Meeting of the Neurodegeneration Drug Screening Consortium, 78 April 2002, Washington, DC, USA. 

Phrase: "Meeting of the Neurodegeneration Drug Screening Consortium,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0556656:Meeting [Health Care Activity]

Phrase: "78 April 2002,"

Phrase: "Washington,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043038:Washington [Geographic Area]

Phrase: "DC,"

Phrase: "USA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]
Processing 00000000.tx.290: Trends Neurosci., 25, 494496.[CrossRef][Medline] Lambert, J., Naeyaert, J.M., Callens, T., De Paepe, A. and Messiaen, L. 

Phrase: "Trends"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040833:trends [Temporal Concept]
  1000   C1521798:Trends [Temporal Concept]

Phrase: "Neurosci.,"

Phrase: "25,"

Phrase: "494496."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Lambert,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1551092:Lambert [Quantitative Concept]

Phrase: "J.,"

Phrase: "Naeyaert,"

Phrase: "J."

Phrase: "M."

Phrase: ","

Phrase: "Callens,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "De Paepe,"

Phrase: "A."

Phrase: "and"

Phrase: "Messiaen,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.291: (1998) Human myosin V gene produces different transcripts in a cell type-specific manner. 

Phrase: "(1998"

Phrase: ")"

Phrase: "Human myosin V gene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   902   C0314604:Human gene [Gene or Genome]
   812   C0017337:Gene [Gene or Genome]

Phrase: "produces"

Phrase: "different transcripts in a cell type-specific manner."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.292: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.293: Biophys. 

Phrase: "Biophys."
Processing 00000000.tx.294: Res. 

Phrase: "Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347379:RES [Finding]
Processing 00000000.tx.295: Commun., 252, 329333.[CrossRef][ISI][Medline] Frischmeyer, P.A. and Dietz, H.C. 

Phrase: "Commun.,"

Phrase: "252,"

Phrase: "329333."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Frischmeyer,"

Phrase: "P.A."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: "and"

Phrase: "Dietz,"

Phrase: "H.C."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.296: (1999) Nonsense-mediated mRNA decay in health and disease. 

Phrase: "(1999"

Phrase: ")"

Phrase: "Nonsense-mediated mRNA decay in health"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   882   C1158013:Nonsense Mediated mRNA Decay [Genetic Function]
           Nonsense-Mediated Decay
   790   C1257758:mRNA Decay [Genetic Function]
   753   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0086597:mediated [Social Behavior]
   753   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]
   753   C0746939:nonsense [Idea or Concept]
   753   C1265875:Decay [Acquired Abnormality]
   753   C2700592:Decay [Phenomenon or Process]

Phrase: "and"

Phrase: "disease."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.297: Hum. 

Phrase: "Hum."
Processing 00000000.tx.298: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.299: Genet., 8, 18931900.[Abstract/Free FullText] Noensie, E.N. and Dietz, H.C. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "8,"

Phrase: "18931900."

Phrase: "[Abstract/Free FullText"

Phrase: "] Noensie,"

Phrase: "E.N."

Phrase: "and"

Phrase: "Dietz,"

Phrase: "H.C."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.300: (2001) A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. 

Phrase: "(2001"

Phrase: ")"

Phrase: "A strategy for disease gene identification"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0679199:strategy [Mental Process]

Phrase: "through nonsense-mediated mRNA decay inhibition."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   804   C0021467:Inhibition [Mental Process]
   804   C0021469:Inhibition [Molecular Function]
   804   C1628982:% inhibition [Quantitative Concept]
   804   C3463820:Inhibition [Activity]
   771   C1158013:Nonsense Mediated mRNA Decay [Genetic Function]
           Nonsense-Mediated Decay
   733 E C0311403:Inhibited [Qualitative Concept]
Processing 00000000.tx.301: Nat. 

Phrase: "Nat."
Processing 00000000.tx.302: Biotechnol., 19, 434439.[CrossRef][ISI][Medline] Moller, L.B., Tumer, Z., Lund, C., Petersen, C., Cole, T., Hanusch, R., Seidel, J., Jensen, L.R. and Horn, N. 

Phrase: "Biotechnol.,"

Phrase: "19,"

Phrase: "434439."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Moller,"

Phrase: "L.B.,"

Phrase: "Tumer,"

Phrase: "Z.,"

Phrase: "Lund,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Petersen,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Cole,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Hanusch,"

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Seidel,"

Phrase: "J.,"

Phrase: "Jensen,"

Phrase: "L.R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "and"

Phrase: "Horn,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0019939:Horn [Body Part, Organ, or Organ Component]

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]
Processing 00000000.tx.303: (2000) Similar splice-site mutations of the ATP7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome. 

Phrase: "(2000"

Phrase: ")"

Phrase: "Similar splice-site mutations of the ATP7A gene"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   767   C0596611:gene mutations [Genetic Function]
   767   C1519478:Splice-Site Mutation [Genetic Function]
   767   C2945843:Site of [Qualitative Concept]
   744   C0026882:Mutations [Genetic Function]
   744   C0205145:Site [Spatial Concept]
   744   C1515974:Site [Body Location or Region]
   744   C2825164:Site [Spatial Concept]
   711 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "lead to different phenotypes"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   770   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   770   C0031437:Phenotypes [Organism Attribute]
   770   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   770   C1522538:Lead [Functional Concept]
   770   C1705242:Different [Qualitative Concept]
   770   C2348269:Lead [Element, Ion, or Isotope]
   770   C3275067:LEAD [Therapeutic or Preventive Procedure]
   737 E C1285572:Phenotype [Laboratory Procedure]

Phrase: ":"

Phrase: "classical Menkes disease"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   901   C0022716:Menkes' Disease [Disease or Syndrome]
   827   C0012634:Disease [Disease or Syndrome]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "or"

Phrase: "occipital horn syndrome."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0268353:Occipital horn syndrome [Congenital Abnormality]
   827   C0019939:Horn [Body Part, Organ, or Organ Component]
   827   C0039082:Syndrome [Disease or Syndrome]
   827   C1184145:Occipital [Body Location or Region]
Processing 00000000.tx.304: Am. 

Phrase: "Am."
Processing 00000000.tx.305: J. 

Phrase: "J."
Processing 00000000.tx.306: Hum. 

Phrase: "Hum."
Processing 00000000.tx.307: Genet., 66, 12111220.[CrossRef][ISI][Medline] Kearney, J.A., Buchner, D.A., De Haan, G., Adamska, M., Levin, S.I., Furay, A.R., Albin, R.L., Jones, J.M., Montal, M., Stevens, M.J. et al. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "66,"

Phrase: "12111220."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Kearney,"

Phrase: "J."

Phrase: "A.,"

Phrase: "Buchner,"

Phrase: "D.A.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0718133:d a [Organic Chemical,Pharmacologic Substance,Vitamin]
   861   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "De Haan,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Adamska,"

Phrase: "M."

Phrase: ","

Phrase: "Levin,"

Phrase: "S.I.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603362:S' [Clinical Attribute]

Phrase: "Furay,"

Phrase: "A.R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Albin,"

Phrase: "R.L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Jones,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443013:Jones [Intellectual Product]

Phrase: "J."

Phrase: "M."

Phrase: ","

Phrase: "Montal,"

Phrase: "M."

Phrase: ","

Phrase: "Stevens,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1551756:Stevens [Population Group]

Phrase: "M."

Phrase: "J. et al."
Processing 00000000.tx.308: (2002) Molecular and pathological effects of a modifier gene on deficiency of the sodium channel Scn8a (Na(v)1.6). 

Phrase: "(2002"

Phrase: ")"

Phrase: "Molecular"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521991:Molecular [Qualitative Concept]
   928 E C0567416:Molecule [Substance]

Phrase: "and"

Phrase: "pathological effects of a modifier gene"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   767   C0681891:effect modifier [Functional Concept]
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "on deficiency"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0011155:Deficiency [Functional Concept]
  1000   C0162429:Deficiency [Disease or Syndrome]
  1000   C1623416:deficiency [Qualitative Concept]
   928 E C1636779:% deficient [Quantitative Concept]

Phrase: "of the sodium channel Scn8a"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1419866:SCN8A [Gene or Genome]
   734   C0037492:Sodium Channel [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(Na(v)1.6"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1423644:V-1 [Gene or Genome]
   812   C0597484:Na+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1272460:{NA} [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.309: Hum. 

Phrase: "Hum."
Processing 00000000.tx.310: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.311: Genet., 11, 27652775.[Abstract/Free FullText] Buchner, D.A., Trudeau, M. and Meisler, M.H. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "11,"

Phrase: "27652775."

Phrase: "[Abstract/Free FullText"

Phrase: "] Buchner,"

Phrase: "D.A.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0718133:d a [Organic Chemical,Pharmacologic Substance,Vitamin]
   861   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Trudeau,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Meisler,"

Phrase: "M."

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.312: (2003) SCNM1, a putative RNA splicing factor that modifies disease severity in mice. 

Phrase: "(2003"

Phrase: ")"

Phrase: "SCNM1,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1427938:SCNM1 [Gene or Genome]

Phrase: "a putative RNA splicing factor"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0035687:RNA Splicing [Genetic Function]
           Splicing
   812   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C1521761:Factor [Functional Concept]
   812   C2610186:splicing [Genetic Function]
   812   C2827422:Factor [Conceptual Entity]

Phrase: "that"

Phrase: "modifies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392747:MODIFY [Functional Concept]

Phrase: "disease severity in mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0521117:disease severity [Qualitative Concept]
   770   C0439793:Severity [Qualitative Concept]
   770   C2983285:Severity [Intellectual Product]
Processing 00000000.tx.313: Science, 301, 967969.[Abstract/Free FullText] Caceres, J.F., Stamm, S., Helfman, D.M. and Krainer, A.R. 

Phrase: "Science,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0036397:Science [Occupation or Discipline]

Phrase: "301,"

Phrase: "967969."

Phrase: "[Abstract/Free FullText"

Phrase: "] Caceres,"

Phrase: "J.F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Stamm,"

Phrase: "S."

Phrase: ","

Phrase: "Helfman,"

Phrase: "D."

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Krainer,"

Phrase: "A.R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]
Processing 00000000.tx.314: (1994) Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. 

Phrase: "(1994"

Phrase: ")"

Phrase: "Regulation of alternative splicing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0851285:Regulation [Governmental or Regulatory Activity]
   770   C1327622:Regulation [Biologic Function]

Phrase: "in vivo by overexpression of antagonistic splicing factors."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1515655:In Vivo [Spatial Concept]
           vivo
Processing 00000000.tx.315: Science, 265, 17061709.[ISI][Medline] Yang, X., Bani, M.R., Lu, S.J., Rowan, S., Ben-David, Y. and Chabot, B. 

Phrase: "Science,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0036397:Science [Occupation or Discipline]

Phrase: "265,"

Phrase: "17061709."

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Yang,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945617:yang [Idea or Concept]

Phrase: "X.,"

Phrase: "Bani,"

Phrase: "M."

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Lu,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024171:LU [Body System]
  1000   C0024176:LU [Geographic Area]
  1000   C2697939:LU [Quantitative Concept]

Phrase: "S."

Phrase: "J.,"

Phrase: "Rowan,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0330667:Rowan [Plant]

Phrase: "S."

Phrase: ","

Phrase: "Ben-David,"

Phrase: "Y."

Phrase: "and"

Phrase: "Chabot,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.316: (1994) The A1 and A1B proteins of heterogeneous nuclear ribonucleoparticles modulate 5' splice site selection in vivo. 

Phrase: "(1994"

Phrase: ")"

Phrase: "The A1"

Phrase: "and"

Phrase: "A1B proteins of heterogeneous nuclear ribonucleoparticles"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   783   C0028589:Nuclear Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   767 E C0949374:Nuclear Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "modulate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443264:modulate [Spatial Concept]

Phrase: "5' splice site selection"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0887917:5' Splice Site [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   923   C1327242:splice site selection [Genetic Function]
   923   C1327244:splice site selection [Genetic Function]
   812   C0036576:selection [Genetic Function]
   812   C0205145:Site [Spatial Concept]
   812   C1515974:Site [Body Location or Region]
   812   C2825164:Site [Spatial Concept]

Phrase: "in vivo."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo
Processing 00000000.tx.317: Proc. 

Phrase: "Proc."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]
Processing 00000000.tx.318: Natl Acad. 

Phrase: "Natl Acad."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268596:ACAD [Disease or Syndrome]
   861   C2700624:ACAD [Cell Function]
Processing 00000000.tx.319: Sci. 

Phrase: "Sci."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3642273:SCI [Professional or Occupational Group]
Processing 00000000.tx.320: USA, 91, 69246928.[Abstract] Anderson, S.L., Qiu, J. and Rubin, B.Y. 

Phrase: "USA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: "91,"

Phrase: "69246928."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Anderson,"

Phrase: "S.L.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439394:s l [Quantitative Concept]
   861   C2603362:S' [Clinical Attribute]

Phrase: "Qiu,"

Phrase: "J."

Phrase: "and"

Phrase: "Rubin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0252873:rubin's [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "B.Y."
Processing 00000000.tx.321: (2003) EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. 

Phrase: "(2003"

Phrase: ")"

Phrase: "EGCG"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0059438:epigallo-catechin gallate [Organic Chemical,Pharmacologic Substance]
   861   C0061012:epigallocatechin [Organic Chemical]
   861   C2348459:Epigallocatechin [Organic Chemical]

Phrase: "corrects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349182:Correct [Qualitative Concept]

Phrase: "aberrant splicing of IKAP mRNA"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C0086934:mRNA splicing [Genetic Function]
   760   C0035687:Splicing [Genetic Function]
   760   C2610186:splicing [Genetic Function]

Phrase: "in cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "from patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with familial dysautonomia."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013364:Dysautonomia, Familial [Congenital Abnormality,Disease or Syndrome]
   861   C0013363:Dysautonomia [Disease or Syndrome]
   861   C0015576:familial [Family Group]
   861   C0241888:Familial [Functional Concept]
   861   C1145628:dysautonomia [Disease or Syndrome]
   789 E C1704727:Family [Conceptual Entity]
Processing 00000000.tx.322: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.323: Biophys. 

Phrase: "Biophys."
Processing 00000000.tx.324: Res. 

Phrase: "Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347379:RES [Finding]
Processing 00000000.tx.325: Commun., 310, 627633.[CrossRef][ISI][Medline] Fujimoto, N., Sueoka, N., Sueoka, E., Okabe, S., Suganuma, M., Harada, M. and Fujiki, H. 

Phrase: "Commun.,"

Phrase: "310,"

Phrase: "627633."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Fujimoto,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Sueoka,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Sueoka,"

Phrase: "E.,"

Phrase: "Okabe,"

Phrase: "S."

Phrase: ","

Phrase: "Suganuma,"

Phrase: "M."

Phrase: ","

Phrase: "Harada,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Fujiki,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.326: (2002) Lung cancer prevention with ()-epigallocatechin gallate using monitoring by heterogeneous nuclear ribonucleoprotein B1. 

Phrase: "(2002"

Phrase: ")"

Phrase: "Lung cancer prevention with"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   909   C0281194:lung cancer prevention [Therapeutic or Preventive Procedure]
   833   C0281206:cancer prevention [Therapeutic or Preventive Procedure]
   770   C0199176:Prevention [Therapeutic or Preventive Procedure]
   770   C1706420:PREVENTION [Research Activity]
   770   C2700409:prevention [Qualitative Concept]

Phrase: "("

Phrase: ")-"

Phrase: "epigallocatechin gallate"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0059438:epigallo-catechin gallate [Organic Chemical,Pharmacologic Substance]
   861   C0061012:epigallocatechin [Organic Chemical]
   861   C2348459:Epigallocatechin [Organic Chemical]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "monitoring by heterogeneous nuclear ribonucleoprotein B1."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0150369:Monitoring [Health Care Activity]
   753   C1516647:monitoring [Research Activity]
   716   C0209851:Heterogeneous Nuclear Ribonucleoprotein B1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   716   C1415636:HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 [Gene or Genome]
Processing 00000000.tx.327: Int. 

Phrase: "Int."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0063789:INT [Organic Chemical]
  1000   C3272375:INT [Intellectual Product]
Processing 00000000.tx.328: J. 

Phrase: "J."
Processing 00000000.tx.329: Oncol., 20, 12331239.[ISI][Medline] Rattan, S.I. and Clark, B.F. 

Phrase: "Oncol.,"

Phrase: "20,"

Phrase: "12331239."

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Rattan,"

Phrase: "S.I."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603362:S' [Clinical Attribute]

Phrase: "and"

Phrase: "Clark,"

Phrase: "B.F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.330: (1994) Kinetin delays the onset of ageing characteristics in human fibroblasts. 

Phrase: "(1994"

Phrase: ")"

Phrase: "Kinetin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "delays"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205421:Delay [Temporal Concept]

Phrase: "the onset of ageing characteristics"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0332162:Onset [Qualitative Concept]

Phrase: "in human fibroblasts."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0016030:Fibroblasts [Cell]
Processing 00000000.tx.331: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.332: Biophys. 

Phrase: "Biophys."
Processing 00000000.tx.333: Res. 

Phrase: "Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347379:RES [Finding]
Processing 00000000.tx.334: Commun., 201, 665672.[CrossRef][ISI][Medline] Olsen, A., Siboska, G.E., Clark, B.F. and Rattan, S.I. 

Phrase: "Commun.,"

Phrase: "201,"

Phrase: "665672."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Olsen,"

Phrase: "A.,"

Phrase: "Siboska,"

Phrase: "G.E.,"

Phrase: "Clark,"

Phrase: "B.F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "and"

Phrase: "Rattan,"

Phrase: "S.I."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603362:S' [Clinical Attribute]
Processing 00000000.tx.335: (1999) N(6)-Furfuryladenine, kinetin, protects against Fenton reaction-mediated oxidative damage to DNA. 

Phrase: "(1999"

Phrase: ")"

Phrase: "N(6"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: ")-"

Phrase: "Furfuryladenine,"

Phrase: "kinetin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0049579:Kinetin [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "protects against Fenton reaction-mediated oxidative damage"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0010957:Damage [Injury or Poisoning]
   748   C0086597:mediated [Social Behavior]
   748   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]
   748   C0311404:Oxidative [Functional Concept]
   748   C0443286:Reaction [Functional Concept]
   748   C1114821:Reaction [Clinical Attribute]
   748   C1883709:Damage [Functional Concept]

Phrase: "to DNA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.336: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.337: Biophys. 

Phrase: "Biophys."
Processing 00000000.tx.338: Res. 

Phrase: "Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347379:RES [Finding]
Processing 00000000.tx.339: Commun., 265, 499502.[CrossRef] Blumenfeld, A., Slaugenhaupt, S.A., Liebert, C.B., Temper, V., Maayan, C., Gill, S., Lucente, D.E., Idelson, M., MacCormack, K., Monahan, M.A. et al. 

Phrase: "Commun.,"

Phrase: "265,"

Phrase: "499502."

Phrase: "[CrossRef"

Phrase: "] Blumenfeld,"

Phrase: "A.,"

Phrase: "Slaugenhaupt,"

Phrase: "S.A.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2603362:S' [Clinical Attribute]

Phrase: "Liebert,"

Phrase: "C.B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1553033:[c] [Quantitative Concept]

Phrase: "Temper,"

Phrase: "V.,"

Phrase: "Maayan,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Gill,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017558:Gill [Body Part, Organ, or Organ Component]
  1000   C1552935:gill [Quantitative Concept]

Phrase: "S."

Phrase: ","

Phrase: "Lucente,"

Phrase: "D."

Phrase: "E.,"

Phrase: "Idelson,"

Phrase: "M."

Phrase: ","

Phrase: "MacCormack,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Monahan,"

Phrase: "M.A. et al."
Processing 00000000.tx.340: (1999) Precise genetic mapping and haplotype analysis of the familial dysautonomia gene on human chromosome 9q31. 

Phrase: "(1999"

Phrase: ")"

Phrase: "Precise genetic mapping"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0008630:genetic mapping [Laboratory Procedure,Molecular Biology Research Technique]
   827   C1283195:Mapping [Activity]

Phrase: "and"

Phrase: "haplotype analysis of the familial dysautonomia gene"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0002778:Analysis [Laboratory Procedure]
   748   C0936012:Analysis [Research Activity]
   748   C1524024:analysis [Functional Concept]

Phrase: "on human chromosome 9q31."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1515519:9q31 [Cell Component]
   734   C0008643:Human Chromosome [Cell Component]
Processing 00000000.tx.341: Am. 

Phrase: "Am."
Processing 00000000.tx.342: J. 

Phrase: "J."
Processing 00000000.tx.343: Hum. 

Phrase: "Hum."
Processing 00000000.tx.344: Genet., 64, 11101118.[CrossRef][ISI][Medline]

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "64,"

Phrase: "11101118."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

